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Immune modulation is an important therapeutic approach. Down regulation using immune
inhibitors can treat autoimmune diseases and prevent transplant rejection, whereas up regulation
using immune augmentors can increase cancer cell killing and better clear viral and bacterial
infections. Currently available immune inhibitors include mitotic blockers, monoclonal antibodies
that reduce activated immune cell numbers or proinflammatory cytokine levels, and specific small
molecule inhibitors that target signaling events involved in immune cell activation and proliferation;
immune augmentors are mostly monoclonal antibodies that help immune cells overcome
inhibitory immune checkpoints. Small molecule immune augmentors are available, but they are
greatly limited by number and mechanisms. There is an unmet medical need to look for more
immune modulators. A cell-based assay was devised using cytotoxic T lymphocytes as a model
cell system in high-throughput screens to look for active compounds. Activation of cells results in
the externalization of lysosome-associated membrane protein to the cell surface, which can be
detected by fluorescent antibody present in extracellular solution in flow cytometry. By using
different methods to activate cells in an increasingly multiplexed design, the assay gains more
power to look for interesting compounds as immune modulators. The first version of the assay
used small molecule stimulants to achieve maximal cell activation, revealing 75 inhibitory
compounds from an NIH chemical library. Mechanism of action analysis subsequently led to 8
novel compounds being identified, and two are being investigated as molecular probes for target
identification. The second version of the assay used antibody-coated beads to achieve a
submaximal level of cell activation, allowing one augmenting compound to be identified from a
natural product library. Mechanism of action analysis determined that it is a potent activator of
protein kinase C, and structural deconvolution led to its identification as teleocidin A-1. The last
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version of the assay incorporated multiple treatment time of cells with compounds using
fluorescent cell barcoding technique. It was used to screen the NCI diversity library, revealing 5
augmenting compounds of lytic granule exocytosis. Therefore, multiplexed assays of cytotoxic T
lymphocyte can be used in high-throughput screens to look for immune modulators.
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Chapter 1: Introduction and Goal of Study
1.1 Overview of immune system components1
The immune system is the first-line defense mechanism composed of innate and acquired
systems under strict regulation. Major components of the immune system include immune cells,
soluble cytokines, complement and chemokines. The role of the immune system is to recognize
non-self organs, tissues, cells and subcellular organisms and mount a cohort of immune response
to clear out the potential threat.
The white blood cells in the immune system derive from pluripotent stem cells located in the bone
marrow. Two major lineages are the lymphoid and myeloid. Typically, cells of lymphoid lineage
regulate the adaptive immune response, and cells of myeloid lineage are the first responders to
infections. The lymphoid progenitors differentiate into T or B lymphocytes that can become
effector cells when activated: T lymphocytes become either CD8+ cytotoxic T lymphocytes to
directly lyse the target cells or CD4+ helper T cells that secrete cytokines to activate other immune
cells; B lymphocytes become plasma cells that produce antibodies which opsonize antigens and
assist antibody-dependent cell-mediated cytotoxicity (Figure 1). The predominant maturation site
for T cells is the thymus, and for B cells is the bone marrow in mammals (bursa of Fabricius in
birds). A third class of lymphoid cells is natural killer (NK) cell that lacks antigen-specific receptors
and therefore belongs to the innate immune system. Dendritic cells are derived from lymphoid
progenitors as well. They function as antigen-presenting cells by engulfing and processing foreign
organisms into recognizable peptides bound to their cell surface proteins.
The myeloid progenitors differentiate into granulocytic monocytic lineage, megakaryocytes and
erythrocytes. Granulocytic monocytic lineage gives rise to granulocytes such as eosinophil,
basophil, polymorphoneutrophils, involved in the initial immune response to a foreign attack; mast
cells that play an important role in the development of allergies; and monocytes that could turn
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into tissue-specific macrophages involved in phagocytosis and antigen presentation.
Megakaryocytes are broken down into platelets that assist blood clotting. The oxygen carrier, red
blood cells, are derived from erythroid progenitors.

Figure 1 An overview of the humoral and cell-mediated responses in the adaptive immune system.
When foreign pathogens enter the mammalian body, B cell-mediated humoral response can generate
antibodies to eliminate the antigen present in the bloodstream, and T cell-mediated immune response can
either recognize target cells hosting intracellular pathogens and directly kill infected cells or secrete
cytokines to regulate the activity of other immune cells. Figure is adapted from Kuby Immunology1.
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Cytokines are the soluble mediators of immune response. They can bind to specific receptors
with very high affinity on their target cell membranes, trigger signal transduction pathways and
cause target cells to activate, proliferate or differentiate. The molecular weight is usually less than
30 kDa, making them diffusible to carry autocrine, paracrine or even endocrine effects. Some
examples of cytokines are interferons, interleukins and tumor necrosis factors. Depending on the
binding receptors, cytokines can fine tune a cell response. Chemokines are chemotactic cytokines
that could attract immune cells to the secretion source, often the site of infection.
Complement is comprised of serum proteins that interact with one another in a catalytic cascade.
They can form membrane attack complexes and cause direct lysis of bacteria. Some complement
subunits enhance antibody responses and antigen presentation process. Others are involved in
clearing immune complexes from tissues and apoptotic cells.
1.2 A typical immune response
Before an antigen is introduced to the body, naïve immune cells circulate between blood stream
and lymphoid tissues such as thymus, lymph nodes, spleen and mucosa-associated lymphoid
tissue. When the body first encounters an infectious agent, myeloid lineage cells are the first line
defense as innate immune system. They can recognize both extracellular and intracellular
pathogens through pathogen-recognition receptors such as Toll-like receptors (TLRs). The
engagement of receptors initiates killing of pathogens directly or alerts the adaptive immune
system to the presence of pathogen. Granulocytes can produce cytokines and chemokines that
attract neutrophils and natural killer cells to the infection site. In turn, neutrophils can produce
more chemokines and attract antigen presenting cells.
Once antigen presenting cells are attracted to sites phagocyte the pathogens, two types of antigen
processing and presentation occur. Type I of major histocompatibility complex (MHC I) presents
cytosolic bacterial or viral proteins and interact with CD8+ T cells. These endogenous antigen
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proteins are processed by the proteasome and pumped into endoplasmic reticulum through
Transmembrane-Associated Antigen Processing (TAP) proteins. Eventually these peptides are
loaded onto MHC I molecules and presented at the cell surface for recognition. Type II (MHC II)
presents processed extracellular pathogens for CD4+ T cells. Exogenous antigens are taken up,
degraded and routed to endosomes. Eventually endosomes fuse with lysosomes, where antigenic
peptides are switched for the invariant chain peptide residual that are initially bound by MHC II.
MHC II loaded with the foreign peptide is then transported to cell surface for antigen presentation.
Antigen presenting cells travel to lymph nodes and present the processed antigens to T cells.
Unprocessed antigens also gain access to lymph nodes and become recognized by B cells.
These antigens could be opsonized by complements and/or antibody complexes, trapped by
specialized macrophages and transferred to B cells.
In the draining lymph nodes, naïve T cells encounter antigen presenting cells and arrest their
movements. They cluster around APCs and start to proliferate once they detach. B cells also
establish stable interactions with helper T cells through surface receptors such as T cell receptorMHC II-peptide and adhesion molecules. These signals, especially CD40 engagement, are
required for B cell proliferation and differentiation. CD8+ T cells are also activated in lymph nodes
via interaction with APCs, CD4+ T cells at the same time. Once activated, they differentiate into
cytotoxic T lymphocytes.
Activated lymphocytes leave the lymph node and circulate in the blood stream. Plasma cells travel
to different sites, depending on the isotypes of antibodies. Effector and memory CD4+ and CD8+
T cells travel to the site of infection following chemokine and cytokine gradients. The proliferation
of all lymphocytes declines within 10-14 days. Once the pathogen is cleared, there is a decrease
in inflammatory signals. Activated T cells engage surface receptor for apoptosis, and regulatory
T cells release anti-inflammatory cytokines to tune down the immune response.
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In response to chemokines, circulating effector lymphocytes express a different profile of celladhesion molecules and chemokine receptors that allow them to interact with inflamed vascular
endothelium at the infected site. They roll along the endothelial cells, become activated through
chemokine and G-protein linked receptors, engage in cell adhesion to the luminal side of the
vessel wall through integrin molecules, and eventually undergo transendothelial migration to the
infected tissue.
1.2.1 Cytotoxic T Lymphocytes (CTLs) Activation and Effector Function
CTLs are CD8+ T cells with cytotoxic effector function, and they can recognize and kill target cells
by releasing their lytic granules2–5. The basic process of activation from the perspective of CTLs
includes T cell receptor engagement, formation of signalosome, downstream signaling events
and effector function (Figure 2). The surface T cell receptor can recognize and bind to MHC I
loaded with foreign processed peptides on target cells, and CD8 molecule stabilizes the
interaction by binding to nonpolymorphic regions on MHC I molecule6. Another important function
of CD8 engagement is the delivery of Lck to immune synapse. This is crucial as Lck has tyrosine
kinase activity that is lacked in TCR cytoplasmic domain7. Lck can phosphorylate the
immunoreceptor tyrosine-based activation motifs (ITAMs) in intracellular domains of CD3 subunit
chains. Phosphorylated ITAMs then recruit Zeta-chain associated protein (ZAP) kinase to the
immune synapse and phosphorylates linker for activated T cells, which recruits multiple proteins
to form a signalosome complex and activates downstream signaling events8.
Among the many proteins in the signalosome complex, phospholipase C plays a key role in T cell
activation, as it cleaves a signal molecule, phosphatidylinositol-4,5-biphosphate (PIP2) into two
parts, inositol triphosphate (IP3) and diacylglycerol (DAG)9. Cytosolic inositol triphosphate binds
to its receptor located on ER membrane and causes storage of calcium ion to be released. The
fall in calcium level in ER causes the conformational change of stromal interaction molecules
(STIM 1), which then bind to calcium release-activated calcium modulator 1 (ORAI 1) on the cell
5

surface. ORAI 1 is the essential subunit of calcium release-activated calcium (CRAC) channel
which is highly selective for calcium ions and can cause calcium influx from extracellular solution
when activated10,11. Increased intracellular calcium can modulate calmodulin and calcineurin
activity, and it is involved in the translocation of nuclear factor of activated T (NFAT) cells from
cytosol to nucleus12,13. DAG is a membrane-bound molecule that can recruit PKC to the cell
membrane by binding to its C1 domain. Conventional PKC activation also requires calcium
binding to C2 domain14. Upon activation, PKC can phosphorylate the downstream kinases and
initiate a three-step kinase cascade: PKC-MAPKK-MAPK. These are important to promote
cytoskeleton polarization in activated T cells15. Both kinase activation and calcium signaling are
indispensable for T cell activation and lytic granule exocytosis.

Figure 2 An overview of TCR signaling events.
T cells become activated through the engagement of TCR with antigen-MHC molecules. The recruitment
of CD4 (or CD8) results in the phosphorylation of ITAMs on CD3 intracellular domains. This recruits ZAP
kinase which activates the key adaptor molecule linker for activation of T cells (LAT) and initiates the
signalosome complex. As a result, PIP2 is cleaved into DAG and IP3, activating downstream kinases and
triggering calcium release respectively. Figure is adapted from Nature Reviews8.
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Effector functions of T cell include direct cytotoxicity via lytic granule exocytosis, engagement of
FasL/FasR, and secretion of soluble mediators2. Microtubule network is polarized towards the
immune synapse and positions lytic granules to close proximity16. Secretory lytic granules contain
granzymes and perforins, and they are released when granule membrane fuses with CTL cell
membrane17. Perforins can perforate the target cell membrane, and granzymes can pass through
those pores into target cell cytosol and initiate caspase-dependent or -independent signaling and
cause target cell death17,18 (Figure 3). Fas ligand externalized onto CTL surface via lysosomal
membrane fusion can engage Fas receptor on target cells and initiate caspase activation
cascade3. CTLs can also cause indirect killing of target cells by releasing INF-γ and TNF-α. When
engaged with these cytokines, INF receptor can upregulate the expression level of Fas receptor
and MHC molecules at the target cell surface, and TNF receptor can activate caspase cascades2.

Figure 3 Direct killing of target cells by CTLs via lytic granule exocytosis.
Once activated through TCR, CTLs undergo signal transduction and reorient the microtubule network to
form an immunological synapse, releasing lytic granule contents to act on the target cell, resulting in target
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cell membrane perforation and intracellular caspase activation. Figure is adapted from Nature
Immunology16.

CTLs are involved in both acute and chronic transplant rejection. Their cytotoxic effects can result
in the lysis or apoptosis of non-self cells in transplant organs. The persistent infiltration of T cells
in transplants can result in progressive graft function decline19. This is to be distinguished from
graft-versus-host-disease, which is a result of transplanted hematopoietic stem cells attacking the
recipient tissues20. Current immunosuppressants are targeting T cell biology, including its
trafficking, activation, proliferation and effector functions. Non-biologics such as glucocorticoids
and rapamycin have side-effects on immune cells other than T cells. Calcineurin is involved in
CTL activation and proliferation, however calcineurin inhibitors such as cyclosporine A have
severe toxicity and cannot be used to prevent long-term transplant rejection19.
CTLs are also found to be involved in the pathogenesis of autoimmune diseases such as
rheumatoid arthritis due to their autoreactive inflammatory behaviors21. Patient samples showed
the presence of CTLs in both synovial fluid and synovial membrane, and they can secrete proinflammatory cytokines that potentiate bone degradation by stimulating osteoclasts22. CD8+T
cells also play a role in the establishment of germinal centers in rheumatoid arthritis patients,
which are follicular structures resembling secondary lymphoid follicles23,24. Current therapies of
autoimmune disease are mostly biologics, and they are focused on inflammation control in order
to relieve the disease symptoms25. However, biologics such as anti-TNF-α and CTLA4 antagonist
are limited by cell surface receptors or extracellular cytokines as targets. The complicated
heterogeneity of autoimmune disease makes it hard to design specific immunosuppressant
biologics. The administration dosage is also limited for biologics.
1.3 Immune modulation is important
The immune system is tightly regulated. On the one hand, results from normal immune activity
may become detrimental sometimes, such as in allergy and transplantation. In the case of allergy,
8

T and B cells become activated and undergo clonal expansion in response to allergens such as
food antigens, autoantigens, infectious agents and superantigens. They migrate to tissues and
initiate inflamed reactions. This in turn results in prolonged survival of inflammatory cells, cytokine
production, chemokine release, and tissue remodeling even function loss26. In the case of
transplantation, recipient’s immune system can recognize new graft or transplant from the donor
and attack them, leading to immediate or chronic transplant rejection; T cells from hematopoietic
stem-cell transplant can recognize recipient’s tissues as foreign and attack them, leading to graftversus-host disease20,27. On the other hand, dysregulated immune activity is often associated with
disease. A dysregulated immune system can be either overactive or under-responsive. An
overactive immune system often leads to self-attack, the onset of autoimmune diseases, where
the immune system mistakenly mounts a response against self-tissues or organ25. In comparison,
an under-responsive immune system is unable to clear transformed cells, leading to tumor
evasion and metastasis28. Therefore, modulating the immune system activity to a proper level is
critical to treat diseases, alleviate syndromes and prevent transplant rejection.
Immune modulation is the regulation of the immune system activity using pharmaceutics, and it
has two directions of modulation. Down-regulatory modulations using immune inhibitors such as
cyclosporine A and glucocorticoids have proven useful in treating autoimmune diseases and to
prevent transplant rejection19. Up-regulatory modulations using immune augmentors such as
imiquimod and interleukin-2 have been shown to improve pathogen recognition and cancer
immunotherapies29,30.
1.3.1 Currently available immune modulators and their limitations
Currently available immune modulators can be categorized into immune inhibitors and immune
augmentors. This section will give some specific examples of immune modulators, explain their
mechanisms and list their limitations. It is worth noting that some drugs categorized into one
mechanism could have effects on other mechanisms as well.
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For immune inhibitors, some drugs work by blocking cell proliferation in general. When responding
to an antigen, lymphocytes need to undergo activation and proliferation to generate enough
effector cells. An anti-proliferative agent or antimetabolite can block activated lymphocyte
proliferation and reduce the number of effector cells. Glucocorticoids bind to intracellular
glucocorticoid receptors and block genes involved in cell proliferation31. Another mechanism in
glucocorticoid-induced immune inhibition is glucocorticoid-induced leucin zipper that inhibits CD3dependent T cell activation, which explains its broad innate immune suppressing effects 32,33.
Methotrexate was first introduced as an antiproliferative agent that blocks purine biosynthesis and
works as a mitotic inhibitor. Later it was found that methotrexate also increases extracellular
adenosine level, which binds to adenosine receptors on the plasma membrane of many immune
cell types. Adenosine is a potent endogenous mediator with anti-inflammatory effects. When
adenosine receptor is activated, it interrupts superoxide anion formation in neutrophils and
protects the vascular endothelial cells. Adenosine can also inhibit Fc-γ receptor in monocytes and
inhibits their phagocytic activity34. Both glucocorticoids and methotrexate have been in use since
the 1950s and are still the gold standard in treating rheumatoid arthritis even with long-term side
effects, including osteoporosis, metabolic disease and increased risk of cardiovascular
disease35,36.
Some immune inhibitors are monoclonal antibodies or decoy receptors, and they can reduce the
number of activated immune cells or proinflammatory cytokines in circulation. For example, IL-2R
antagonist can block the proliferation signal needed for activated T cells37. Antithymocyte globulin
is synthesized by other animals in response to human thymocytes, and it can bind to human
lymphocytes in vivo and results in their phagocytosis38. They can both reduce activated
lymphocyte number in circulation. A major proinflammatory cytokine is TNF with various effects
on immune responses. There are five approved biologics that target the proinflammatory cytokine
TNF, and they are among the best sellers on the drug market. Infliximab, adalimumab,
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certolizumab, golimumab and eternecept can bind to both the soluble and the transmembrane
form of TNF39. Although both forms of TNF are biologically active, the soluble form drives the
inflammatory response, and the transmembrane form maintains the innate immune response to
infections such as tuberculosis, listeriosis and leishmaniasis40,41. Inhibiting both forms at the same
time could explain the side effects associated with currently available TNF inhibitors, including
active tuberculosis, invasive fungal infections, viral or bacterial infections due to opportunistic
pathogens including Listeria and Legionella39. IL-1 is a highly active proinflammatory cytokine
involved in autoinflammatory diseases such as gout and type 2 diabetes. Rilonacept is a decoy
receptor for soluble IL-1. It binds to IL-1, prevents it from binding to its endogenous receptor, and
reduces its inflammatory effects42.
There are small molecule immune inhibitors that act more specifically to target signaling events
involved in immune cell activation. For example, cyclosporin A inhibits calcineurin activity, a key
phosphatase that removes phosphate groups from NFAT protein, unmasking its nuclear
localization sequence and allowing it to bind IL-2 promoter gene sequences43–45. Rapamycin binds
to mammalian target of rapamycin (mTOR) and blocks T cell activation, proliferation and
differentiation, currently in use to prevent kidney transplant rejection46. Jak-STAT inhibitor such
as tasocitinib inhibits the important kinase involved in cell proliferation and survival47. Fingolimod
was first synthesized from an immunosuppressive natural product, myriocin, and it is found to
interact with sphingosine 1-phospate (S1P) receptors and can reduce peripheral lymphocyte
count in multiple sclerosis48. S1P is one member of the lysophospholipids (LP) family, which bind
to specific cell surface G-protein coupled receptors to transduce signals. Other members of LPs
family and their receptors are also explored for their involvement in autoimmune diseases,
neurodegenerative
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brain lyso-PS lipase to generate more lyso-PS in cells51,52. A small-molecule inhibitor of
ABHD16A, KC01, can deplete lyso-PS from cells, including lymphoblasts derived from subjects
with polyneuropathy, indicating the central role of ABHD12-ABHD16A in lyso-PS metabolism and
potential targets for treating neuroimmunological disorders53.
For immune augmentors, most pharmaceutical interventions are antibodies against cell surface
receptors that serve as inhibitory immune checkpoints. For example, T cell surface molecule
programmed death-1 (PD-1) binds to programmed death-1 ligand 1 (PD-L1) expressed by many
tumor types and sends an inhibitory signal to T cells by antagonizing PI3K activity directly54.
Therefore, antibodies against either PD-1 or PD-L1 can interfere their binding and overcome the
inhibitory effect of PD-1 engagement. Some examples of anti-PD-1 are nivolumab (by BristolMyers Squibb), MK3475 (by MERCK), pidilizumab (by Medivation). Some PD-L1 antibodies are
BMS-936559 & MPDL3280A (by BMS and Genentech). Both PD-1 and PD-L1 antibodies are
currently used to treat metastatic melanoma, renal cell carcinoma and non-small cell lung
cancer55. Another example is T cell surface molecule cytotoxic T lymphocyte antigen-4 (CTLA-4),
which competes with CD28 to bind to B7-1 and B7-2 on APC cell surface. CTLA-4 inhibits
downstream Akt and generates an inhibitory signal that blocks T cell response56. Therefore, an
anti-CTLA-4 antibody can overcome this inhibitory immune checkpoint. Some examples include
ipilimumab (used to treat metastatic melanoma, by BMS) and tremelimumab (by MedImmune
LLC)57. Even innate immunity can be enhanced with biologics. Irilumab is a newly licensed, firstin-class antibody by Bristol-Myers Squibb against natural killer cell immunoglobulin-like receptors
(KIRs). KIRs are expressed on NK cell surface to interact with MHC I on normal cell surface and
prevent NK cell killing of healthy cells58. Irilumab can overcome the inhibitory checkpoint by
blocking KIRs interaction with MHC I and increase NK cell activity in killing multiple myeloma cells
and acute myeloid leukemia blasts59–61.
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Antibody-based immune modulators are associated with immune related adverse events (irAEs),
such as inflammatory infiltration of solid organs by T cells and increased serum inflammatory
cytokines. These could have severe side effects and lead to inflammatory pneumonitis, thyroiditis,
inflammatory diarrhea/colitis62. All antibody-based therapies require intravenous injection, and
their dosage is often limited to reduce side effects63. Monoclonal antibodies are also limited by
their targets to cell surface receptors or soluble cytokines due to their large molecular size and
poor membrane permeability57,64,65. To add on that, antibodies are expensive to manufacture, and
their stability and bioavailability in vivo are hard to predict66,67. A recent trend in antibody drug
design is to use fragment antibodies such as antigen-binding fragments (Fab), single-chain
variable fragments (scFv), and third generation (3G)68,69. Due to a lack of Fc domain, fragment
antibodies are subject to rapid degradation and short circulating half-life70. It also increases the
risk of antibody aggregation during production and purification. When used in vivo, fragment
antibodies cannot initiate Fc-mediated functions such as antibody-dependent cell-mediated
cytotoxicity and complement-dependent cytotoxicity71.
Small molecule immune augmentors may be more desirable, because they are easier to
administer and cheaper to manufacture. However, they are greatly limited by number. Currently,
there are only two small molecule immune modulators available, imiquimod and lenalidomide.
Imiquimod belongs to a group of synthetic small molecule drugs called imidazoquinolones. They
were first synthesized in an effort to find antiviral drugs using nucleoside analogs29. Imiquimod
activates Toll-like receptor 7 (TLR7) and triggers MyD88/NFkB cascade, activating
proinflammatory cytokine production of INF-α, TNF-α, and IL-1272,73. These proinflammatory
cytokines create a milieu biased towards Th1 cell medicated immunity with enhanced killing of
target cells hosting intracellular virus or bacteria74. It functions as an innate immune response
modifier and is currently used at 5% in a crème to treat external genital warts, superficial basal
cell carcinoma, and also some other skin diseases75.
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Lenalidomide is an analog of thalidomide that was first introduced to treat morning sickness in
pregnant women. Due to its association with severe birth defects and neuropathy, it was
withdrawn from the market76,77. But later thalidomide was found to have anti-angiogenic properties
(which explains its side effects of birth defects) and T-cell costimulatory activities78,79. It was
investigated as a treatment for certain cancers. In an effort to look for more molecules with
immune augmenting effects, analogs of thalidomide were synthesized and tested80. Lenalidomide
and pomalidomide are both structural analogs of thalidomide with potent anti-tumor and immune
costimulatory effects81,82. Currently lenalidomide is used to treat multiple myeloma and other B
cell neoplasms, and it is used in combination therapy with monoclonal antibodies83. Interestingly,
the exact molecular mechanism for lenalidomide remained unknown until recently, which did not
interfere with its marketing as an anti-tumor small molecule augmenting immune cell activities.
Lenalidomide recruits two zinc finger transcription factors to E3 ubiquitin ligase complex and
cause their ubiquitination and subsequent degradation. Both transcription factors are important
for B cell differentiation, and multiple myeloma cells require ongoing expression of both for
survival84.
Adjuvants work as immune augmenting agents, and when used in combination with vaccines for
inoculation, they can greatly enhance the immune system activity. Effects of adjuvants include a
depot effect or the slow release of antigens (oil emulsions), and the non-specific activation of
phagocytes and all leukocytes (alum precipitate and bacterial toxins). Complete Freund’s
Adjuvant is the most potent adjuvant for immunizing experimental animals, and it is a combination
of mineral oil and killed Mycobacteria. The mineral oil slows down the antigen release, and the
bacterial wall peptidoglycan serves as pathogen-associated molecular patterns. Alum precipitate,
a combination of aluminum hydroxide and aluminum phosphate, is used in some human vaccines.
It has been shown to activate NLRP3 inflammasome, thereby enhancing IL-1 and IL-18 secretion,
leading the activated T cells to become Th2 cells, which promote strong antibody responses1.
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Recent efforts in finding new adjuvants are focused on pattern-recognition receptors, such as less
harmful versions of lipopolysaccharides (monophosphoryl lipid A and glucopyranosyl lipid A).
TLR3 ligand poly I:C (synthetic double-stranded RNA) can activate innate immune response and
is investigated in clinical trials for antitumor vaccines85. TLR9 ligand CpG DNA (bacterial DNA
mimic) preferentially elicits Th1 response for inducing cell-mediated cytotoxicity86.
Interestingly, the heat shock protein (HSP) family, known for their functions as molecular
chaperon for unfolded proteins under physiological and stress conditions, is found to be involved
in antigen processing as well. Certain members of HSP family can augment tumor antigen
processing by dendritic cells and enhance NK cell killing. Therefore, HSP is being investigated as
an antitumor adjuvant87. When incubated with purified tumor antigens under heat shock
conditions, HSP binds to the exposed hydrophobic regions and help form a recombinant tumor
antigen, such as in the case of breast cancer antigen her-2/neu+HSP11088,89.
Other innate immune stimulators can also be developed into adjuvants. For example, C-type lectin
receptors (CLR) such as Dectin-1 and -2, contain carbohydrate-binding domains and can
recognize carbohydrate motifs on microbes. Beta-glucan is found in the cell walls of bacteria,
yeast and fungi, and it is a known ligand of Dectin-1. Recognition of beta-glucan by Dectin-1
activates the spleen tyrosine kinase-NFκB axis to induce pro-inflammatory cytokine production90.
Retinoic acid-inducible gene I (RIG-1)-like receptors (RLRs) are cytoplasmic RNA sensors that
can activate interferon promoter stimulator 1 (IPS1) to induce type 1 interferons91,92. There are
three members within the family of RLRs: RIG-1, melanoma differentiation associated factor 5
(MDA5), and laboratory of genetics and physiology 2 (LGP2)93. During viral infection, the
repressor C terminal domain of RLRs bind to RNA-PAMP, undergoes a conformational change
and releases the caspase activation and recruitment domains (CARD), allowing it to interact with
IPS1, and RLRs can enhance antibody development driven by vaccine administration93. The
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Scripps Research Institute holds a patent of several small molecules used for RIG-1 modulation
(Patent WO2011115892 (A1)).
Stimulator of interferon gene (STING) is an ER adaptor molecule that can induce type 1 INF
production in response to intracellular DNA. They mediate DNA-based adjuvant activity94. Cyclic
dinucleotides are agonists of STING and are being used as vaccine adjuvants for anti-tumor
therapy (Johns Hopkins University and Aduro Biotech, Patent ID US2015010613 (A1)).
Bromodomain-containing proteins (BRD) are components of transcription factor complexes and
determinants of epigenetic memory. Several members have been shown to fuse with nuclear
protein in testis (NUT) and form novel fusion oncogene BRD4-NUT found in highly malignant form
of epithelia neoplasia. Modulating BRD may be useful as a treatment for cancer by altering the
epigenetic expression of certain genes in cancer cells. Dana-Farber Cancer Institute has patented
the method of combining a BRD inhibitor and an immune modulator for hematological cancer
treatment95.
The Tufts University holds a patent for a small molecule inhibitor, PT-100, of mammalian
dipeptidyl peptidase (DPP) IV activity and/or structural homologues thereof (DASH) serine
proteases. DASH is involved in tumor progression, immune system regulation and T cell
activation96. Recently they have developed the second generation of DASH inhibitor, ARI-417597,
which can modulate immune-cell subsets and function in mice98.
P-glycoprotein ABCB5, an ATP-binding cassette transporter, is found to be highly expressed in
melanoma cells, which may contribute to the resistance of melanomas to chemotherapy by efflux
of anti-cancer drugs. Bioxcel Corp. holds a patent of anti-ABCB5 antibody, when used in
combination with PD-1 agonist, can induce IL-2 production in the mixed cultures of hPBMCs and
melanoma cell lines (Patent WO2016179576 (A1)).
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The University of Texas holds a patent of using a small molecule tryphostin to treat immune
suppression and enhance T cell functions. Tryphostin induces immunostimulatory cytokines,
costimulatory

molecules

and

intracellular

signaling

in

macrophages,

and

enhanced

phosphorylation of Lck and ZAP-70 was observed (WO2008121858 (A1)).
In conclusion, immune modulators, especially small molecules as immune augmentors, are
severely limited by numbers. There is a great unmet medical need to look for novel small molecule
immune modulators. Traditional basic research aims to study cell phenotypes and their
mechanisms, aiming to yield potential molecular targets that underlie the phenomenon. These
targets can then be used to design target-based assays to screen for potential drug candidates
to modulate the target activity. These candidate molecules will then need to be tested in relevant
cell or animal models to observe their effectiveness in modifying the phenotype. In comparison,
a phenotypic assay allows us to bypass the intermediate steps and test compounds based on
their effects on cell phenotype. Any compound that shows activity in phenotypic screen based on
an immune cell assay is an immune modulatory compound. Even with their mechanisms
unknown, small molecule augmentors can still be useful in treating tumors as in the case of
lenalidomide.
1.4 Immortalized CTLs and their advantages for screening
CTLs serve as an excellent cell model to look for immune modulators. They share similar
activation mechanisms as other immune cell types such as T helper cells and B cells99. Inhibitors
that block the activity of CTLs could also inhibit other immune cells activated by similar
mechanisms. Other immune cells are not suitable cell models for HTS. For example,
measurement of T helper cell activation through the secretion of IL-2 secretion using ELISA takes
hours and multiple washing steps, whereas CTL lytic granule exocytosis takes place within 10
minutes, greatly decreasing the time needed to conduct HTS. Using monensin or brefeldin A can
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block cytokine secretion, but the intracellular flow cytometry analysis requires cells to be fixated
and permeabilized.
CTLs have a reliable protein marker that can be easily measured in flow cytometer. Lysosomeassociated membrane protein-1 (or LAMP-1, also known as CD107a, referred to as LAMP in the
rest of the thesis) is located on the lysosome membrane in unstimulated CTL cells. When cells
become activated and undergo lytic granule exocytosis, lytic granule membrane fusing with cell
membrane. As a result, LAMP gets externalized to the cell membrane, which can be detected via
fluorescent antibodies present in the extracellular solution. The binding of LAMP antibody can be
measured in flow cytometer without washing away excess antibodies, an important design feature
for HTS. The signal for LAMP externalization is robust, giving the assay a large separation band
between negative and positive samples to detect any changes.
CTL inhibitors identified through a phenotypic screen could be working on novel molecular targets.
By conducting follow up assays, we can test inhibitors against the known signaling pathways
involved in CTL activation. As a result, compounds with novel mechanisms could be identified
and used as chemical probe candidates to study CTL biology and activation mechanism.
Therefore, our assay serves as a general screen for lymphocyte inhibitors. There is no other easy
way of devising an immune cell-based assay looking for immune modulators.
T Acute Lymphoblastic Leukemia (TALL)-104 immortalized cells were used as model cell line for
CTLs. TALL cells were first introduced in the early 90s by Santoli group at Wistar Institute of
Anatomy and Biology in Philadelphia. TALLs demonstrated cytotoxic effects against a wide range
of targets and can sustain tumor killing activity for 2 years in vitro100. TALL cells had been used
as cell model system in previous research to investigate signaling events required for CTL
activation101–104. TALL-104 cells are αβ T-cells but they kill in MHC non-restricted manner100. In
particular, TALL cells can be activated with small molecules that bypass TCR and result in lytic
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granule exocytosis105. LAMP externalization as a measurement of CTL cell activation and lytic
granule release is also well established in TALL cells106.
LAMP-1 is used as a protein marker for cell activation in our assays. It also has physiological
functions. LAMP-1 belongs to the LAMP family. There are also LAMP-2 and -3. LAMP-2 is
involved in sorting perforin from the trans-Golgi network into outgoing transport vehicles, with
adaptor protein-1 as part of the sorting complex107. In humans, mutations in LAMP-2 cause Danon
disease, a fatal myopathy, likely a result of autophagic material accumulation in the striated
myocytes108. In mice, LAMP-1 deficiency results in an upregulation of LAMP-2 but no other
phenotypic changes109. Evidence from cDNA shows that LAMP-1 and -2 are homologous proteins
that share similar structures and sequences, which could explain for their overlapped
functions110,111. As a result of this, LAMP-1 function still remains unclear, yet deletions of both
LAMP-1 and LAMP-2 cause embryonic lethality in mice112. LAMP-3 is mainly expressed in lungs
and activated dendritic cells, hence they are also known as dendritic cell-LAMP113. LAMP-3 is
found to be upregulated upon proteasomal inhibition, therefore deleting LAMP-3 increase cell
vulnerability to proteasomal inhibition114. Apart from LAMP family proteins that make up ~50% of
all lysosomal membrane proteins, there are also other membrane proteins such as lysosomal
integral membrane proteins, lysosomal membrane glycoproteins, and V-type H+ ATPase pump
which is critical to acidify the lysosomal lumen 110,115,116.

1.5 Two types of high-throughput screens: phenotypic and target-based approaches
Traditional drug discovery was experience-oriented, mostly based on serendipitous findings or
isolation of the active ingredients from traditional remedies. Starting in the 1980s, advancement
in technology drove the modern drug discovery campaigns towards an era of high-throughput
screening (HTS)117. The process of HTS involves testing large numbers of chemicals from a
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library collection against a cell line or a molecular target in an automated fashion, in order to
rapidly identify compounds with activities that could alter the phenotype or target activity toward
the desired level. These active compounds or mixtures are referred to as “hits”, and they are often
the starting points of modern drug development process.
There are two approaches in HTS: the phenotypic approach and the target-based approach. A
phenotypic screen is carried out with cells, tissues or even animals. The phenotypic screen is
more physiologically relevant and less artificial, because intact cells are used for screening and
the interrogated system is its native state. By definition, hits from a phenotypic screen
demonstrate activity on the systemic level118, yet mechanisms of phenotypic hits could remain
unknown. To identify the molecular mechanism of action (MMOA) for these hits, follow up
experiments are often performed. Effects of hits are tested against known signaling events
involved in the onset of the phenotypic change119. In comparison, a target-based screen is
conducted on select molecular targets, such as protein kinases, ion channels or certain genes in
a reporter assay. These targets are chosen because they demonstrate a causal link to the disease
phenotype. Affecting the target activity is believed to alleviate the disease state. Hits from a targetbased screen are active against the target that the assay was designed for. To ensure that these
hits can indeed affect the phenotype, they need to be tested in follow up experiments using
relevant cell lines or animal models.
In the pipeline of drug discovery, phenotypic screens are often the starting point as they can be
conducted with limited understanding of mechanisms120. Records have shown that phenotypic
screens yield more first-in-class medicines121. Since phenotypic hits could be targeting any
molecular targets involved in the altered phenotype, it has the potential of obtaining useful hits as
probe candidates to identify novel molecular targets through affinity-based methods. These novel
targets, once established as valid targets, can then become candidates for target-based screens
in the next stage. The target-based approach is more successful in identifying best-in-class
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medicines122, and it offers important support for a molecular target as a therapeutic target,
because the molecular target activity can be altered using perturbants. Both approaches are
helpful in generating candidates, yet the phenotypic approach in particular contributes to the
progression of knowledge.
Historically, phenotypic screening was the classical way of drug screening. For example, as part
of anticancer drug screen effort, 60 representative cancer cell lines were selected and screened
against NCI library of over 40,000 compounds in a cell proliferation assay123. The phenotypic
approach went out of fashion with the emergence of genome sequencing and protein studies, but
now it is becoming popular again124. Although the phenotypic screen has less prevalence in drug
discovery effort, it has been more successful in identifying new drug candidates, especially those
working on novel targets122. Recently, with the advantage of image acquisition and data
processing platforms, image-based screen is becoming popular. This is one type of phenotypic
approach that involves taking pictures of compound-treated cells or organisms followed by imagebased data processing. Since multiple measurements can be collected from each individual
image, it is called high-content screen. It is worth noting that with the advances in modern flow
cytometry, flow cytometer-based assays can also become high-content screens. A new technique
of cell labeling using fluorescent dyes has emerged, also referred to as “fluorescent cell
barcoding” (FCB)125. By using combinations of dyes with different fluorescence spectra and at
different loading levels, multiple cell samples can be mixed together for compound treatment or
phospho-staining, sampled by the flow cytometer, and later deciphered based on dye loading.
Combing the powerful FCB technique with many fluorescence channels available on modern flow
cytometers enables researchers to investigate more than one parameter of cells at a time125.
The final outputs of phenotypic and target-based approaches in HTS reflect their underlying
ideology of holistic and reductionism: the holists believe in polypharmacology, and that a
phenotypic approach can reveal drug candidates that interact with multiple targets like “magic
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shotguns”. In comparison, reductionists correlate the origin of a disease with a single target, such
as an overexpressed protein or a mutant gene, and the target-based approach can identify
compounds highly active against one particular target like a “silver bullet” 126. Since the targetbased approach is a hypothesis-driven process, it could fail to yield any useful drug candidates if
the hypothesis is false and proof-of-concept studies fail to reject it.
1.5.1 Why a phenotypic assay?
A phenotypic assay measures the final cell activity as the output, and it can be performed with
limited knowledge of underlying molecular mechanisms of action. Compounds identified active
through this approach are guaranteed to work on the cellular level, and they are not limited by
potential targets. When proper follow up testing was carried out on active compounds to
investigate their molecular of action, we could obtain compounds that work on both known and
yet to be identified molecular targets. For the purpose of obtaining specific probe candidates, a
phenotypic assay is more feasible than a target-based approach.
We choose to use flow cytometry to detect fluorescent antibody binding as a result of granule
exocytosis. Flow cytometers take up cell samples in suspension and then focus them into a single
cell stream via hydrodynamic focusing. Individual cells are interrogated by a laser beam with
minimum amount of bathing solution included. This feature limits the interference from
background fluorescence present in the solution, making the flow cytometer a better platform than
the plate reader in reducing background noise. The plate reader samples the fluorescence of
each well uniformly, and it does not differ cell-associated fluorescence from solution-associated
fluorescence. In flow cytometry, cells do not need to be washed to remove excess unbound
antibodies, which is also favored for HTS. Flow cytometer can easily measure the fluorescence
of thousands of individual cells in under a minute, from which the average cell activity of the
population can be determined. This is much faster than microscopy when the same number
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measuring the cell fluorescence intensity of several fields in microscopy, and the data analysis is
much faster in flow cytometry than fluorescent microscopy.
The invention of the HyperCyt platform enables higher throughput of cell samples in flow
cytometer-based assays. HyperCyt uses peristaltic pump coupled with an autosampler, and each
well sample is separated by an air gap due to continuous sampling of the sip. A 1536-well plate
can be sampled by four sips coupled to four cytometers at the same time to reduce the overall
sampling time (<15 min). The software can then deconvolute the flow data for individual well
based on the air gap-separated feature127.
1.6 Types of Libraries used in HTS
Chemical libraries are collections of stored chemicals usually used in HTS to look for potential
drug candidates. There are two general types of chemical collections for screening: synthetic and
natural product (NP). Some drugs are defined botanical mixture, NP-derived, NP mimics or
synthetic drugs but with NP pharmacophores, and they belong to the NP category. A review of
new approved drugs over 33 years from 1981-2014 (n=1562) showed that 51% are NP, NPrelated or NP-inspired synthetic drugs, and only 27% are synthetic drugs128. It has been
recommended that more NPs should be incorporated into libraries for screening, as the current
medicinal chemistry space does not overlap with the bioactive space129. There are also
discussions as to how to increase the biogenic bias in chemical library design, in order to include
more diverse ring scaffolds into library collections for screening130.
Over the past 30 years, technology development in monoclonal antibody production has enabled
library collections of antibodies to be used for screening, and Boehringer Ingelheim is a leading
pharmaceutical company in this area. However, biologics library development requires high-end
facility for animal maintenance, and library collections of this type are often proprietary and
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inaccessible for outside screening. Therefore, they are not included in the discussion of this
section.
Traditional drug discovery relied on NPs, and people in all cultural groups have been looking for
therapeutic remedies from natural sources for thousands of years. The earliest written record in
traditional Chinese medicine dates back to 200 AD, yet a collection of 365 herbal plants were
compiled into Shen-nung Pen-tsao Ching, during a historical time believed to be around 2800 BC.
Many remedies are used even nowadays such as ginseng, jimson weed and cinnamon bark. The
Indian holy books Vedas (1500-1000 BC) mentioned 107 miracle herbs as plant-based treatment
for different ailments, and some ingredients are used today as culinary spices such as nutmeg,
cardamom, clove. The Ebers Papyrus (1500 BC) is an Egyptian medical papyrus containing 700
formalas and remedies, and it covers some interesting topics including contraception, intestinal
disease and parasites, eye and skin problems, dentistry and the surgical treatment of abscesses
and tumors131.
NPs are small or intermediate size molecules produced by biological sources. They can be
directly isolated from natural sources such as herbal extraction, or they could be secondary
metabolites synthesized and secreted by organisms. Compared to synthetic small molecules,
NPs have more diverse chemistry and novel structures; they are synthesized by organisms, so
by definition they have binding partners in nature; they possess privileged structures and drug
likeliness due to the long evolutionary history132. With modern technology in extraction and
purification, pure compounds can be isolated to achieve higher efficiency in modulating target
activity, such as the successful extraction of artemisinin that is used to treat malaria133. NP could
be difficult for de novo synthesis, so efforts have been put into devising strategies for
semisynthesis from NP precursors as starting molecules, such as the synthesis of paclitaxel from
10-deacetylbaccatin134.
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Libraries of synthetic molecules emerged as new sources for drug screening campaigns in the
last century. Synthetic molecules through organic chemistry or medicinal chemistry are usually
derived from a common scaffold. The molecular weight range is lower than NP, and they tend to
be more hydrophobic. The hypothesis is that most molecular targets are regulated through the
active sites or allosteric sites with hydrophobic pockets, and drug-like molecules should have the
same hydrophobic feature. Also, hydrophobic small molecules tend to cross the plasm membrane
more easily and bind intracellular molecular targets. Indeed, most commercial vendor libraries are
dominated by small, simple, sp2-rich heteroaromatic compounds135. Once identified as hits,
synthetic molecules are easier to conduct follow up assays such as structure-activity-relationship.
If selected as drug candidates, synthetic molecules are cheaper to manufacture, easier to upscale
the production. To ensure oral availability, Lipinski’s “rule of five” was proposed for small molecule
drug design136: molecular mass <500 Da, number of hydrogen-bond donors <5, number of
hydrogen-bond acceptors <10 and calculated octanol–water partition coefficient (LogP) <5.
However, synthetic molecules could contain undesirable chemical groups that affect cell viability.
Secondary assays are necessary to rule out simple cytotoxicity effect of synthetic molecules.
Recent advancement in computer technology and large chemical databases also allows for in
silico screening, or virtual screening, where a ligand-docking assay is performed in the computer
software. The assessment of binding affinity between a target protein and compound collections
in libraries can be performed without bench work, and it has been shown to improve the accuracy
of HTS hit list, such as in the case of angiogenin inhibitor screen for small molecules with antiangiogenic properties137. This type of screening requires the molecular target to be structurally
deconvoluted at high resolution, and prior knowledge must be obtained through crystallography.
Apart from randomized library collections, there are also targeted libraries, such as kinase
inhibitor panel, GPCR agonist/antagonist library, PI3K/Akt inhibitor library, ion channel ligand
library, etc. SelleckChem offers commercial library collections of different types. Particularly, FDA25

approved drug library (Prestwick Chemical Library) has been routinely used as a small sized
library in pilot screening for assay validation or optimization. Since all chemical collections are
FDA-approved drugs, this type of libraries serves as a platform for drug repurposing. Some
pharmaceutical companies also have a subset collection of chemical libraries with drug-like or
lead-like properties, and they can be used for pilot screening in a new assay.
1.7 Goal of my study
The goal of my study is to develop and refine cell-based assays of CTL lytic granule exocytosis
so that they have the greatest ability to detect interesting compounds to serve as
immunomodulators. To achieve this, I used different methods to trigger CTL activation and
increasingly sophisticated designs for assay multiplexing.
The initial version of the assay used small molecule stimulants to achieve the maximal level of
cell activation, which allowed for immune inhibitors to be identified. The ultimate purpose of this
inhibitor screen was to obtain hits, subject them to mechanism testing, and, by a process of
elimination, identify novel inhibitory compounds that could be used as chemical probes for
ultimate target identification. An HTS was carried out using this assay format and confirmed hits
were put through secondary assays to analyze their MMOA. This revealed several novel inhibitors
that could be used as chemical probes in target identification. The initial assay was a good way
to screen for look for immune inhibitors, but the maximal stimulation of cell responses did provide
an opportunity to screen for augmenting compounds.
In the second version of the assay, CD3 antibody-coated beads were used to achieve a
submaximal activation level of CTLs, which allowed for immune augmentors screening. In
addition, changes in light scatter caused by bead binding allowed us to separately analyze cells
bound or not bound to beads in a mixed sample. This allowed us to distinguish between immune
stimulators and immune enhancers. We differentiated immune enhancers, compounds that
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enhance the cell response after they become activated via anti-CD3 bead binding, from immune
stimulators, compounds that stimulate cells on their own. This is the first dimension of multiplexing
the assay. A natural product library was screened, and we identified an immune enhancing hit.
The hit was shown to contain teleocidin A-1, a known PKC activator, a mechanism that could
enhance CTL lytic granule exocytosis. We next screened an NCI diversity set library collection
and found more immune augmentors as well as inhibitors, yet they were only active at high
concentrations. A short incubation time of cells with compounds could explain why only
compounds active at high concentrations were identified in such screening.
In the third version of the assay, we sought to increase the power even more by including multiple
treatment times with compounds. An inert fluorescent dye was used at different concentrations to
label cells before they are added to compound-containing plates at different time points. Being
able to test compounds effects at multiple time points is the second dimension of multiplexing the
assay. This allowed compounds with multiple modes of actions to be identified. Immediate effect
targets could be calcium release inhibitors, PKC inhibitors, whereas long-term effect targets range
from activated PKC degradation to gene activation. The NCI diversity set was re-screened at short
and long-time points, revealing several immune augmenting compounds that showed activity after
long-term incubation.
With each multiplexing step of the assay, the power is greatly increased to screen for interesting
compounds that can act as immune modulators. The assay based on CTL granule exocytosis
serves as a quick and robust cell model to reveal active compounds in HTS. Combined with follow
up testing for molecular mechanism of action for hits, compounds can be categorized into two
groups, those working via known mechanisms that can then be tested in other immune cells, and
more importantly, those working via novel mechanisms that can then be developed into chemical
probes to identify their targets (Figure 4).
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Figure 4 Using chemogenomics to study the relationship between a phenotype and a molecular target.
In forward chemogenomics, a cell-based assay is used to screen for small molecules that can alter the
phenotypic activities of a cell. By studying their mechanisms of action and ruling out those working on
known targets, novel hits can be developed into chemical probes that can then be used to reveal novel
molecular targets. This direction answers the question: what is the underlying molecular mechanism that is
driving a cell phenotype? Reverse chemogenomics typically uses a target-based assay to screen for small
molecules that can alter the target activity. These molecules are then tested in cell systems to determine
whether they could also result in phenotypic changes. They serve as tool molecules in the traditional target
validation. This direction answers the question: is the molecular target sufficient in causing the cell
phenotype?
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Chapter 2: Materials and Methods
2.1 Chemicals, Cells, and Solutions
TALL-104 cells were obtained from American Type Culture Collection (Manassas, VA) and grown
in Iscoves’s modified Dulbecco’s medium (Sigma I3390) supplemented with 1% pen-strep, 2% Lglutamine, 10% characterized fetal bovine serum and 200 IU/ml human recombinant IL-2 (NCI
Frederick). They were grown in a humidified incubator at 37 °C in 10% CO2. Ringer’s Experimental
saline (ES) was composed of 155 mM NaCl, 4.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5 mM
HEPES, and 10 mM glucose. The pH was adjusted to 7.35-7.45 with NaOH, and 2% (w/v) Bovine
Serum Albumin (BSA) was added to make 2% normal Ringer’s solution (2%NR). Powder
resupplies including analogs of substance ID (SID) 7977862 were from Chembridge (San Diego,
CA) and the University of Kansas. Powder resupply of SID103159345 was synthesized by Dr.
Jeff Aubé, then at the University of Kansas. Alexa647-conjugated anti-LAMP antibody (0.5 µg/mL
final concentration) was purchased from BD Pharmingen (San Jose, CA). Phorbol 12-myristate
13-acetate (PMA) was from Alexis Biochemicals (San Diego, CA). Thapsigargin (TG) was from
AdipoGen (San Diego, CA). Paraformaldehyde 16% (PFA) was from Alfa Aesar (Ward Hill, MA)
and was diluted to 2% in phosphate-buffered saline (PBS). Dynabeads coated with anti-CD3 or
anti-CD8 monoclonal antibody (Thermo Fisher, Waltham, MA) were washed in ES according to
the manufacturer’s protocol, and then resuspended beads were added to cell suspension at a
ratio of one bead per cell. Calcein AM (Thermo Fisher, Waltham, MA) at indicated concentrations
was incubated with cells in ES, and then washed with dye-free ES solution twice.
2.2 Screening of Libraries
2.2.1 HTS of the Molecular Library Small Molecule Repository (MLSMR)
HTS was carried out by Mark Haynes, Bruce Edwards and Oleg Ursu at the University of New
Mexico Center for Molecular Discovery. The detailed procedure is described our publication138.
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In brief, screening of the library was performed in 1536-well plates. Cells were dispensed into
wells containing compounds (10 uM final concentration) or DMSO (1%), and stimulation solution
containing 2 uM TG+50 nM PMA+anti-LAMP antibody (final concentrations) were added. Plates
were sealed, rotated end-over-end to mix, and incubated for 2 hours at 24°C then overnight at
4°C. On the following day, warmed samples were collected on a custom HyperCyt HTS platform
with four sampling probes linked to four Accuri C6 flow cytometers.
A pooled fluorescence intensity histogram of unstimulated cells from all control wells containing
DMSO alone (positive controls for inhibitors) was used to establish an intensity threshold above
which we detected fewer than 5% of the unstimulated cells. Cells from compound-containing wells
with fluorescence intensity exceeding this threshold were considered to be responsive to the
TG+PMA stimulation, and subthreshold cells were considered to be unresponsive. Typically, 80–
100% of cells from DMSO control wells treated with TG+PMA (negative controls) were
responsive.
The response range for the assay was defined as the difference between the averages of %
responsive (%resp) cells in the negative control (Ncntrl, stimulated) wells and in the positive
control (Pcntrl, unstimulated) wells, respectively. Response inhibition mediated by compounds in
sample wells was calculated as follows:
Equation 1 % inhibition in MLSMR screen

100 ∗

Nctrl%resp − Sample%resp
Nctrl%resp − Pctrl%resp

Compounds inhibiting 55% or more were considered to be active, a threshold chosen to generate
~2500 active compounds. Wells in which fewer than 10 cells were detected within the viability
gate were not analyzed further due to insufficient sample size; 767 of 364,202 tested compounds
(0.2%) were labeled undetermined as a result.
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2.2.2 Bead Assay and Screening Condition
For tunicate-associated bacterial extract library screening, 1 µL of bacterial extracts (stock
concentration of 1 mg/mL in DMSO) or DMSO was added to test plates (Corning 3603) prior to
cell addition. One hundred microliters of ES-washed TALL-104 cells (2.5 × 106/mL) was added to
each well, mixed with DMSO or bacterial extracts, and incubated at 37 °C for 30 min. Ten
microliters of stimulation solution (ES supplemented with 20 µM TG and/or 1 µM PMA, anti-CD3
beads, anti-LAMP) or control solution (ES + 4% DMSO, anti-CD8 beads, anti-LAMP) was added
and mixed, and the plate was incubated for an additional 50 min in the dark at room temperature
with constant rotation. One hundred microliters of 2% PFA was added to each well, and samples
were transferred to flow tubes for cytometric analysis. Samples were collected on a two-laser
FACSCalibur (BD Biosciences).
2.2.3 Multiple-treatment time protocol for bead assay
For screening, 1 µL of compound at a concentration of 1mM in DMSO or 1 µL of DMSO was
added to wells of test plates (Greiner 675076, Kremsmünster, Austria). One hundred microliters
of medium-washed TALL-104 cells (1.25 x 106/mL) were added to each well, mixed with the
compound or DMSO, and incubated at 37C for 24 hours. This comprised the 24 hour treatment
time sample. Cells for the 30 minute treatment time were maintained in medium at 37C for 23
hours, before being bar-coded with 20nM calcein AM and added to the plate in 10 µL cell solution
(1.25 x 107/mL). Each well was thoroughly mixed and incubated at 37C for 30 minutes. To
stimulate cells, ten microliters of anti-CD8 bead solution (medium supplemented with anti-CD8
beads, anti-LAMP1, 4% DMSO), anti-CD3 bead solution (medium supplemented with anti-CD3
beads, anti-LAMP1, 4% DMSO), or stimulation solution (medium supplemented with anti-CD3
beads, anti-LAMP1, 1 µM PMA, 20 µM TG) was added to the appropriate wells and mixed by
repeated pipetting. All manipulations were performed with digital multichannel pipetters. Plates
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were incubated at room temperature for 1 hour with constant rotation (resulting in plate inversion),
before it was sampled.
2.3 LAMP and BLT-Esterase Assays
One hundred microliters of ES-washed TALL-104 cells (2.5×106/ml) was added to each well,
mixed, and incubated at 37 °C for 30 min. Five microliters of stimulation solution (ES
supplemented with 20 µM thapsigargin and 1 µM PMA) or control solution (ES + 4% DMSO) was
added and mixed, and the plate was incubated for an additional 90 min in the dark at room
temperature. The plate was centrifuged, and 50 µl of supernatant was transferred to a new plate
for BLT-esterase assays, which measure the release of granzyme B by monitoring the cleavage
of a synthetic substrate, benzyloxycarbonyl-L-lysine thiobenzyl ester.11 Meanwhile, 50 µl of ES
containing 0.6 µg/ml anti-LAMP antibody was added to the wells containing the pellets, mixed,
and incubated for 30 min in the dark at room temperature with constant rotation prior to the
addition of 100 µl/well of 2% PFA. The geometric mean value of LAMP fluorescence or the
absorbance values at 410 nm were determined from unstimulated (U) or stimulated (S) DMSOtreated or stimulated compound-treated (C) cells, and the percent inhibition of LAMP
externalization or BLT-esterase secretion by each compound was calculated as follows:
Equation 2 % inhibition of down assay

100 ∗ (1 −

𝐶−𝑈
)
𝑆−𝑈

2.4 Intracellular Calcium measurement
2.4.1Fura-2 Protocol for Plate-based assay
Ninety microliters of ES was added to each well of a black flat-bottomed plate laid out with DMSOand compound-containing wells, then it was mixed, and the fluorescence excited at 340 and 380
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nm measured at 510 nm emission (F340 and F380) was acquired (reading 1, blank B). TALL-104
cells were loaded with 0.5 µM Fura-2 AM for 25 min in the dark at room temperature, then washed
with ES and incubated for 20 min. 2.5×107 cells in 10 µl ES were added to each well of the test
plate and mixed. The plate was incubated for 30 min at 37 °C and read again (reading 2). Finally,
5 µl of stimulation solution (ES supplemented with 40 µM thapsigargin) or control solution (ES +
4 % DMSO) was added and mixed. After 50 min, the third fluorescence reading was taken
(reading 3). U calcium levels were reading 2 from DMSO-treated cells. S calcium levels were
reading 3 from DMSO- or compound-treated cells. Blanks for each well were subtracted for F340
and F380 prior to computation of the F340:F380 ratio. Percent inhibition of calcium rise was
calculated using Equation 2.
2.4.2 Fluo-4 Protocol for Flow Cyometry-based Assay
TALL-104 cells were loaded with 1 µM Fluo-4 AM (Molecular Probes, Eugene, OR) in culture
medium at room temperature for 25 min, washed to remove excess dye, and resuspended in ES
without 2% BSA. Anti-CD3 or anti-CD8 beads were added, or cells were left untreated, and
samples were analyzed cytometrically at selected time points over 1 h.

2.5 Assays for Protein Kinase C (PKC), and Mitogen-Activated Protein Kinase Kinase
(MAPKK) Activity
One hundred microliters of ES-washed TALL-104 cells (2.5×106/ ml) was added to Eppendorf
tubes containing compound or DMSO and incubated at 37 °C for 30 min. Five microliters of
stimulation solution or control solution (as above for LAMP and BLT-esterase measurements)
was added and mixed, and tubes were incubated for an additional 50 min in the dark at room
temperature with constant rotation. After incubation, cells were fixed with 100 µl of 2% PFA and
permeabilized by the addition of 1 ml of ice-cold methanol. Cells were washed with FACS buffer,
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incubated with primary antibodies [rabbit anti-active PKC substrate (Cell Signaling 2261; Cell
Signaling, Danvers, MA), 1:100; and mouse anti-p44/p42 MAPK (Cell Signaling 9106), 1:1000] in
FACS buffer, then incubated with secondary antibodies (6 µg/ml Alexa488-conjugated donkey
anti-rabbit and 7 µg/ml Cy 5-conjugated donkey anti-mouse) and washed. The geometric mean
value of Alexa488 and Cy5 fluorescence was determined for U or S DMSO-treated or stimulated
C cells. The percentage inhibition of PKC substrate phosphorylation or extracellular signalregulated kinase (ERK) phosphorylation was calculated using Equation 2 % inhibition of down
assay
𝐶−𝑈

100 ∗ (1 − 𝑆−𝑈 ).
2.5.1 Intracellular p-ERK Staining in Bead Assay
ES-washed TALL-104 cells were treated with anti-CD3 or anti-CD8 beads and incubated for 50
min at room temperature with constant rotation. Immunocytochemistry was carried out as
previously described.
2.5.2 PKC Activity Dose Response by Immunocytochemistry
TALL-104 cells were resuspended in culture medium and treated with PMA or compound E1 at 9
concentrations ranging in a threefold dilution series from 0.01 nM to 200 nM for 30 min at 37 °C,
followed by 50 min at room temperature with constant rotation. Immunocytochemistry was carried
out as previously described. Values of geometric mean of fluorescence at different concentrations
were fitted to Equation 3 Hill equation.

2.6 Immunoblotting to Detect Effects on Calcineurin Activity
TALL-104 cells were nucleofected as described previously with CaNAR1 complementary DNA
(cDNA). Five hours later, 1×106 ES-washed transfected cells in 400 µl were added to each tube
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containing 4 µl test compound at an initial concentration of 3 mM or 4 µl DMSO, mixed, and
incubated for an additional 30 min at 37 °C. Six hundred microliters of stimulation solution (ES
supplemented with 1.67 µM TG and 83.3 nM PMA) or control solution was added and mixed, and
the tube was incubated for another 50 min in the dark at room temperature with constant rotation.
Cell pellets were lysed in standard radioimmunoprecipitation assay buffer supplemented with 10
mM EGTA, 10 mM EDTA, protease, and phosphatase inhibitor cocktails, and processed for
immunoblotting on nitrocellulose membranes.
2.7 Immunocytochemical Determination of Compound Effects on ERK Catalytic Activity
TALL-104 cells were nucleofected with ERK activity reporter (EKAR) cDNA. Five hours later, 100
µl ES-washed transfected cells (2.5×106/ml) were treated with test compound or DMSO and
stimulated. Cells were fixed and permeabilized, then stained with rabbit anti-phospho Cdc25c
antibody (Cell Signaling 9527), followed by a Cy5-conjugated secondary. FL-1 signals
[corresponding to yellow fluorescent protein (YFP) expression level] and FL-4 signals
(corresponding to anti-phospho-Cdc25C staining intensity) were collected. Percent inhibition was
calculated as described above.
2.8 Plate Reader and Flow Cytometer
All plate measurements for follow-up experiments were performed with a BioTek Synergy 2-plate
reader (BioTek). Most flow cytometry experiments were conducted on a FACSCalibur (BD
Biosciences) equipped with 488 nm and 640 nm lasers. NCI library screen at two time points was
conducted on a five-laser (350 nm, 405 nm, 488 nm, 540 nm and 640 nm) BD Fortessa X-20 with
a plate reading unit. Both instruments are housed in the University of Connecticut’s Flow
Cytometry Facility. Flow cytometry data were analyzed with FlowJo Software (Tree Star Inc.,
Ashland, OR).
2.9 Natural Product Library Generation
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Tunicate-associated bacterial extract library was constructed by Dr. Marcy Balunas lab at the
School of Pharmacy, University of Connecticut. The detailed procedure was described in our
publication139.
In brief, tunicate specimens were collected in Long Island Sound, CT, the Bahamas, and the
Republic of Panama by scuba diving or from shallow water dock lines. Tunicates were sterilized,
homogenated, and biomass was streaked onto plates. Bacteria colonies were isolated from
plates, expanded in liquid culture, and extracted via Diaion HP-20 beads with consecutive washes
of methanol and acetone. The resulting bacterial extract was suspended in DMSO in 96-well
plates for storage and screening.
2.9.1 Isolation and Identification of Teleocidin A-1
The detailed procedure was described in our publication139.
In brief, the augmenting hit was fractionated via C18 reversed-phase solid-phase extraction
chromatography with gradient methanol:water elution. Each eluted fraction was tested in bead
assay, and the most active fraction was subject to liquid chromatography-mass spectrometry
characterization. NMR spectra for 1H and 13C were collected for structural deconvolution.
Teleocidin A-1 was isolated from Streptomyces sp. strain AVP053U2, isolated from the
tunicate Styela clava, collected from shallow water dock lines at Avery Point, CT, in May 2011
(41° 18.975 N, 72° 3.647 W). The bacterium was isolated from ISP4 agar, replacing water with
Instant Ocean (United Pet Group, Blacksburg, VA), and cultured at room temperature. The
morphology of AVP053U2 resembled an actinobacterium, with a yellow base and green spores.
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Chapter 3: HTS of CTLs Granule Exocytosis Led to Identification of Novel
Immunosuppressants
3.1 Overview
This chapter describes the first version of CTL lytic granule exocytosis assay used in an HTS
campaign screening for novel immunosuppressants. Findings from this project were published in
Journal of Biomolecular Screening138. CTLs kill cancerous and virus-infected cells via lytic granule
exocytosis, and they are involved in transplant rejection and autoimmune diseases140. Current
small molecule immunosuppressants are not specific to T cells and have several side effects, so
there is a need to look for novel immunosuppressant compounds to serve as drug candidates 19.
CTLs lytic granule exocytosis serves as a good cell model, because the process is fast, the
detection is robust and signaling pathways for CTL activation are shared by other immune cell
types106,141. CTLs were activated with small molecules that bypass T cell receptor, and the
externalization of LAMP to cell membrane was detected by fluorescent antibody present in the
extracellular solution. Antibody binding was measured in flow cytometer in a no-wash fashion,
suitable for HTS142. We reasoned that a phenotypic assay would allow us to identify compounds
with either known or unknown mechanisms of actions, and the latter could lead to valuable probes
for target identification. The screen >300,000 small molecules in the collection of Molecular
Library Small Molecule Repository (MLSMR) from National Institute of Health led to the
identification of 31 novel immunosuppressant candidates working through known mechanism(s)
and 8 inhibitors with novel molecular mechanisms of action. Two novel inhibitors were confirmed
from powder resupply and are being developed into probe molecules.
3.2 Results
3.2.1 LAMP assay of TALL-104 cells
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Previously a phenotypic assay was devised based on CTL lytic granule exocytosis, where the
translocation of LAMP onto the cell surface can be detected by fluorescent antibody present in
extracellular solution142. The assay can be performed without washing away excess antibodies in
96- and 384-well plates (Figure 5A). The fluorescence of cells was collected on the flow cytometer
and the background fluorescence interference was reduced to minimum. Eliminating the washing
step in LAMP assay is advantageous for HTS, where plate washing can be a laborious step and
increases the cost of the screen. The plate uniformity testing included maximally stimulated cells
treated with TG+PMA, half stimulated cells treated with TG only, and unstimulated cells. Z’ factor
was calculated between unstimulated cells and maximally stimulated cells by TG+PMA treatment.
Control samples repeatedly showed Z’ factor > 0.6, which indicated excellent assay quality143.

Figure 5 LAMP assay can detect the level of lytic granule exocytosis.
Detecting exocytosis via anti–lysosome associated membrane protein (LAMP) antibody binding without
washing. (A) Histograms of anti-LAMP antibody fluorescence for cells that were washed (top) or not washed
(bottom). Unstimulated cells are represented by a dashed line, whereas stimulated cells are denoted by a
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solid line. Note the shift in the fluorescence of the unwashed unstimulated cells compared with the washed
unstimulated cells. (B) Plot of the geometric mean of anti-LAMP antibody fluorescence from a test
conducted in a 96-well plate. PMA, phorbol 12-myristate 13-acetate; TG, thapsigargin. (C) Illustration of the
experiment procedure for a no-wash LAMP assay.

3.2.2 HTS of MLSMR library
In collaboration with the University of New Mexico (UNM) Center for Molecular Discovery, we
performed the assay in 1536-well plate to conduct a HTS of the compound collection of 364,202
small molecules from MLSMR. At UNM, a clustered HyperCyt was used to sample each plate in
four quadrants. Prior to screening the library compounds, control plates were set up to downscale
the assay volume for 1536-well plate. Figure 6B shows a column and a quadrant from a control
plate, where half of the cells were stimulated with TG+PMA and the other half were left
unstimulated. Each well was sampled for 900ms and an interwell air gap was 400ms. This allowed
a 1536-well plate to be finished in ~10.5min. In the validation runs, this resulted in the acquisition
of ~1150 cells/well.
As seen in Figure 6C, the assay showed a bivariate nature in anti-LAMP fluorescence profile for
unstimulated versus stimulated cells, and therefore we explored two different ways of analyzing
data: geometric mean and percent positive. Geometric mean calculates the average of a
logarithmically distributed data, so it directly reflects the amount of antibody bound to cells and
the level granule exocytosis. Percent positive calculates the percentage of cells among a
population with a fluorescence intensity above the predefined threshold, which was decided
based on the level of cell responses in negative and positive controls. Analyzing data by
determining the percentage of responding cells was found to give better reproducibility than the
MFI analysis, and it was therefore used to analyze primary screening data. Using that analysis,
1195/1208 plate quadrants (98.9%) had Z values > 0.5, consistent with the idea that the assay
had appropriate statistical reliability for HTS. Hits from plates that had Z < 0.5 were not excluded.
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Seven hundred and sixty-seven wells had fewer than 10 cells in the live cell gate and were scored
as inconclusive. A low event number may not reflect compound toxicity; a number of issues, such
as problems with dispensing cells or acquiring samples, can reduce the event number.
Figure 6D shows a representative row of data from a plate in the primary screen where a potential
inhibitor is indicated. Within each plate, two columns on the left are left unstimulated and therefore
serve as positive control for inhibitor screening, and one column on the right is stimulated with
TG+PMA and serves as negative control. They are indicated by arrows in Figure 6E with the color
scale corresponding to percent positive cells in each population. The lines across the plate
indicate the sampling by four cytometers simultaneously.
We wanted to select ~2500 compounds for follow-up. Using an arbitrary threshold of 55%
inhibition yielded 2404 hits. One thousand four hundred and sixty of these substances were
available and did not have obvious chemical liabilities (reactive groups, dye moieties, or
unsuitable properties for chemical optimization). These were obtained and retested. One hundred
and sixty-one substances were confirmed active (11% confirmed), and these were selected for
dose–response testing. Possible reasons for the lower confirmation rate include: the liquid
handling system used for ultra-HTS can be problematic at times where no stimulation solution
was added to the well; inter-cytometer difference where a lower response level was observed
from the 3rd quadrant of the sample plate (Figure 6E), yet a uniformed threshold was used for hit
selection across all samples; low cell numbers in some wells (~50 cells) were not excluded from
the analysis.
Dose–response measurements were performed by testing the effects of compounds at 9
concentrations ranging in a threefold dilution series from 7 nM to 15 µM. Data were fitted to Hill
equation as in Equation 3.
Equation 3 Hill equation
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% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

𝑡𝑜𝑝 − 𝑏𝑜𝑡𝑡𝑜𝑚
1 + 10(𝑙𝑜𝑔𝐸𝐶50−𝑥)∗𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒

where top is the maximum inhibition; bottom is the response of stimulated cells in the absence of
compound; logEC50 is the logarithm of the EC50 (in µM); and Hillslope is the Hill coefficient. Fortyfive compounds exhibited acceptable dose-dependent inhibitory curves (monotonic dose
dependence with EC50 < 10 µM and least 1 point defining an intermediate region of the curve)
when analyzed using the percent positive analysis strategy described above. Additional
compounds demonstrated acceptable dose–response behavior, however, when curves were fit
to the MFI measurement. Based on these considerations and the availability of compounds, a
resupply of 75 substances was obtained for further analysis. Figure 7 outlines the decision points
leading from 364,202 substances screened to the 75 that were selected for follow-up.

Figure 6 Screening the National Institutes of Health (NIH) Molecular Libraries Small Molecule Repository
(MLSMR) in a 1536-well format with high-throughput cluster cytometry.
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(A) Plot of forward scatter versus side scatter from an experiment validating the 1536-well format of the
assay. The circled region represents live cells, which were selected for analysis. (B) Representative data
from row A (top) and the entire first quadrant (bottom) of a test plate in which half the columns contained
unstimulated cells, whereas the other half contained stimulated cells. (C) Histogram of FL-4 fluorescence
for all live-cell events in a validation plate showing the bivariate nature of the distribution of fluorescence
corresponding to unstimulated (to the left of the line) and stimulated (to the right of the line) cells. (D)
Representative data from 1 row of a library screening plate. (E) Heat map for a representative plate from
the primary screening campaign. Arrows in the upper left indicate columns that were not stimulated to serve
as positive controls. Arrow in the upper right designates stimulated negative controls. The color scale used
to display data (indicated to the right) ranges from 0% response (purple) to 85% response (red). Dashed
lines demarcate quadrants. (F) Histogram of Z values for the 1208 quadrants analyzed.
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(0.7% hit rate)

(11.0% confirmed)

(5.1% selected)

Figure 7 Flow chart showing hit selection process from the primary screening.
The number at each step indicates the number of compounds that are excluded from or included into the
hit selection.

3.2.3 Confirming the activity of selected hits
We first confirmed the activity of the substances using a protocol that combined a repeat of the
LAMP assay with BLT-esterase assays144–146, a standard means for measuring granule
exocytosis (Figure 8). We combined the 2 measures to minimize compound use and reduce the
chance for error. Compounds were tested at 30 µM to achieve maximal inhibition of exocytosis.
Such a high concentration was chosen because our major goal was to identify compounds with
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unknown MMOA, and we felt that using a relatively high concentration would likely reveal any
effects on known MMOA. In flow data, we did not observe striking effects on the fraction of cells
in the live cell gate in these experiments, suggesting that toxicity in the short term was not a
problem.

Figure 8 Confirming compound activity in a combined format of the primary assay and orthogonal assay.
Plot of inhibition measured in flow cytometer-based LAMP assay versus inhibition measured in the plate
reader-based BLT-esterase assay. The dashed line has a slope of 1 and passes through the origin,
indicating the behavior expected for a perfect correlation between the 2 measures. The solid line is a bestfit regression line for the data from 75 cherry-picked hits. Compounds with negative numbers in % inhibition
are those that resulted in slightly higher cell responses than DMSO-treated controls.

Cells were pretreated with compounds or DMSO, then, except for control wells, stimulated with
TG+PMA. Fifty minutes after stimulation, plates were centrifuged, and samples of the supernatant
were collected for BLT-esterase assays. The pelleted cells were stained with anti-LAMP
antibodies for 15–20 min, then fixed and analyzed via flow cytometry. We have shown previously
that staining cells after stimulation yields essentially similar results as stimulating them in the
presence of the antibody105.
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We found that 48 substances blocked granule exocytosis by >50% as measured by LAMP
staining. BLT-esterase measurements reported on average ~20% less inhibition of exocytosis
than LAMP staining. Despite this, 41 substances also inhibited lytic granule exocytosis >50% as
measured with the BLT-esterase assay. For 7 compounds, there was a sufficient discrepancy
between the 2 measures of exocytosis that compounds scored as active on the basis of LAMP
externalization were scored as inactive based on BLT-esterase assays. A number of factors,
including a modest degree of compound toxicity, could be responsible for this. Those compounds
were further investigated.
3.2.4 A strategy to identify MMOA of confirmed hits
Follow-up experiments were intended to determine the mechanism by which hit compounds block
exocytosis (Figure 9). We envisioned 7 testable known MMOAs that could block lytic granule
exocytosis. Sustained calcium influx, which is required for exocytosis 99, could be inhibited by two
MMOAs: (1) blockade of store-operated calcium channels, which are known to mediate calcium
signals in CTLs11; or (2) blockade of K+ channels, which maintain a favorable driving force for
calcium entry13,147,148. (3) Inhibition of PKC could block exocytosis149, as could (4) inhibition of the
activation of the MAPK ERK150 by upstream MAPKKs or (5) block of ERK catalytic activity, (6)
calcineurin activity could be inhibited, either directly or (7) as a result of inhibition of calmodulin or
of calmodulin binding to calcineurin. We reasoned that it would be most efficient to put assays
that could be conducted entirely in plate format early in our experimental design. When possible,
we interrogated multiple processes simultaneously. In addition, we reasoned that we might not
need to test each known MMOA individually, provided we could interrogate a common output. For
example, inhibition of calcium influx can result from block of calcium channels or block of K+
channels; either will be revealed by assessing intracellular calcium increases. Similarly, block of
either calmodulin or calcineurin’s catalytic activity will result in decreased calcineurin-dependent
dephosphorylation; both can be assessed by examining dephosphorylation of calcineurin
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substrates. In the end, 4 sets of experiments allowed us to test all of the MMOAs described above.
All experiments to determine MMOA described below were performed at least twice, and average
results are reported.

Figure 9 Rationale behind experiments testing the MMOA of hit compounds.
(A) Diagram (modified from a previous paper99) indicating known signal transduction components triggered
by TG and PMA treatment (bold), and the order in which tests were conducted (red). (B) Flow chart
illustrating the order of follow-up assays employed to identify MMOA of compounds, and the results of those
experiments.

3.2.5 Testing for inhibition of [Ca2+]i increases
To assess effects on intracellular [Ca2+] (Figure 10), a calcium sensitive dye Fura-2 was used to
load TALL cells. The excitation spectral shift due to intracellular calcium level increase results in
a ratio increase of the dye fluorescence when excited with two different wavelengths. To obtain
information about any potential compound fluorescence and avoid their influence on our ability to
measure intracellular calcium level, we measured the fluorescence of substance-containing
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solutions at 340 and 380 nm excitation prior to adding Fura-2 loaded cells. We then dispensed
Fura-2 loaded cells into the wells and incubated them for 15 min with test substances. We
measured fluorescence at 340 and 380 nm excitation to estimate resting [Ca2+]i levels, then
stimulated cells with TG and measured fluorescence again after 50 min, a time point at which
[Ca2+] elevations depend entirely on Ca2+ influx. We found that 8 of the substances that blocked
lytic granule exocytosis had sufficiently high fluorescence at 340 and/or 380 nm excitation that we
were not able to acquire meaningful Fura-2 signals from cells treated with them. Of the substances
with sufficiently low fluorescence that we could acquire Fura-2 signals, 15 inhibited increases in
the Fura 340:380 ratio by 50% or more. We retested the highly fluorescent substances with the
related dye Fura-Red in flow cytometry, because this dye has the same Kd for calcium as Fura-2
but different spectral characteristics. We loaded cells with Fura-Red, then treated them with
substances for 15 min at 37 °C. Half of the substance-treated cells were stimulated with TG+PMA,
and half were left unstimulated. Samples were analyzed 50 min later. We found that 6 out of the
8 substances decreased the Fura-Red fluorescence of unstimulated cells in at least 1 of the trials,
an effect that could be an artifact related to leakage of the dye from cells or that could reflect
elevation of resting calcium levels. Because these possibilities cannot be distinguished with a
single wavelength indicator, we were able to measure with confidence only the blocking effects
of 2 substances, neither of which inhibited calcium signals >50%. Figure 10B plots the percent
inhibition of LAMP responses versus the percent inhibition of Fura signals for substances that
decreased exocytosis by >50% (filled squares). The 6 substances for which we could not reliably
measure effects on [Ca2+]i with Fura-2 or Fura-Red were not pursued further.

47

Figure 10 Measuring effects of compounds on calcium influx.
(A) Pseudo color representations of Fura-2 ratios prior to (top) and after (bottom) TG stimulation. Black
indicates wells for which fluorescence measured prior to the addition of cells was sufficiently high that ratios
could not be acquired. The leftmost and rightmost columns contain DMSO-treated cells. Half of these wells
were stimulated, whereas half were left unstimulated. The color scale used to display data (indicated to the
right) ranges from a ratio of 0.04 (purple) to 0.5 (red). (B) Filled squares plot the inhibition of LAMP
responses as a function of the inhibition of the Fura-2 signal for all test substances that inhibited exocytosis
>50% in the experiments shown in Figure 8. Open circles are plots of LAMP responses versus inhibition of
Fura-2 signals caused by varying the concentration of extracellular Ca2+, normalized to the responses at
2 mM Ca2+. The solid curve is a fit of a sigmoidal function to the data in the open circles. The dashed lines
outside the solid curve represent 99% confidence bands for the fit. The straight lines denote 50% levels for
Fura-2 and LAMP inhibition, respectively.

Overall, 15 of 48 exocytosis-inhibiting substances blocked Fura signals by >50% (Figure
10 and Table 1), a level that we thought was appropriate to use as a cutoff to discriminate
compounds likely to work by blocking Ca2+ increases [all hits are listed by their SIDS, and
information

about

them

can

be

found

by

searching

PubChem

Substance: http://www.ncbi.nlm.nih.gov/pcsubstance]. To confirm that this level of inhibition of
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Ca2+ mobilization is sufficient to block exocytosis, we measured Fura-2 ratios and lytic granule
exocytosis while varying extracellular Ca2+ from 0 to 2 mM (Figure 10, open circles). We plotted
the relative amount of exocytosis at each concentration of Ca2+ versus the Fura-2 ratio we
measured, allowing us to estimate the dependence of granule exocytosis on Fura-reported
measures of intracellular [Ca2+]. Inhibiting the increase in Fura ratios by 50% or more reduced
lytic granule exocytosis by >50%. Thus, we considered compounds that block exocytosis by >50%
but inhibit Ca2+ increases <50% as likely to have an alternate MMOA.
Table 1 Summary of MMOA Testing for confirmed inhibitors from MLSMR screen.

% Inhibition
Substance
ID
(PubChem)

LAMP

Calcium inhibitors
24817911
101
22417005
100
51090459
100
17408817
100
92764822
100
49673940
100
92764425
99
49721823
99
4246714
99
49714966
99
99495188
98
51089860
98
26728166
73
26728904
70
99456627
56
MAPKK inhibitors
3713060
100
24810923
99
124755744
95
26727153
95
56324549
95

Orthogonal
BLT

91
95
91
90
81
96
88
97
94
88
86
67
63
68
68

Calcium
ERK
CaN
p-ERK
by
Phosphorylation activity activity
Fura-2
59
78
69
63
67
91
57
76
116
79
70
51
91
80
81

99
80
76
92
55

84
79
51
66
87
49

17414945
89
72
99359838
78
61
Calcineurin inhibitor
92764285
100
97
Inhibitors of more than one pathway
14737268
85
73
124755743
94
64
24840307
98
83
99359840
60
45
124755736
95
74
24815073
81
51
Inhibitors with unknown MMOA
7977862
93
89
49677461
87
52
49665798
85
67
103060008
83
77
17387000
80
68
103159345
79
54
103073958
70
63
103074366
53
64
103075418
53
41

67
53
100
18
37
27
20
38
42

40
37
36
35
28
12

16
0
0
13
6
14

0
0
39
23
0
4
32
40
11

17
0
0
0
38
0
0

0
0
0
0
0
0
0

0
0
0
0
0
0
0

0

0

0

3.2.6 Testing for Effects on PKC and Activation of ERK MAP Kinases
We next tested compounds whose inhibitory effects on granule exocytosis were unlikely due to
their effects on calcium rise in cell assays that measure PKC activity and the activation of ERK
using immunocytochemistry (Figure 11A). Cells were incubated with test substances before
treated with PMA to activate PKC, and then they were fixed, permeabilized and stained for
intracellular kinases. To test for PKC activity, active PKC substrates were measured, and
simultaneously to test for MAPKK activity, p-ERK was measured using different fluorophoreconjugated secondary. As a control, we treated cells with the compound Ro31-8220, which blocks
PKC and thus PMA-stimulated activation of MAPKKs103. Ro31-8220 inhibited PKC substrate
phosphorylation by 82% and ERK phosphorylation by 95%. Seven of the exocytosis-blocking
compounds tested inhibited ERK phosphorylation by >50%, but none significantly reduced the
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fluorescence intensity of anti-phospho PKC substrate staining (see Table 1). We conclude that 7
compounds likely inhibit granule exocytosis by inhibiting MAPKK activation downstream of PKC.
3.2.7 Testing for Effects on Calcineurin Activity
We tested the effects of substances whose effects on exocytosis were not due to effects on Ca2+,
PKC, or ERK for their ability to inhibit the activity of the Ca2+-dependent phosphatase calcineurin,
which is required for granule exocytosis. To measure calcineurin activity, we used a genetically
encoded reporter construct151 based on the transcription factor NFAT, the best-known calcineurin
substrate. Because NFAT is highly phosphorylated in resting cells, dephosphorylation resulting
from calcineurin activity increases the reporter construct’s apparent mobility on SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) gels from ~125 kD to ~110 kD. Four
sets of gels and transfers were required to run all of the samples; Figure 11B is a montage of the
results (see legend for details of its assembly). In unstimulated cells (column 1), immunoreactivity
was present as 2 bands. As expected, stimulation of cells caused a shift in the pattern of
immunoreactivity to a single band of low molecular weight (column 2). Treatment of cells with the
calcineurin inhibitor cyclosporin A prior to stimulation caused immunoreactivity to shift exclusively
to the high-molecular-weight form (blot 4, column 5). One of the substances we tested, SID
92764285 (blot 3, column 7), completely blocked the shift of the sensor to lower molecular weight,
resulting in a single band of high molecular weight, identical to the effect of cyclosporin A. Other
substances were without apparent effect.
3.2.8 Testing Effects on ERK Catalytic Activity
Last, we tested whether compounds for which an MMOA had not yet been determined blocked
the catalytic activity of ERK (Figure 11C), because this possibility was not excluded by our
experiments with the phospho-ERK antibody, which detects activation of ERK by upstream
MAPKKs. We used cyto-EKAR152, a genetically encoded sensor of ERK activity that contains the
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phosphorylation site of Cdc25c and an ERK docking motif (Figure 11C). We used an anti-phospho
Cdc25c antibody to detect activity. In unstimulated cells, increasing expression of the sensor (as
detected by YFP fluorescence) was accompanied by higher levels of anti-pCdc25c staining.
Stimulating cells with TG+PMA increased anti-pCdc25c staining specifically in the YFP-positive
cells (Figure 11Ci). This increase in anti phospho-Cdc25c staining was inhibited when cells were
treated with the PKC inhibitor Ro31-8220 (Figure 11Cii), a result consistent with the involvement
of PKC activation in activating ERK. We found that none of the compounds inhibited the increase
in anti-pCdc25c staining by >30%, whereas Ro31-8220 blocked by 83%. This suggests that no
compound is likely to block lytic granule exocytosis solely by inhibiting ERK catalytic activity.
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Figure 11 Testing the effects of compounds on PKC and MAPKK activity, NFAT dephosphorylation, and
ERK catalytic activity.
(A) Histograms of anti-phospho PKC substrate antibody staining (left) and anti-phospho ERK staining
(right) are shown for unstimulated control cells, stimulated control cells, cells treated with Ro31-8220, and
cells treated with SID 56324549, 1 of 7 substances (see Table 1) that we conclude inhibit exocytosis by
blocking MAPKK activity. (B) Western blotting to assess calcineurin activity was performed on control and
compound-treated lysates from cells transfected with CANAR. The image displayed is a montage. Each
row is from a single blot. Columns corresponding to molecular weight standards have been digitally
removed, and lanes to their right have been moved horizontally to the left. In each row, samples in column
1 are from unstimulated DMSO-treated cells, and samples in column 2 are from DMSO-treated cells
stimulated with TG+PMA. In blot 4, the sample in column 5 was prepared from cells treated with the
calcineurin inhibitor cyclosporin A, which serves as a positive control, whereas the sample in column 4 was
treated with Ro31-8220, serving as an additional negative control. Note the single experimental sample
(blot 3, lane 7) with high-molecular-weight immunoreactivity corresponding to inhibition of calcineurin. (C)
Flow cytometry was performed on EKAR-transfected cells to assess ERK catalytic activity. (i) Contour plots
of anti-phospho Cdc25C staining intensity versus yellow fluorescent protein (YFP) fluorescence for
unstimulated control cells (top) and for cells stimulated with TG+PMA (bottom). The vertical line indicates
the cutoff that was used to gate YFP-positive cells. (ii) Histograms of anti-phospho Cdc25C staining
intensity for YFP-positive cells from the samples shown in (i), and also for stimulated cells treated with the
positive control Ro31-8220 and with a test substance, SID 16952891. Stimulation with TG+PMA causes a
shift to higher anti-phospho Cdc25c fluorescence intensity that is inhibited by Ro31-8220.

3.2.9 Two compounds were obtained from powder and their activities were confirmed
Sixteen compounds did not inhibit a single pathway tested by >50%. Eight of those, however,
exerted effects on multiple pathways that, although separately of insufficient magnitude to account
for the block of granule exocytosis, could be imagined to exert summed effects large enough to
inhibit release. The compounds with significant multiple inhibitory effects are detailed in Table 1.
Because we know relatively little about how varying the strength of the different signals affects
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exocytosis, it is difficult to determine whether the effects of these compounds on known MMOAs
completely account for their ability to block exocytosis or whether they have additional effects.
Our choice to use a relatively high concentration of compounds for MMOA testing may play a role
in generating cases of apparent multiple activities. The final 8 compounds had, however, summed
inhibitory effects that seemed unlikely to be of sufficient magnitude to account for blocking.
To develop novel inhibitors into molecular probes that could be used to identify their binding
partners in cells, we obtained powder resupplies for two of the novel inhibitors with novel MOA
from Chembridge Corporation (San Diego, CA): SID7977862 and SID103159345. Compound
powders were reconstituted with anhydrous DMSO and tested in LAMP assay to confirm their
inhibitory activity. Both showed >75% inhibitory at 30 uM on cell granule exocytosis when
stimulated with TG and PMA (Figure 12 and Figure 13). Dose responses of compounds showed
IC50 within micromolar range (4.6uM for SID7977862 and 6.9uM for SID103159345). To confirm
the compounds do not affect known signaling events from powder resupply, each compound was
subject to all the mechanism testing assays. Consistent with previous results, two compounds
from powder resupply did not block intracellular calcium rise, ERK activity or calcineurin activity.
We next tested the cytotoxicity of compounds using PrestoBlue reagent (Life Technologies,
Carlsbad, CA), which could be reduced by metabolically active cell and show a fluorescence
change. In Figure 12D, a standard curve of cell number was used to compare compound- and
DMSO-treated samples. When cells were treated with 100uM SID7977862 for 1.5 hours, a much
higher concentration than its IC50, there was no change in live cell number. In Figure 13D, dose
responses of SID103159345 was carried for the incubation time of 1.5 hours or 24 hours.
Prestoblue was added in the last one hour. Although higher concentrations (30 and 100uM) at 24
hours resulted in cell death, there is no dose dependent cell killing at 1.5 hours, the usual time
span of LAMP assay. In conclusion, neither compound had acute toxic effects on cells within 1.5
hours, so their inhibition on lytic granule exocytosis is unlikely to be a result of killing the cells.
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Figure 12 Confirming the effects of SID 7977862 from powder.
(A) Structure of SID 7977862. (B) Histograms of anti-LAMP fluorescence for unstimulated control (blue),
stimulated control (red), and SID 7977862–treated cells. Experiment was conducted in ES without 2% BSA.
(C) Dose–response testing using LAMP externalization. Data are the average of 2 separate experiments
conducted in ES. IC50=4.6 uM, hill rate=2. (D) Assessing toxicity using the PrestoBlue reagent (Life
Technologies, Carlsbad, CA). Cells were pretreated with 100 µM SID 7877962 (triangle, 250,000 cells) or
DMSO (circles, different numbers of cells), and PrestoBlue fluorescence was measured. Different numbers
of DMSO-treated cells treated with Triton X-100 (open circles) were used as an additional positive control.
(E) Testing for inhibition of calcium influx. (F) Measuring effects on ERK phosphorylation. Experiments were
conducted as in Figure 11A. (G) Measuring effects on ERK catalytic activity. Experiments were conducted
as in Figure 11C. (H) Testing for inhibition of calcineurin. Experiments were conducted essentially as
in Figure 11B.
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Figure 13 Confirming the effects of SID 103159345 from powder resupply.
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(A) Structure of SID 103159345. (B) Histograms of anti-LAMP fluorescence for unstimulated control (blue),
stimulated control (red), and SID 103159345-treated cells (green). Experiment was conducted in cell culture
medium. (C) Dose response testing using LAMP externalization. Data are representative of two
independent repeats in cell culture medium. IC50=6.9uM, hill rate=1.3. (D) Dose response testing shortterm and long-term cytotoxicity of SID 103159345 using PrestoBlue reagent. Cells were pretreated with
DMSO or different concentrations of the compound for 30 minutes or 24 hours in culture medium, before
PrestoBlue was added and incubated for 1 hour, and the fluorescence was measured. (E) Testing for
inhibition on calcium influx. Fura-2 loaded TALLs were incubated with DMSO or 30uM of SID 103159345
for 30 minutes, before 2uM TG was added and a kinetics reading of Fura-2 fluorescence was measured.
(F) Measuring effects on ERK phosphorylation. (G) Measuring effects on ERK catalytic activity. (H) Testing
for inhibition of calcineurin.

3.2.10 Structure-Activity Relationship Study of SID7977862
To obtain structure-activity-relationship of SID7977862, 8 analogs were ordered from ChemDiv
Corporation and 21 analogs were synthesized by University of Kansas Center of Excellence in
Chemical Methodologies and Library Development (Table 2). Except for 1-(4-Methoxyphenyl)2,5-pyrrolidinedione (analog 1), all other analogs showed >90% inhibitory at 30uM. Analog 1 is a
partial structural breakdown of the parent compound, and its loss of inhibition indicates that
keeping the sulfide bond in the core structure is important for its inhibitory activity. All other
analogs are substituted with different chemical groups at R1 and R2 positions, and 16 analogs
showed >75% inhibition at 1uM.
Dose responses were carried out for all analogs to test their potency in blocking lytic granule
exocytosis. When polar substitutions are introduced to R1 position, the presence of an orthohydroxyl group decreased analog potency (analogs 2-6). Yet this decrease was reversed when a
para-bromobenzene is introduced to R2 position (analog 5). Next, we examined what effects other
polar substitutions on R2 position could have on the analog potency. When R1 position remains
the same as the parent compound, the presence of 3,4-dichloro-benzene on R2 greatly increased
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the potency (analog R), which turned out to be the most potent analog among all others, showing
an IC50<0.03uM and over 150-fold increase over the parent compound (IC50=4.6uM). Two other
analogs sharing the same R2 substitution as analog R showed slightly lower potency when R1
was changed (para-chlorobenzene for S and para-methylbenzene for T). When the number of
chlorides on R2 benzene ring is reduced to one, analog potency is decreased (analogs E-H), yet
it is still higher than the parent compound. In comparison, a benzene ring for R2 resulted in a loss
of potency regardless of the functional groups for R1 (analogs A-C), and this suggests that polar
substitutions on R2 are important for efficient inhibition. In conclusion, a polar substitution on R2
with a nonpolar substitution on R1 could improve analog potency.
Next we wanted to know how the analog inhibitory activities compare to their cytotoxicity. To test
long-term cytotoxicity, cells were incubated with analogs at different concentrations for 24 hours,
before PrestoBlue reagent was added and fluorescence was measured. Culture medium was
used to ensure cell survival for 24 hours. To compare these results to LAMP assays, dose
response testing LAMP externalization was redone in culture medium. Surprisingly, most analogs
showed improved IC50 in culture medium compared to Ringers solution supplemented with 2%
bovine serum albumin, likely a result of serum protein-assisted uptake. However, there is no
apparent correlation between TC50 and IC50 of analogs. Analog R had the highest ratio between
TC50/IC50, indicating an improvement of therapeutic window for drug development. However,
within the scope of this study, none of the analogs were intended to be used as drug candidates,
and compound cytotoxicity is not the primary concern in probe development.
To examine lipophilicity of analogs, logP value was calculated by Molinspiration Cheminformatics
Website based on SMILES. Some analogs had values close to 5 (analogs S and H), and others
were within the range of 2-4. A high value of logP indicates lipophilic compound and usually poor
absorption. All analogs are within the desirable range according to Lipinski’s rule-of-five136.
Another parameter, LiPE153, was used to examine the ligand-lipophilic efficiency of analogs, which
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takes into account the analog potency in relative to its lipophilicity. A high LiPE indicates high
quality of compounds, and analog R had the highest value among others.

Table 2 Structure activity relationship (SAR) study of SID7977862

MW

IC50 in
2%NR2

IC50 in
culture
medium

TC50 in
culture
medium2

LogP3

LiPE4

SID7977862

381

4.58

1.15

3.92

2.6

2.8

2

435

7.11

2.3

0.82

3.2

2.0

3

367

16.79

3.74

4.5

2.3

2.5

4

381

7.24

1.05

2.9

2.7

2.4

5

446

1.99

1.24

1.72

3.1

2.6

6

439

9.8

4.55

2.15

2.8

2.2

7

365

2.03

3.52

1.33

3.0

2.7

8

351

9

4.98

3.48

2.6

2.5

Analog
designation1

R1

R2
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A

351

3.76

3.30

1.85

2.6

2.9

B

365

10.50

16.48

2.17

3.0

2.0

C

381

13.22

14.85

1.96

2.6

2.3

D

386

0.42

0.22

1.15

3.2

3.1

E

420

0.50

0.30

1.52

3.9

2.4

F

400

0.65

0.17

1.70

3.7

2.5

G

416

1.01

0.63

2.05

3.3

2.7

H

455

1.03

0.30

2.32

4.5

1.5

I

365

0.70

0.28

1.47

3.0

3.2

J

400

0.78

0.62

1.77

3.7

2.4

K

379

0.77

0.13

2.33

3.5

2.7

L

395

1.69

0.30

3.28

3.1

2.7

M

381

0.40

0.49

1.44

2.6

3.8

N

416

0.55

0.27

1.45

3.3

3.0

O

395

0.62

0.39

1.48

3.1

3.1

P

411

1.24

0.88

1.88

2.7

3.2

62

Q

450

0.73

0.31

1.57

3.9

2.2

R

420

<0.03

0.12

0.53

3.8

4.0

S

455

0.12

0.16

0.91

4.5

2.4

T

434

0.24

0.14

0.97

4.3

2.3

U

450

0.28

0.23

1.26

3.9

2.6

1

205

0.2

N/A

1Powder

No inhibition

resupply of the parent compound was from Chembridge Corporation. Analogs 1-8 were purchased

from ChemDiv Corporation, and analogs A-U were synthesized by the University of Kansas Center of
Excellence in Chemical Methodologies & Library Development.
2Dose

response parameters were from fits to the Hill equation. Compound concentrations ranged from 0.1-

30uM (1-8) and from 0.03-10uM (A-U). Dose response testing was performed twice in 2%NR, and once in
complete culture medium. Compound cytotoxicity testing was performed once. Cells were treated with
analogs for 24 hours in complete culture medium.
3LogP

4LiPE

value was predicted by Molinspiration Cheminformatics based on SMILES.
was calculated as pIC50-LogP

3.3 Discussion
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Our initial HTS campaign worked essentially as anticipated. Using clustered cytometers, we were
able to miniaturize the assay to a 1536-well format, resulting in a substantial decrease in the
amount of reagents—primarily, cells and antibody—required. Overall, we had 161 confirmed hits,
a number that seemed low to us considering the complexity of the cellular phenotype we were
interrogating. This hit rate, however, appears consistent with results from the most directly
comparable screening campaign conducted on the MLSMR that we were able to identify. That
screen looked for inhibitors of thrombin-stimulated platelet dense granule release using luciferase
to detect adenosine triphosphate release accompanying granule exocytosis. Primary screening
[assay ID (AID) 1663] of 302,517 compounds identified 661 that were active. Subsequent
confirmation (AID 1189) and counterscreening for compounds that inhibit luciferase activity (AID
1891) yielded ~250 active compounds that inhibited platelet granule release. This effort resulted
in the discovery of a probe that targeted protease-activated receptor 1154. Surprisingly, given what
we would anticipate would be many similarities between exocytosis in CTLs and platelets,
including the involvement of signaling pathways like PKC and calcium influx, as well as the
involvement of SNARE (soluble N-ethylmaleimide-sensitive factor activating protein receptor)
proteins155,156, there was only 1 compound active in that screen that we also found to be active.
SID 17414945, which we found blocked lytic granule exocytosis and MAPKK activation, inhibited
lytic granule exocytosis with an EC50 of ~0.3 µM, but it apparently inhibited platelet granule release
much less potently, with an EC50 of 19 µM. We cannot account for these results. It seems unlikely
to result from our use of a cell line, because TALL-104 cells recapitulate key features of CTL
function. A second potentially comparable phenotypic screening campaign used a luciferase
reporter construct to look for inhibitors of NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) activation in Jurkat cells stimulated with PMA and ionomycin. That effort
identified 735 confirmed active compounds (initial screen in AID 435003, and confirmation in AID
435020). Although the hit rate in that screening campaign was ~5 times higher than ours, the
phenotype interrogated includes the entire transcriptional and translational apparatus required to
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generate the reporter, together with the proteins required for ubiquitination157, which may account
for the larger number of hits.
One of our hypotheses was that a phenotypic cellular endpoint assay followed by appropriately
designed mechanism testing could be used as a high-content screen for important targets.
Consistent with this idea, our experiments revealed a number of substances that act on important
pathways, including 15 inhibitors of calcium influx, 7 MAPKK inhibitors, and 1 calcineurin inhibitor.
Were any of these activities defined in previous screens of the MLSMR? Determining this is,
unfortunately, not straightforward and was not facilitated by the structure and query capabilities
of the PubChem web interface. To the best of our knowledge, no screen has looked for inhibitors
of calcium influx in nonexcitable cells. We were, however, able to identify 3 screens of >100,000
MLSMR compounds conducted on calcium-permeable channels and 5 conducted on potassium
channels. Blockers of these channels could be envisioned to block calcium or potassium channels
in CTLs, although this is by no means certain. None of the substances we defined as inhibiting
calcium signals were reported to block calcium-permeable CAV3 (confirmation in AID 489005),
TRPC4 (confirmation in AID 2247), or TRPC6 (confirmation in AID 488961) channels. One
substance that blocked Fura-2 signals, SID 49721823, was reported to inhibit KCNK9 potassium
channels (confirmation in AID 492992). KCNK9 (also known as TASK-3) channels have been
found in lymphocytes, and inhibitors reduce proliferation and cytokine production158. SID
49677461 blocked lytic granule exocytosis and KIR2.1 potassium channels (confirmation in AID
2032), but it gave inconclusive results in our Fura assays. Similarly, SID 4964129 blocked lytic
granule exocytosis and KCNK3 potassium channels (confirmation in AID 651638), but it also gave
inconclusive results in our Fura assays.
There has been a screen of MLSMR compounds on ERK activation by MAPKKs. That effort (AID
1454) used AlphaScreen technology to assess levels of phosphorylated ERK in lysates of cells
treated with epidermal growth factor. Of the 8 MAPKK inhibitors we found, only 2 appear to have
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been tested in that screen, which tested an earlier version of the MLSMR containing fewer
compounds. Of the 2 substances both active in our assay and tested in theirs, they found SID
24810923 to be inactive, and SID 26727153 gave inconclusive results. We were unable to identify
any screens of the MLSMR that might have been expected to reveal calmodulin or calcineurin
inhibitors. The substance that we found to inhibit NFAT dephosphorylation [SID 92764285, 2chloro-3-(3,5-dimethylmorpholin-4-yl) naphthalene-1,4-dione] was, as expected based on its
chemistry, fairly broadly active in deposited assays, but it had no confirmed effects that suggested
to us possible effects on either calmodulin or calcineurin.
In addition to revealing important actions of compounds on known targets, we suspected that a
screen of lytic granule exocytosis could reveal substances that might work via an unknown
MMOA. This appears to be the case because we identified SID 7977862 and SID 103159345,
both blocking lytic granule exocytosis without inhibiting any of the pathways we tested. Inspecting
the reported effects of this compound does not lead to well-supported hypotheses about its
MMOA. A high-content screen (AID 1381) found that SID 7977862 inhibited dynein motor protein
activity, but whereas dynein has been reported to be involved in reorientation of lytic granules to
the site of contact with target cells159, there is no evidence for dynein involvement in TCRindependent exocytosis. There was a confirmatory assay and a dose response study conducted
for active hits of dynein inhibitors, but SID 7977862 was not included. Furthermore, >1000 other
compounds were active in AID 1381, but none of them inhibited lytic granule exocytosis in our
screen. If dynein were a common target in both assays, we would have expected more extensive
overlap. SID 103159345 was shown to be an inhibitor of isocitrate dehydrogenase 1 (AID
686970), which results in the production of onco-metabolite 2- hydroxyglutarate and is associated
with acute myeloid leukemia160,161. In another assay (AID 743279), it was shown to be an inhibitor
inflammasome signaling. However, inflammasome signaling is activated in antigen-presenting
cells but not CTLs162, it remains unknown how the compound is inhibiting lytic granule exocytosis.
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Examination of the confirmed activities reported in the PubChem database for each of the 6 other
substances for which we were unable to determine a MMOA also failed to suggest plausible
mechanistic hypotheses for any of their actions. In addition to the MMOAs we were able to test,
other possible targets include SNARE proteins and associated components of the exocytic
machinery (see Schwarz et al.163 for a recent review). Note that in preliminary experiments, we
tested the effects of DMSO stocks of all 8 substances with undefined MMOA on CD3-stimulated
interleukin-2 secretion by Jurkat human leukemic T lymphocytes, and we found that all inhibited,
suggesting that each is likely to have broad immunosuppressive activity rather than being a
specific inhibitor of lytic granule exocytosis (J. Doucette and A. Zweifach, unpublished
observations).
Our assay was configured specifically to detect inhibitors. One way we achieved that was the use
of very strong artificial stimulation with TG and PMA. We therefore did not—and did not expect
to—detect enhancers of exocytosis. A recent study with human NK cells screened the Prestwick
Compound Library (PCL) for agents modulating FCGRIII-stimulated lytic granule exocytosis,
integrin activation, and protein synthesis164. This study found 56 inhibitors and 12 enhancers. Our
screen of the PCL2 identified several of the inhibitors they found, including amoxapine,
desloratidine, thimerosol, and zotepine. Differences in assay conditions—particularly protein
concentration in the buffer used—likely account for incomplete overlap of inhibitors.
Despite an emphasis in recent years on target-based approaches, a recent analysis demonstrates
that a majority of first-in-class new drugs released between 1999 and 2008 were discovered by
phenotypic screens121. Our screen of lytic granule exocytosis identified a number of previously
undescribed actions of compounds on known targets that could serve as leads for
immunosuppressants, and it also identified several compounds that may work via an unknown
MMOA. We determined that at least 2 of these have probe-like properties. This confirms that our
phenotypic screen based on lytic granule exocytosis may be a good means of identifying
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immunosuppressive compounds. Furthermore, we suggest that our basic strategy of screening a
complex cellular phenotype that incorporates multiple potential targets and then defining MMOAs
for active compounds may be a useful means of identifying interesting biologically active small
molecules in compound collections.
3.4 Future Direction for novel inhibitors - Target deconvolution using affinity-based
approach
Three approaches for target deconvolution include direct biochemical method (affinity-based
purification and isolation)165, genetic interaction (yeast or mammalian three-hybrid systems)166,
and computational inference method167–169. For the scope of our research, I’ll focus on affinitybased target identification approach.
It is currently in collaboration with Dr. Dennis Wright Lab to develop SID 103159345 into a
chemical probe for affinity-based target identification. The affinity-based method involves
chemical modification of the small molecule ligand by attaching a functional group to the structure
without affecting its activity. The functional group is known as a linker, which could later link the
small molecule to a solid matrix for isolation purpose. If the linker is too short, it could generate
steric hinderance and prevent the ligand to engage the molecular target. If the linker is too long
and hydrophobic, it could result in auto-aggregation or nonspecific binding170. Ideally, the specific
interaction between the ligand molecule and its target ensures only the protein of interest remains
on the column after sufficient washing. The bound protein can be recovered by increasing amount
of ligand and subject to mass spectrometry for protein identification.
Advantages for affinity-based method: it uses cell lysate containing protein complexes, allowing
evaluation of polypharmacology. Also, cell lysate retains the molecular target in its original
conformation including all post-translational modification. Testing small molecule efficacy also
gives information about its toxicity and offers support for its target as druggable. Affinity-based
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approach is the classical way of target deconvolution171. From the earliest insulin receptor
isolation from liver homogenates, to FK506 binding protein identification from lymphocytes,
researchers have relied on the high affinity and specificity of probe to its molecular targets 172,173.
Thalidomide teratogenic effect is also elucidated by affinity-based method174.
The premise for affinity-based method is a high-affinity ligand that binds a relatively abundant
target protein. If the binding is weak, or if the target protein is not abundant, the affinity purification
will not work, as the target protein will be washed away in the process. The washing step also
inevitably generates bias towards highest-affinity interactions. However, physiological interactions
of compounds with proteins often occur at much lower concentration in cellular contexts175.
Higher-affinity probes can be synthesized to overcome the affinity barrier. The binding efficiency
of probe to its molecular target is not determined by the on rate but rather the off rate176.
Dissociation constant is determined by the strength of the compounds. Both our compounds are
general affinity ligands with EC50 within micromolar range, which corresponds to a retention time
of seconds. To improve the probe efficiency, analogs of much higher efficiency need to be
synthesized and tested. If EC50 could be improved to nanomolar range, they become high affinity
ligands and the retention time will be extended to minutes, which represent a manageable length
of time to work with.
Recent advances to overcome the affinity barrier include UV light-induced cross-linking that
covalently links the chemical probe to its binding partner under UV light177,178. It works great for
low-abundance proteins or low-affinity targets. However, UV-clickable chemical probes generate
high, nonspecific background noise due to cross-linking. Also, if the cross-linking is on the
functional group of small molecule probe, it will generate false negative results. Click chemistry
can also be used to covalently bind the probe to its molecular target, such as the use of
cycloadditions of azides and acetylenes179.
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Enriching the relevant protein species can be achieved by pre-purification of samples. Our
phenotypic hits are presumed to be targeting signaling molecules involved in CTL granule
exocytosis. Pre-washing cell lysate with the probe molecule could be carried out to reduce
nonspecific binding. Previously, to identify the binding partner of quinoline drug used to treat
malaria, purine binding proteome were obtained first based on structure similarity to quinone, and
this led to the identification of quinone reductase as a molecular target180.
To verify the on-target binding of the chemical probe, comparison variant such as an inactive
analog of the ligand could be used to indicate nonspecific protein binding181. Competition assays
using excess un-conjugated ligands can also be performed, and they should result in less target
protein binding182. By running the isolation process in parallel with the original probe, the
comparison variant or excess un-conjugated ligands, probe-target protein binding can be
validated. For example, to ensure prohibitin as a true target for melanogenin, a comparison variant
of melanogenin was used and resulted in less prohibitin protein binding 183. A purine derivative
QS11 was shown to bind to the GTPase activating protein of ADP-ribosylation factor 1 and
modulate Wnt/β-catenin signaling through an effect on protein trafficking. The target protein band
disappeared when the affinity column was run in the presence of excess QS11 in a competition
assay184.
Two new approaches that circumvent chemical probe immobilization: thermal/protease stability
shift upon small molecule binding, also known as DARTs (drug affinity responsive target
stability)185, and characteristic shift in retention time upon compound binding, also known as TICC
(target identification by chromatographic co-elution)186. DARTs involves incubating cell lysate with
free ligand molecules and then subjecting them to protease catalytic activity or temperature
increase. The binding of ligand to protein target can stabilize the protein in dynamic equilibrium
towards more stable conformation and therefore protect proteins from degradation or proteolysis.
It has been used to elucidate or confirm ligand-target interaction in cases such as FK50670

Calcineurin, rapamycin-TOR etc. TICC uses HPLC to elute samples and measure protein
concentration in the fractions. When free ligands bind target proteins in treated cells, they cause
a shift in the elution profile of cell lysate (compared to untreated cell lysate) and allow the target
protein peaks to be identified subject to mass spectrometry. It was used to identify methotrexate
with its primary target dihydrofolate reductase, radicicol and sordarin, trichostatin A and
nucleosome remodelling and histone deacetylation (NURD) complex.
Recently, a newly emerged methodology of compound-centric quantitative proteomics has been
applied to reveal protein targets for small molecules187. It combines high-resolution mass
spectrometry with bioinformatics analysis. Cell lysate was treated with compound, but there is no
clickable reaction, allowing bound proteins to be eluted and subject to SDS-PAGE or shotgun
proteomics analysis. Compared to traditional target identification, chemical proteomics is
unbiased and applies to the whole proteome, great for proteins with post-translational
modifications and proteins at their natural expression level. However, it is subject to high
background and gives no indication of compound IC50. It uses two types of labeling to achieve
protein quantification and demonstrate ligand-target protein interaction: metabolic labeling as in
stable-isotope labeling by amino acids in cell culture (SILAC)188 and chemical labeling as in
isotope-coded affinity tag (ICAT)189. SILAC allows sample pooling early in the process, eliminates
quantification errors due to sample handling, but it is limited to immortalized cell lines; ICAT and
iTRAQ can label more versatile sample types, but they rely on peptides to generate labels and
are prone to more variation and less accuracy later in the proteomic workflow.
In conclusion, there are many affinity-based methods that allow for protein target to be identified
with a chemical probe.
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Chapter 4: Enhanced Phenotypic Screen of CTLs Identified Augmenting
Compounds
4.1 Overview
This project modified the CTL assay to achieve submaximal cell activation for detecting
augmenting effects. Results from this project were described in two publications190,191. One more
paper is currently in revision. Immune modulation, especially augmentation by small molecules
(referred to as IMiDs, immune modulatory drugs), is of therapeutic importance in tumors or
cancers, viral or bacterial infections and vaccination adjuvants192–194. A limited number of IMiDs
are available and there is a demand for modulators with novel mechanisms83,195,196. However, the
signaling pathways leading to immune cell activation are not fully understood, making it hard to
devise target-based screens. In the modified assay, anti-CD3 coated beads were used to activate
CTLs in a T cell receptor-dependent manner. The assay was used to screen >300 NPs and >900
small molecules. It led to the isolation and identification of teleocidin A-1 and seven small
molecules with augmenting effects only after prolonged incubation.
In the previous chapter, a CTL-based assay was used to screen for novel immunosuppressants
in a HTS campaign. The assay used small molecules that bypass the TCR to achieve maximal
cell stimulation and granule exocytosis. This worked well for inhibitor screen, however the
maximal stimulation did not leave any room for augmenting effect. In addition, the use of small
molecule stimulants did not interrogate signaling events upstream of IP3 and DAG. In this chapter
we modified the CTL assay so that it is able to achieve submaximal level of CTL activation in vitro.
Submaximal activation is important for the augmentor screen because it leaves room to observe
any augmenting effects. There are two ways of activating CTL submaximally in vitro, target cells
that engage T cell receptor (TCR) and co-receptor on the cell surface, and immobilized anti-CD3
antibodies that engage TCR145. In the first method, target cells would significantly complicate a
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cell-based assay because cytotoxic killing is also affected by the ratio of target:effector197, and
the liquid handling system must be very accurate to achieve the same ratio throughout a plate in
a HTS setting. In the modified assay, I used microscopic dynabeads coated with anti-CD3
antibodies to activate CTLs through TCR engagement. CD3 is the major component of TCR, and
immobilized anti-CD3 can cause TCR to cluster on T cell surface, thus activating CTL as a target
cell would have (Figure 14). Anti-CD3 immobilized to test plates can also achieve TCR
stimulation, but in this case, cells remain attached to the plate and would require a detaching step
prior to flow cytometric measurement. One additional benefit of using dynabeads is that their
binding changes the scatter profile of cells in flow cytometer. This allows us look at both TCRactivated cell response and unstimulated cells in a mixed population. The simultaneous
assessment of compound effects on activated cells and resting cells is one step in multiplexing
the assay towards high-content screening.

Figure 14 Activation of CTL lytic granule exocytosis through TCR engagement by anti-CD3 beads.
T cell receptor becomes clustered and activated when CTL contacts anti-CD3-coated bead. Lytic granules
reposition near site of contact and undergo exocytosis. As a result, LAMP is externalized to cell membrane
and can be detected by fluorescent anti-LAMP present in extracellular solution.

4.2 Results
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4.2.1 Light scatter profile allows for the identification of cells bound by beads
In order to achieve a submaximal level of cell stimulation that would allow for augmenting
compound screening, we replaced small molecule stimulants with antibody coated beads. Cell
samples treated with beads showed different side scatter profiles on flow cytometer, and this
feature allowed us to differentiate the population of cells bound by beads from cells left unbound
from the same sample (Figure 15A). Increasing the ratio of bead:cell resulted in new populations
with higher side scatters, reflecting the increased granularity of multiple beads bound to one cell.
Since the dynabeads are made of supramagnetic material that likely has autofluorescence, we
examined the fluorescence intensity of bead-treated cells in multiple channels and found that the
it is maximal in FL3 (Ex488/Em670LP on FACS Calibur). In Figure 15B, cells bound by beads
(black) were well correlated to bead alone (blue) for their fluorescence intensity in FL3 channel.
In fact, the linear relationship between SSC and FL3 fluorescence remains the same when
examining cells treated with more beads (Figure 15B, right). Therefore, we devised the following
gating strategy to obtain cells bound by different number of beads: first using FSC-SSC profile to
obtain two separate populations (no-bead and one-bead population), then using FL3 fluorescence
to refine the two populations. Because dynabeads are autofluorescent in multiple channels (data
not shown), we need to compensate for their fluorescence contribution in other channels. By
treating them as a separate fluorophore, we were able to generate the compensation matrix that
removes their autofluorescence (<20%) in FL1 (Ex488/Em530) and FL4 (Em635/Em661)
channels. All histograms and calculations shown in this chapter are based on compensated flow
data.
To ensure that anti-CD3 bead binding can activate cells, we measured intracellular calcium level
and PKC activation following bead treatment, two signaling events necessary for granule
exocytosis. As a negative control, anti-CD8 coated beads were used to treat cells, since CD8
molecules lack intracellular ITAM domains for PLC activation. We hypothesized that if anti-CD3
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beads can activate cells through ITAM domains, and given that bead-bound cell population can
be gated on flow files based on scatter profile and fluorescence in FL3 channel, we should see
cell activation in only anti-CD3 bead-bound population but not anti-CD8 bead-bound population
or unbound cell population in anti-CD3 bead-treated sample. In Figure 15C, cells loaded with
calcium sensitive dye were treated with beads and measured on flow cytometer at indicated time
points, and only anti-CD3 bead-bound cell population showed an increase in intracellular calcium
level upon bead binding. Unbound cells from the same anti-CD3 bead-treated sample did not
show calcium level rise. Anti-CD8 beads did not activate T cells as there was no increase in
calcium level whether cells were bound by beads or not. The level remained the same through
the time course as the untreated samples (black). To test for PKC activation, cells were treated
with different beads, fixed and permeabilized, and then stained for intracellular kinase using
phospho-specific antibodies against p-ERK, a downstream signaling molecule of PKC activation.
As shown in Figure 15C middle panel, cells bound by anti-CD3 beads showed an increase in pERK level but not cells bound by anti-CD8 beads. In anti-CD3 bead treated sample, cells that
were never bound by a bead did not show any ERK phosphorylation. Finally, the level of granule
exocytosis was assessed for cells treated with beads. Anti-LAMP was used to detect LAMP
externalized onto cell membrane in cells treated with either beads without permeabilization. In
anti-CD3 bead-treated cell sample, the one-bead population showed a submaximal increase in
cell response, whereas the no-bead population from the same sample showed no response. In
anti-CD8 bead-treated cells sample, neither population showed any exocytosis (Figure 15C
bottom). In conclusion, anti-CD3 beads can bind to cells and activated exocytosis through both
calcium signaling and PKC activation.
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Figure 15 Changes in scatter allow detection of cells bound to antibody-coated beads.
(A) Plots of forward scatter vs. side scatter from cells (top) and cells treated with increasing amounts
(middle, bottom) of anti-CD3 beads. Arrows indicate cells alone and cells bound by beads from a mixed
sample. (B) Left: Plot of FL3 fluorescence vs. side scatter of two samples overlaid: cells + anti-CD3 beads
(black) and beads alone (blue). The bead sample includes some doublets. Right: Plot (linear scale) of side
scatter vs. FL-3 fluorescence for the population shown in A, bottom. (C) Top: Plot of Fluo-4 fluorescence
vs. time cells bound to anti-CD3 beads (red triangles), unbound cells from the same population (red open
triangles), cells bound to anti-CD8 beads (blue squares), and unbound cells from the same population (blue
open squares). Untreated cells are shown in black circles. Middle: Anti-phospho-ERK staining from beadbound and bead-free cells from populations to which anti-CD3 or anti-CD8 beads were added. Bottom:
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Anti-LAMP staining from bead-bound and bead-free cells from populations to which anti-CD3 or anti-CD8
beads were added. Experiments were representative of more than three independent repeats.

4.2.2 Design of bead assay for immune modulator screening
Anti-CD3 beads activate cells through TCR, whereas small molecules TG and PMA can bypass
TCR and activate downstream signaling events. We hypothesized that in the presence of small
molecule stimulants TG and PMA, CD3-triggered response could be increased to a higher level.
To assess the level of granule exocytosis in these conditions, anti-CD8 and anti-CD3 beads were
used to treat cells in the presence of TG and/or PMA. As shown in Figure 16A, cells responded
to anti-CD3 bead (red) binding but not anti-CD8 bead (blue) binding as previously observed.
When PMA is added together with anti-CD3 beads to cells (orange), cells bound by beads showed
an increase in LAMP externalization, whereas cells not contacted by beads remained
unstimulated. Since PMA can activate PKC, and kinase activation alone is not enough to trigger
granule exocytosis, cells from no-bead population did not show any response. In one-bead
population, cells were activated through TCR, and with the addition of PMA, kinase signaling was
maximized and therefore generating a higher response compared to anti-CD3 beads alone. When
TG is present in anti-CD3 bead-treated samples (green), there is a slight increase in granule
exocytosis level in one-bead population, and no-bead population also showed increased level of
exocytosis. TG can trigger calcium release, and increased calcium can activate conventional PKC
isoforms. When both TG and PMA are present (pink), cells responded maximally in both onebead and no-bead population, supporting our hypothesis.
With anti-CD3 bead-stimulated response serving as a baseline for screening, we expect to
observe three kinds of immune modulatory actions: immune inhibitors that decrease the level of
granule exocytosis when TCR is activated, and anti-CD8 bead-treated sample serve as a control
for this type of modulation; immune enhancers that increase the level of granule exocytosis in
one-bead population but not no-bead population, and anti-CD3 bead+PMA serve as a control for
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this type of modulation; immune stimulators that increase the cell response in both one-bead and
no-bead populations, and anti-CD3 bead+TG or anti-CD3 bead+TG+PMA serve as a control.
To assess the plate uniformity and assay robustness, we tested cells treated with beads in
different conditions on 96 well plate (Figure 16B). Each column of the plate contained wells treated
with the same conditions in repeats, and the plate was incubated with anti-LAMP with constant
rotation for one hour, before being fixed with PFA and sampled on flow cytometer. The cells were
not washed prior to sampling, because our prior experience with LAMP assay showed that
fluorescence signal by LAMP staining acquired on flow cytometer was robust enough without
washing away the excess antibody present in the solution142. There is no apparent drift in cell
activity level over the course of sampling, indicating a stable baseline for LAMP measurements.
We tested a total of three control plates, each on a different day. A standard statistical method Z’
factor was used to assess the assay robustness, and repeated plate testing yielded Z’ > 0.5
between anti-CD8 bead- and anti-CD3 bead-bound cell samples, as well as between anti-CD3
bead-bound cells and anti-CD3 bead+TG+PMA, indicating excellent assay quality for both
inhibitor and augmentor screening.

Figure 16 Anti-CD3 beads trigger submaximal exocytosis facilitating a robust plate-based assay format.
(A) Histograms of anti-LAMP fluorescence for the conditions indicated. (B) Plots of the geometric mean of
anti-LAMP fluorescence from a 96-well plate containing cells and anti-CD8 beads (circles), anti-CD3 beads
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(squares), anti-CD3 beads + PMA (diamonds), and anti-CD3 beads + TG + PMA (triangles). Responses
from cells assessed as bound to beads by scatter are shown on top. Responses from cells that are not
bound to beads are on the bottom. Experiments were conducted more than three times. TG and PMA were
used at final concentrations of 2 µM and 100 nM, respectively.

4.2.3 Bead assay can detect inhibitory compounds of granule exocytosis
In our previous study, a total of 161 inhibitors of granule exocytosis were identified from screening
the MLSMR library. We made use of the cherry-picked 75 inhibitory hits from the primary screen
and tested their effects on cells stimulated by anti-CD3 beads. Not all of the inhibitors were
confirmed on retesting with TG+PMA stimulation (Figure 8), so we expected to see a wide range
of compound activity in bead assay. Shown in Figure 17A is a comparison of compounds effects
on cells in response to anti-CD3 bead stimulation between LAMP assay and BLT esterase assay,
a standard measurement of granzyme release from lytic granule exocytosis. By conducting the
two assays in a combined procedure on the same cells as previously described, we hope to
minimize the difference between testing and offer a direct comparison between the two
measurements. The dotted line indicates linear regression fit of data, and it shows a good
correlation between LAMP measurement and the esterase release measurement in bead
stimulated samples (r=0.88). When collecting supernatant for esterase assay, there was no
differentiation between esterase released from bead-bound cells and random release from
unbound cells. Whereas all LAMP measurements were cells bound by beads from gated samples.
This could explain some discrepancies in data.
We next compared cell response to anti-CD3 beads and TG+PMA using LAMP assay to assess
how the modified assay performs (Figure 17B). We found that the two assays correlate for most
compound activities (r=0.77). Some inhibitory compounds showed higher % inhibition in TG+PMA
stimulated cells than anti-CD3 bead stimulated cells, probably due to the more upstream signaling
events initiated by anti-CD3 bead binding. Similar result is obtained when comparing compounds
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effects on cells stimulated with anti-CD3 beads vs TG+PMA using BLT esterase assay (Figure
17C, r=0.72). We concluded that bead assay can reliably detect inhibitory compounds based on
LAMP staining, and BLT esterase served as an orthologous biochemical testing.
Finally, we chose two inhibitory compounds (SID 7977862 and SID 103159345, Figure 12 and
Figure 13) that were confirmed from powder resupply to test in the bead assay, and compared
their dose response curves to LAMP assay with TG+PMA stimulation (Figure 17D). Both
compounds block lytic granule exocytosis without affecting any known signaling pathways, and
prior dose responses conducted with TG+PMA stimulation indicated that SID 7977862 is more
effective. In anti-CD3 bead-treated samples, SID 7977862 showed similar dose-dependent
effects on cell response, with the IC50 lower than the other compound. Dose responses obtained
by using different types of stimulation yielded similar results for each compound, indicating good
correlation between the bead assay and TG+PMA stimulation.
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Figure 17 Detection of exocytosis-inhibiting compounds.
(A) Plot of inhibition of anti-LAMP fluorescence vs. inhibition of BLT esterase release for cells that were
treated with 75 compounds from the NIH’s MLSMR, 48 of which were confirmed to inhibit lytic granule
exocytosis, then stimulated with anti-CD3 beads. All compounds were tested at a final concentration of 30
µM. Numbers are compound identifiers. (B) Plot of the inhibition of anti-LAMP responses measured from A
vs. inhibition of responses measured previously for cells stimulated with TG + PMA. (C) Plot of the percent
inhibition of BLT esterase activity for cells stimulated with anti-CD3 beads vs. percent inhibition of BLT
esterase activity measured previously for cells stimulated with TG + PMA. For A–C, data represent the
mean of three independent experiments conducted with anti-CD3 beads and four experiments conducted
with TG + PMA. Lines are regressions, fit using Minitab software. (D) Dose–response curves for inhibition
of anti-LAMP staining for cells treated with SID7977862 (closed symbols) or SID103159345 (open symbols)
stimulated with anti-CD3 beads (triangles) or TG + PMA (circles). Data are the mean ± SEM of three
separate experiments. Dashed lines represent fits to the Hill equation, with IC50 = 0.6 and 0.7 µM for TG
+ PMA–stimulated and anti-CD3 bead–stimulated inhibition by SID7977862, and IC50 = 3.4 and 10 µM for
TG + PMA–stimulated and anti-CD3 bead–stimulated inhibition by SID103159345.

4.2.4 Screening of tunicate-associated bacterial extract library led to the isolation of an
immune enhancer identified as Teleocidin-1
Using the bead assay, we conducted a screen of natural product library obtained from Dr. Marcy
Balunas lab from the School of Pharmacy. Tunicate specimens were collected from shallow water
dock lines in three different locations and tunicate-associated bacteria were isolated for culture in
lab. Bacterial products were extracted using bead binding followed by consecutive washing. By
screening bacterial product library, we hope to identify some novel immune modulatory NPs.
Tunicates are marine invertebrate animal, and they belong to Chordata-Tunicata. Tunicates can
replicate by budding and become colonies. Adult tunicates are often permanently attached to hard
surfaces such as rocks on the ocean floor, though some tunicate species can also swim freely in
the ocean. Tunicates feed on planktonic particles by filtering sea water through their tube-like
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bodies with two openings, known as siphons. They are closely related to vertebrates because of
their tadpole-like form during the larval stage198. The name tunicate comes from their unique outer
covering or "tunic", which is formed from proteins and carbohydrates, and acts as an exoskeleton.
In some species, it is thin, translucent, and gelatinous, while in others it is thick, tough, and stiff.
Previously, didemnins were isolated from tunicates collected in the Caribbean Sea. The cyclic
depsipeptide compound was investigated in several phase II clinical trials for various cancer
treatment, but it was eventually withdrawn due to its high cytotoxicity and anaphylactic
reactions199.
Tunicates possess both cell mediated immunity and humoral immunity. Their immune cells
express histocompatibility molecules and demonstrate cytotoxicity. They can also secrete soluble
molecules such as defensins and cytokine-like molecules to inactivate certain antigens200.
Therefore, bacteria associated with tunicates are likely to synthesize and secrete molecules to
modulate the host immune system. In addition, marine NPs are favored over terrestrial NPs,
because they possess chemical and biological novelties201. Given the earth is largely covered by
ocean, and that marine animals constant live in an environment filled with bacteria, fungi and
other microorganisms, it is not surprising that ~70% of molecular scaffolds are used exclusively
by marine agents202. One common problem in natural product study is the resupply of materials.
In our study, tunicate-associated bacteria are first cultured in laboratories and processed to obtain
extracts, so resupply of natural product can be achieved by expanding bacterial culture.
A total of 320 extracts were screened at the final concentration of 10ug/ml, and we found two
extracts that increase cell response to a higher level when cells are bound by anti-CD3 beads.
Figure 18A shows the screening result of one of the library plates that contained the more
enhancing extract. Each black circle represents cell response to anti-CD3 bead binding in the
presence of an extract. The arrow indicates an augmenting extract which was later confirmed
using LAMP assay. Further testing of cells incubated with the extract in the presence of anti82

LAMP also showed that it did not stimulate granule exocytosis on its own. Since each extract
potentially contains multiple compounds, we further fractionated the extract based on polarity and
tested each fraction on cell response. The activity-guided fractionation helped isolate the most
active fraction (Figure 18B). It can augment the level of cell response to five-fold of that of antiCD3 bead binding. From the most active fraction, a purified compound E1 was isolated using RPHPLC with a retention time of ~7 minutes. A dose response of purified compound E1 indicated
augmenting activity within the nanomolar range (Figure 18C, EC50=1.2nM).
Next we wanted to identify MMOA for E1 by conducting follow up assays. As mentioned
previously, both calcium rise and protein kinase activation are required for lytic granule
exocytosis. We felt it unlikely that E1 is acting on cells through calcium signaling, because it had
no stimulatory effect on cells by its own. This was confirmed using cells loaded with calcium
sensitive dye Fura-2 and treated with E1 for live cell imaging (data not shown). We then tested
E1 effects on kinase signaling using phospho-specific antibody against active PKC substrate. E1
was found to be an activator of PKC, and the activating effect was independent of calcium. To
measure E1’s activating potency, a dose response was carried for cells treated with E1 alone and
then subject to permeabilization and antibody staining (Figure 18D). Compared to PMA as a
positive control for PKC activator, E1 demonstrated similar activity range with an EC50 of 6.9nM
(3.6nM for PMA).
Structural elucidation of E1 was carried out using 1D and 2D-NMR as well as mass spectrometric
analysis. These led to the identification of E1 as teleocidin A-1, a known PKC activating metabolite
also known as lyngbyatoxin A203. Further testing using optical rotation and circular dichroism
confirmed the configuration of E1 to be teleocidin A-1204.
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Figure 18 Detection and activity-guided isolation of an exocytosis-enhancing PKC-activating compound.
(A) Screening a plate of bacterial extracts at the final concentration of 10 µg/mL. The geometric mean of
anti-LAMP fluorescence is plotted for cells treated with anti-CD3 beads and bacterial extracts (black), cells
treated with anti-CD8 beads (blue), or cells treated with anti-CD3 beads (red). The arrow indicates an
enhancing hit. (B) Fractions (A–F) of the extract in well A2 tested for anti-CD3 bead–stimulated lytic granule
exocytosis. (C) Dose–response measurement of the effects of compound E1 on lytic granule exocytosis
(normalized anti-LAMP fluorescence to anti-CD3 bead–stimulated response). EC50 = 1.3 uM, hill rate =
1.2. (D) Dose–response measurement of PKC activation by compound E1 isolated from fraction E of the
extract in well A2 (circles) and PMA (squares). Lines indicate fits to the Hill equation. Experiments were
conducted three times in C and twice in D.
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4.2.5 Screening of NCI diversity set V plates
We wanted to use the enhanced assay to identify more active compounds so that we can subject
them to the secondary assay flow, such as testing compound effects on cytokine production by
helper T cells, antigen presentation and immunoglobulin secretion by B cells. The enhanced
assay was used to screen NCI diversity set V (Figure 19). This set prioritized molecules with rigid
formations and pharmacologically desirable features.
The primary screen was carried out over 15 days for 12 plates. Compounds were screened at the
final concentration of 100 µM in complete culture medium. The concentration was determined to
identify compounds that could work on cells in a short time (30 minutes). When normalizing data
to anti-CD3 bead controls treated with DMSO, we observed an offset in cell responses to the
majority of the library compounds (Figure 19A). This is likely due to different DMSO used in
compound resuspension. Since the library plate received was in DMSO form without excess
solvent in control columns, we used our own DMSO as controls. One way to compensate for the
offset is by normalizing compound-treated samples to the median cell response in each plate.
However, some plates are not normally distributed and it requires more labor to select the median
value for each plate. Therefore, we resolved to use a more stringent threshold for inhibitor
selection and a more flexible one for augmentor selection. Among 960 compounds tested, 42
inhibitors (>90% inhibition) and 14 augmentors (150% compared to anti-CD3 bead control) were
identified. Two augmenting compounds were activating cells on their own and were categorized
as stimulating hits. Confirmation run resulted in 12 inhibitors at 10 uM and 8 augmentors at 100
uM. A lower concentration was chosen for inhibitory compounds in the confirmation run to reduce
the number of inhibitors for followup assays. In comparison, augmenting compounds are more
interesting and in greater demand regardless of their mechanisms of actions.
Dose response testing was carried out for all confirmed hits (Figure 19C). All of the augmenting
hits were active at 30 µM or 100 µM, but not at lower concentrations. Compounds active only at
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higher concentrations were more likely to be activating cells in non-specific ways. Their dose
responses cannot be fitted to Hill equation properly due to missing data points within the high
concentration range. However, the highest concentration obtainable was restricted by the library,
which contained 10 mM stocks of compounds. At 1% DMSO the final concentration in cell solution
is 100 µM. Inhibitory compounds showed similar dose responses, with most activities observed
only at 10 µM. Two inhibitors even lost their activity at 10 µM likely due to compound degradation
from repeated freeze-thaw cycles.

Figure 19 Screening NCI diversity set V with bead assay led to both augmentors and inhibitors.
(A) Compounds in diversity set were screened at the final concentration of 100 uM in complete culture
medium. Cells bound by beads were gated in flowjo software and analyzed for APC fluorescence. The ratio
of APC to CD3 control was plotted for the whole library as a histogram, with the line indicating CD3 control.
(B) Formula molecular weight of compound was collected from library map and plotted against ratio of APC.
The horizontal lines indicate the arbitrary thresholds set for selecting augmentors (150% of CD3) and
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inhibitors (90% below CD3). (C) Dose response was carried out for confirmed compounds. The augmentors
concentrations ranged from 0.1-100 uM and inhibitors from 0.01-10 uM in 3-fold serial dilution. Dose
responses were fitted to Hill equation for 8 inhibitors.

We wondered whether longer incubation time with augmenting compounds could shift their dose
responses. We tried 4 hours of incubation with augmenting compounds over the same
concentration range, and augmenting activities were obtained only at the highest concentrations.
One compound caused cell death according to FSC-SCC profile at 100 µM. There was no clear
shift in compound potency with prolonged incubation time (data not shown).
4.2.6 Incorporating Multiple Treatment Times in Bead Assay
The diversity set screening indicated that the length of compound treatment time can determine
what type of compounds can be identified through the screen. A short incubation time could yield
less specific compounds that are only active at high concentrations. Treating cells with
compounds at lower concentration for prolonged time could lead to more potent compounds being
revealed. To facilitate identification of compounds with a wider variety of MOAs, it may be
desirable to devise an assay format incorporating varying lengths of compound treatment time.
We envisioned that compounds active after short-time incubation are likely to target immediate
effects in cell activation, such as calcium release and PKC activation; compounds active after
long-time incubation may affect PKC degradation, IL-2R gene activation.
Fluorescent cell barcoding technique was incorporated to enable multiple treatment time. The
technique was described previously by Nolan group to reduce antibody consumption in 96-well
plated phospho-specific flow cytometry125. Here we used it to multiplex the bead assay in the time
dimension. In the process, cells were first labeled with an inert fluorescent dye, Calcein AM, prior
to being added to the plate containing test compounds at different times. Different levels of dye
labeling allowed cell mixtures to be resolved later for different treatment time (Figure 20A). Calcein
AM dye was chosen because its fluorescence spectrum has the least overlap with that of LAMP
87

antibody or bead autofluorescence. Once taken in by cells, Calcein fluorescence is retained by
cells for a long time (Figure 20B). Mixing cells barcoded with different levels of dye for up to 6
hours showed clear separation of each individual populations. We determined on using the
highest level of dye loading to barcode the cells for 30-minute treatment time, intermediate level
for 6-hour, and unloaded cells for 24-hour to avoid potential dye leakage. Cell testing showed that
calcein dye, even at its highest loading concentration, does not interfere with cell response to
different stimulants (Figure 20D).
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Figure 20 Multiple treatment time with compounds is achieved by fluorescent cell barcoding.
(A) FSC-SSC of a mixed cell population barcoded with different concentrations of Calcein dye at 0, 50 nM,
200 nM. Cell populations were washed in dye-free medium before being combined. FITC fluorescence
reveals three individual populations of cells indicated by different fluorescence intensities. (B) Calcein dye
fluorescence is retained by cells for 6-hour after labeling. Square: 0 uM, open circle: 50 nM, closed circle:
200 nM. (C) Proper compensation matrix removes fluorescence spillover between the channels for Calcein
dye, bead autofluorescence, and LAMP antibody. (D) Mixed cell population from A were treated with small
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molecule stimulants TG+PMA versus control DMSO, or bead stimulant anti-CD3 beads versus control antiCD8 beads, in the presence of LAMP antibody. Samples were resolved based on Calcein fluorescence
intensity and results shown are compensated LAMP histograms.

We first compared MOAs of imiquimod and PMA using the multiple treatment time (Figure 21A).
Previously we have shown that imiquimod is able to enhance the level of CTL granule exocytosis
in response to anti-CD3 bead treatment after 6-hour incubation time, whereas PMA has
stimulatory effect on CTLs within one hour. Here we treated cells with imiquimod or PMA for
different time in 96 well plate to test the multiple treatment time protocol in screening format. After
resolving cell populations from mixed samples in repeat wells, we compared the LAMP
fluorescence of bead-bound subset between different treatment and between different incubation
time. As expected, the stimulatory effect of PMA on anti-CD3 bead-treated cells was most clear
in 30-minute cell population, and it disappeared in 24-hour cell population. In comparison, the
augmenting effect of imiquimod was not observed in 30-minute but started showing in 24-hour
cell population. The different modes of action would have been missed if we carried out the screen
at only one time point.
We implemented the multiple treatment time protocol to the re-screening of diversity set library at
10 uM. A lower concentration of library compound was chosen to decrease chances of cytotoxicity
over long incubation time. We anticipated more authentic hits would be identified using lower
concentration with longer treatment time. To simplify the screening procedure, we decided on a
2-time point protocol, 30-minute for short term effects, and 24-hour for long term effects. We
reasoned that compounds showing long-term effects could be analyzed in time course experiment
to determine the onset of their effects. The re-screen of the NCI diversity set V library led to the
identification of 14 augmenting compounds (conducted by Liza Henowitz), and seven augmentors
were confirmed from powder resupply (Table 3). All but one showed augmenting activities on
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bead-triggered lytic granule exocytosis after 24-hour treatment with cells, and one compound
(NSC 11643) showed augmenting activities in 30-minute treatment as well (Figure 22).

Figure 21 Multiple treatment time allows for detecting compounds with different mode of actions.
(A) Cells were treated with DMSO control, 10 uM Imiquimod or 100 nM PMA for indicated time. After
incubation, cells were treated with anti-CD3 beads or anti-CD8 beads in the presence of LAMP antibody.
Data were resolved from barcoded cell mixture. Each data point represents an individual repeat with
average and standard error shown. (B) Dose response of one augmenting hit NSC 125095 identified from
diversity set screening and found to be active only after 24 hours of compound treatment. Geometric mean
of LAMP fluorescence for cells+anti-CD3 bead was compared to that of DMSO treated control.
Table 3 Augmenting hits of CTL lytic granule exocytosis identified from NCI diversity set over long-term
incubation.

NSC
159632
7420
9782
11643*
154127
34219
125095

MW
236
298
282
288
281
313
375

CAS
53043-28-0
6284-50-0
3129/8/6
n/a
n/a
n/a
80789-71-5

LogP
-0.72
3.64
3.47
3.38
4.52
4.88
4.98

SMILES
C(=O)C1=C2C=C(C)OC=C2C(O)C(C)(O)C1=O
Oc1c(cc(Br)cc1C2CCCCC2)C(N)=O
CC12CCC3C(C=Cc4cc(O)cc(C)c34)C1CCC2=O
N(CC)(c1ccccc1)c2nc(Cl)nc3N(C)N=Cc23
N(C1CCCCC1)c2nnc(Cl)c(Cl)c2Cl
Clc1cc2OCOc2cc1C3OCC(CC)C(CCC)O3
Oc1cc(nc2ccc(cc12)C(=O)OCC)c3ccc(cc3)S(F)(=O)=O
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*Compound was augmenting bead-triggered cell response in both 30-minute and 24-hour treatment time.
LogP was predicted by Molinspiration based on SMILES.

Figure 22 Augmenting compounds of CTL granule exocytosis from NCI diversity set V library screen.
Structures for augmenting compounds confirmed from powder resupply with their NSC numbers shown.
Refer to Table 3 for detailed information.

4.3 Discussion
We have shown that we can identify TALL-104 cells bound to anti-CD3 or anti-CD8 beads in
cytometry via changes in light scatter. This makes it possible to study events associated with
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quasi-physiological activation specifically in cells that have received the activating stimulus.
Importantly, it also makes it possible to conduct two-way screens in which compounds that either
inhibit or enhance lytic granule exocytosis can be detected. When using the assay, comparison
of responses in cells that have bound a bead to responses in cells that have not bound a bead
makes it possible to distinguish between compounds that stimulate exocytosis on their own and
compounds that enhance receptor-stimulated exocytosis (Figure 16A). Thus, the modified version
of the assay is capable of identifying three classes of compounds: (1) inhibitors; (2) stimulators,
compounds that trigger responses; and (3) augmenters, compounds that enhance receptorstimulated responses but are not themselves capable of producing responses. We believe that
the strategy could facilitate studies of signal transduction and, although we have not tested this
here, suspect the strategy could likely also be applied to other cell types, including primary T
lymphocytes and other cell types that respond to stimuli presented on a solid phase. Similar beads
are routinely used to stimulate cells for functional experiments, and so we think it highly likely that
the method will be more generally applicable. Note that the requirement that cells respond to
solid-phase stimulation can also be seen as a limitation of the method, as some cells may respond
only to soluble stimuli. Also, some types of bead may not produce optical scatter properties that
allow their identification. The assay is suitable for screening natural compound collections, and
can be used as part of an activity-guided isolation scheme. In preliminary experiments, we found
that further miniaturization to the 384-well format is possible (B. E. Edwards, A. Zweifach,
unpublished observations.) If, as we strongly anticipate should be possible, the assay can be
translated to the 384-well format, it will be possible to conduct HTS for immunologically active
compounds. As it is, a 96-well format enables screening of moderately sized collections.
Our assay has both similarities to and differences from an assay that used anti-LAMP antibodies
to

assess

exocytic

responses

in

NK

cells

stimulated

with

plate-bound

activating

antibodies164. Both assays use flow cytometry to assess exocytosis via binding of anti-LAMP
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antibodies. However, that assay was not able to distinguish responses from cells that did or did
not receive the activating stimulus. Thus, while they were able to identify a number of stimulatory
compounds in the Prestwick compound library—along with a number of inhibitors—they were
unable to distinguish whether those compounds cause exocytosis on their own or augment
receptor-stimulated responses. One powerful feature of their assay was that they multiplexed
detection of exocytosis with measurements of protein synthesis and inside-out changes in cell
adhesion. It is possible that we could enhance our assay by adding additional antibodies able to
detect other cellular events. However, the fluorescence of the beads would limit the additional
channels that could be used.
In another study, AID 2052 used primary murine CD8+ T cells in a cell-based HTS to look for
small molecules that could affect the interaction of LFA-1 and ICAM-1 and therefore achieve
immune inhibition of CTLs. The assay was also multiplexed by combining different measurements
of vehicle binding to T cells. More interestingly, they proposed for a combined analysis of highcontent screening, in that arbitrary coefficients were assigned to each parameter and a combined
activity score was calculated for each compound. They screened 326,161 molecules and
identified 221 active hits (0.07% hit rate) that inhibited LFA-1 and ICAM-1 binding at 7uM.
Potential mechanisms for inhibitors are inside-out signaling and protein-protein interactions. The
assay was within 2 hours, so gene transcription level change is unlikely to be a mechanism.
Our assay’s ability to identify inhibitors of lytic granule exocytosis was confirmed by the fact that
we were able to detect a number of inhibitory compounds with different MMOA that we originally
identified with the prior version of the assay (Figure 17). Just as important, many compounds that
ultimately proved not to be inhibitory using the prior assay also did not inhibit using the new format.
Agreement between the results with the old and new assays was not perfect, but that might be
explained by degradation of compounds in storage over time or by differences in the dependence
of granule exocytosis on strength of signals when cells were stimulated with soluble TCR94

independent chemicals compared to stimulation through their TCRs. Little is known about how
the strength of signals is translated to lytic granule exocytosis, and so it is not clear that perfect
correspondence in the degree to which exocytosis is inhibited by compounds should always be
expected. Supporting the ability of the new assay to identify compounds that enhance lytic granule
exocytosis, the compound we identified from bacterial extracts, teleocidin A-1, is a known PKC
activator, and has been shown to enhance granule-dependent cytotoxicity in primary human
lymphocyte preparations203,205–207.
The assay we developed was successfully utilized to screen 320 natural product extracts from
tunicate-associated bacteria. Compared to screening synthetic compound collections, screening
of natural product extract libraries presents several difficulties in the search for novel compounds
with biomedically relevant activities208. Extracts are complex mixtures of compounds that often
range in polarity and solubility. Active natural product compounds may be present in only minute
quantities, and their activity may be overshadowed by other bioactive components or interfering
nuisance compounds within the mixture. Crude extracts often contain pigmented compounds and
may also contain autofluorescent metabolites. In addition, compounds may be less soluble when
isolated and/or be unstable when not in the extract matrix.
That our assay is suitable for screening both synthetic compound collections and complicated
natural product mixtures for exocytosis-suppressing and exocytosis-enhancing compounds
suggests it might be a powerful means of discovering immunologically active small molecules
from diverse sources. Using short compound treatment times, as we did with tunicate-associated
bacterial extract library, we suspect that the assay is most likely to find compounds that, like
teleocidin A-1, enhance signals leading to lytic granule exocytosis. In addition, we could likely
detect compounds with other mechanisms of action with longer treatment times as in diversity set
library screen. In a trial compound testing, we found that treating cells with the known
immunomodulator imiquimod increased anti-LAMP staining by ~75% in cells bound to anti-CD3
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beads after a 6 h incubation. Compounds that affect lytic granule exocytosis would affect immune
functions that involve lytic granule exocytosis, and on this basis might be expected to modulate
antiviral and antitumor immunity. Furthermore, we would anticipate that many compounds
identified as active in a screen based on lytic granule exocytosis would also affect the activity of
other immune cells. Thus, the assay we describe here may provide a general means of screening
compound collections for immunologically active small molecules. We surmise that one reason
there are so few immunomodulatory small molecules is that to date, there has not been a
convenient way to screen for them. With our assay, the ease of screening both synthetic and
natural extract libraries should make for more rapid discovery of new small-molecule
immunomodulators.
4.4 Future direction of novel immune augmenting compounds
Seven compounds emerged from the NCI mechanistic set screening with multiple treatment time.
They are all augmentors of CTL lytic granule exocytosis after long-term incubation. Does this
mean they are all immune augmenting compounds? Not necessarily. As discussed in detail in
this section, augmenting lytic granule exocytosis may not lead to increased target cell killing.
To test whether these compounds possess general immune augmenting activities, a future
direction is to develop a set of secondary assays with other immune cell types. CTL hits that show
activity in other immune cell types are broadly immune modulatory compounds, and they could
have immense therapeutic values in treating complicated diseases, such as reverting the immune
inhibitory effect by the tumor microenvironment. If broadly immune modulatory compounds work
via novel mechanism, they are potential chemical probes that can be exploited to investigate novel
regulators conserved across multiple immune cell types. Once characterized, these protein
targets can be used to design target-based screenings to look for pharmaceutics that can regulate
immune cell activity.
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I selected the following cell models to test in vitro with a focus on adaptive immunity, and I
compiled assays that measure each cell activity individually (Figure 23). These cell types are
chosen because their assays are well developed and relatively easy to perform. Additionally,
assays in this section are designed to prioritize hits, instead of selecting hits. All hits at this stage
are worth follow-up. The purpose is to prioritize hits that could affect more than one immune cell
types.

Figure 23 Follow-up testing of immune augmentors in other cell types.
(left) Adaptive immune response to virus infection209. (right) Selected cell types will be tested in cellular
assays according to the flow chart.

Target cell killing assay by CTLs to select physiologically relevant hits – Hits identified through
LAMP externalization can affect lytic granule exocytosis, but they may have no effect or
detrimental effects on target cell killing activity of CTLs. CTLs are capable of serial killing, and
only ~15% of granules are needed per killing. Releasing more granules upon the first target cell
encounter may reduce the number of granules available for subsequent target cells210,211. Calcein
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release assay is a standard measurement for target cell killing efficiency. Raji B cells serve as
target cells for CTLs. Raji will be loaded with calcein dye, then treated with bispecific antibody
CD19/CD3 to allow CTL recognition, and last mixed with TALL-104 cells pre-treated with hits. The
release of fluorescent calcein into supernatant can be measured on plate reader, and the
remaining calcein in cells can be measured after cells are lysed with Triton. % of calcein release
can be calculated as supernatant/(supernatant+cell lysate).

Testing hits effects on helper T cells using ELISA to measure IL-2 secretion – Helper T cells can
produce cytokines to regulate other immune cell activity, so they are important regulators in
adaptive immunity. The standard method to detect helper T cell activity is through enzyme-linked
immunosorbent assay (ELISA) on interleukin-2 (IL-2) secretion by Jurkat cell line212. First Jurkat
cells will be incubated with hits or equal amount of DMSO in test plates. Then soluble anti-CD3
and anti-CD28 will be added to Jurkats in the presence of cross-linking goat-anti-mouse IgG. After
6 hours, supernatant will be collected, and cells will by lysed to release the remaining IL-2.
Standard ELISA will be carried out to measure the amount of IL-2 present in supernatant and cell
pellet. The addition of the two represents total IL-2 synthesized and released by Jurkat, and it
could be affected by hits on the protein synthesis level. The ratio of supernatant/(supernatant+cell
lysate) represents the fraction of IL-2 secreted by Jurkats, and the ratio could be affected by hits
on the level of granule secretion. To find a concentration of antibody for submaximal cell
activation, I will titrate anti-CD3 from 0.1~10 µg/ml.

Testing hits effects on natural killer cells using antibody binding to measure lytic granule
exocytosis – NK cells share similar effector functions as CTLs. Active hits identified through CTLbased screen are likely to be active in NK cells. To assess NK cell activity, I will measure LAMP
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externalization using fluorescent antibody in flow cytometry213. NK-92 cell line will be used
because they can be stimulated by TG+PMA or a target cell line such as K562 cells214. To achieve
a submaximal cell response for augmentor testing, target cell K562 will be used in this followup
assay. Effector:target ratio will be investigated from 5:1 to 20:1 to identify a submaximal activation
condition. NK-92 cells will be loaded with Calcein dye to differ from target cells, pre-treated with
hits, then incubated with target cells in the presence of anti-LAMP, and sampled on the flow
cytometer.

Testing hits effects on B cells using endocytosis assay – B cell is an important component of
adaptive immunity. It can secrete antibodies specific for antigens to neutralize pathogens. To
measure B cell activity, flow cytometer will be used to measure the amount of protein B cells can
endocytose upon cell activation. Ramos B cell line can be activated by anti-IgM, and activated
Ramos display increased endocytosis activity215–217. The amount of anti-IgM will be titrated to
identify a submaximal level of B cell activation. Anti-CD40 will be used in addition to anti-IgM to
achieve maximal cell activation. FITC-labeled Ovalbumin protein will be used to for B cellmediated endocytosis. Cells will be treated with hits, then activated for 3 hours and read on flow
cytometer. The amount of FITC fluorescence indicates the level of cell activation.

Testing hits effects on dendritic cells using antibody binding to measure antigen presentation –
Antigen processing and presentation by dendritic cells, although belonging to innate immune
response, is necessary to elicit the adaptive immunity. In order to assay for dendritic cell activity,
cross-presentation of ovalbumin peptide (SIINFEKL) on the cell surface will be monitored by flow
cytometry. So far there is only one human dendritic cell line MUTZ-3, but it requires days to
present a given antigen218. Murine DC2.4 cells will be used as a cell model for dendritic cells,
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since they are established dendritic cell line that can take up soluble ovalbumin in vitro219. Upon
endocytosis, ovalbumin is digested by proteasomes and presented on MHC I molecules.
Activated dendritic cells can be stained with antibody against ovalbumin peptide when bound to
MHC I (H-2Kb-SIINFEKL, eBioscience), and the amount of fluorescence can be measured on
flow cytometry220. I will titrate ovalbumin from 10-1000µg/ml. The concentration that generates a
submaximal level of cell activation will be used for hit testing. I envision that active hits could affect
antigen presentation via affecting cytoskeleton-mediated phagocytosis, the maturation of
endosome to antigen-processing compartment, or the protease activity in the compartment.
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Chapter 5: Discussion on Modern Drug Discovery and Development
5.1 NPs vs. Synthetic Molecules: Learning Lessons from Nature
In traditional cancer drug discovery, almost half of drugs were either NPs or directly derived from
them128,221. A recent study listed several important drugs derived from NPs and their clinical
uses222. NPs are synthesized or secreted by organisms, so by definition they have binding
partners and are more likely to be biologically relevant. They also have more diverse structures
and cover larger chemical space, especially the biologically relevant space223,224. NPs are often
underrepresented in numbers by most libraries, yet they have higher success rates to become
drug candidates134,225. Despite the advantages of NPs, they are not favored by modern
therapeutics discovery programs, because they don’t follow easy chemistry or possess druglikeliness (according to Lipinski’s rule of five, even though he himself noted that these rules do
not apply to NPs226) and often material resupply is an issue especially for mass production. Fast
dereplication process is also needed for natural product in order to avoid repeated effort of
isolating previously known molecular entities.
In our cell-based assays, natural product libraries tend to give a higher hit rate than small molecule
libraries. Balunas lab had a natural product library composed of ~300 tunicate-associated
bacterial extracts, from which 2 augmenting hits were identified and confirmed (hit rate is ~0.7%).
In another screening conducted with mushroom extracts, we identified and confirmed 6 inhibitory
fractions from only four plates of ~340 extracts (hit rate ~1.8%). Although both hit rates were
calculated using small sample sizes from in-house natural product libraries, it shows the rich
activities in NPs compared to small molecules. The hit rate is observed to be lower in libraries of
synthetic small molecules (MLSMR screen had a hit rate of ~0.04% with 161 hits confirmed from
364,202 compounds). The main reason for this low hit rate could be attributed to the poorly
curated library, where chemical liabilities often exist. Especially in the case of MLSMR, after we
identified 2404 hits in the primary screen, 40% (944 hits) were not available or had chemical
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liabilities and were therefore not included in the confirmatory screening. The purpose of large nonproprietary libraries is to include as many chemicals as possible, instead of assembling drug-like
or lead-like chemicals for drug screening campaigns. Even so, it fails to represent the chemicals
in the ratio of their success rates in drug discovery and development efforts, as NPs only account
for ~1% of total MLSMR of 2010 version135. Chemicals shown as hits could be unavailable from
source depositor after several years, and chemicals that routinely showed activities (likely to be
nonspecific effects when those activities were observed in different types of assays screened)
were not excluded from the library collection. In another effort of screening the BROAD Institute
diversity-oriented synthetic (DOS) library, we identified and confirmed the inhibitory activity of 26
compounds among ~10,000 (hit rate ~0.3%), and all hits showed inhibition in either calcium
signaling or MEK activity. In addition to library composition, different assay types could account
for the differences in hit rates. Bead activation used for the natural product library screen
interrogated pathways downstream of TCR activation, whereas small molecules used for MLSMR
and BROAD-DOS screen lie downstream of IP3 and DAG. One recent study looked at subsets of
chemical libraries and analyzed effects of different chemical forms on the screening result
retrospectively. They found that NPs subset, being the most diverse compound class, had
significantly higher hit rates compared to traditional synthetic libraries and combinatorial
libraries227. A historical review of all new approved drugs from 1981 to 2010 showed that among
1355 drugs, only 29% (387) are purely synthetic compounds, 50% are NPs (including natural
product mimics and derivatives) and synthetic molecules with a natural product pharmacophore.
The rest 21% belong to vaccines and biologicals225. The reason for this higher hit rate and success
rate could be explained by the long evolutionary history of NPs, and there are efforts of biologyoriented synthesis that try to enrich for compounds that resemble the structures of NPs228. Given
the higher molecular weights of NPs, they are very good candidates to regulate protein-protein
interactions (PPI), which are typically hard to access with small molecules228. In more complicated
phenotypic screening assays based on pathways, systems or even organisms, where PPI plays
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an important role, NPs may show higher hit rates because they could access and interfere PPI
sites better than small molecules. For example, a microbial product tacrolimus (also known as
FK506) can bind with FKBP12 and inhibit calcineurin activity43. A fungal metabolite Chlorofusin
was identified as an inhibitor of p53-MDM2 interaction229. A closer look at the chemical structures
and ring structures of the compounds found in commercially available libraries and the generated
database of 26 million compounds revealed that a lot of molecules with higher molecular weights
actually resemble their NPs and metabolite neighbors. This bias towards biogenic molecules also
resulted in the success rates of screening, and 12,977 (83%) of the ring scaffolds found in NPs
are unrepresented in commercial molecules130. In fact, if synthetic chemistry is striving to
synthesize chemicals that resemble NPs, what is the reason of not using natural product library
directly in the screening?
The risk of isolating previously known compound is one major concern of using NPs in screening
campaigns. NPs libraries used for a screen are often crude extracts or pre-fractionated mixtures,
so the process of isolating and identifying the active ingredient(s) from hit wells is necessary
following the screening process. This is also known as the dereplication process. In collaboration
with Balunas lab, we identified two augmenting bacterial extracts on granule exocytosis process.
We investigated the hit with the higher augmenting level, and activity-guided fractionation led to
the isolation of an active compound, which later became identified to be teleocidin A-1 using 1D
and 2D NMR. The family of teleocidin is a known tumor promoter as it was previously isolated
and shown to activate PKC206,207,230. Our work identified a new source of teleocidin A-1
synthesized by marine tunicate-associated bacteria Streptomyces sp. strain. With the advances
of NMR technology, chemical structures can be determined with raw materials as few as
micrograms231,232. To allow for fast dereplication, modern metabolomics workflow also couple LCNMR stations, analysis software and databases such as Dictionary of Natural Product and
Chemspider. Results from such workflows are subject to principal component analysis and pattern
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recognition allow for fast comparison of chemical structures to the known chemicals in the
database223. A recent review introduced the common procedures of dereplicating microbial
products from colony isolation, spectroscopic description, re-fermentation and purification, to
compound structure identification233. Proper use of these procedures should help avoid investing
efforts in studying previously known compounds in early stage of HTS using natural product
libraries. Importantly, pre-fractionation methods combined with UHPLC-MS profiling of library for
library construction also simplifies the dereplication process following the identification of a hit.
One important aspect to consider when constructing a natural product library is to remove
nuisance chemical, such as polyphenol tannins from plant extracts234. Chemists and biologists
also need to consider the possibility of a hit that showed activities in multiple assays be
contaminations from culture broth or the leachable from pre-fractionation procedure, such as
mycotoxins from fungal culture and plasticizers from equipment coating235,236.
Another concern with NPs is the resupply of more materials. Due to the extreme complex
structures of NPs, it is considerably hard to conduct de novo synthesis. In the case of tunicateassociated bacterial product library screening, our collaborators from Balunas lab collected
tunicates from different geographical locations, and then cultured tunicate-associated bacteria in
laboratories. Since bacterial culture was processed to obtain extracts used in the screen, resupply
of natural product can be achieved by expanding the bacterial culture. Natural product material
supply issue can also be solved by genome mining201. Some databases also support the virtual
screening of NPs, such as Chinese Natural Product Database237 and Database from historical
and medicinal plants DIOS238,239.
With the current libraries where NPs are under-represented, chemicals tested in screenings often
do not reflect bioactive space. NPs are born with the advantages in the field of antimicrobial and
PPI perturbant screening. There is an urge to explore more chemically and structurally diverse
NPs in the upcoming era, and there are grants that encourage synthetic chemists to donate their
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results including intermediate molecules to the national library, in order to enrich the compound
composition135,240,241. It’s my strong belief that more drug candidates and even lead molecules can
come from largely unexplored natural sources. Coupled with modern technology that allows for
fast dereplication of natural product material, using an in-house chemical library with a smaller
size yet more biological relevance should increase the hit rate in a screening campaign. With
more researchers coming to realize that NPs are valuable sources for potential candidates, the
success rate of discovery effort would greatly improve.

5.2 Phenotypic vs. Target-based Screens: Grow Your Own Fruits in Novel Target
Discovery
Historically, a lot of screenings were conducted using cell lines, especially the early anticancer
drug discovery efforts, where cancer cell proliferation rate was measured after compound
incubation123. Recently the HTS efforts shifted to focus on target-based assays, as more is
learned about how cells function, and upregulated proteins or mutated kinases are often thought
to have caused the disease. Modern technology even enabled screenings based on biologics
entities242,243. I think the phenotypic approach is undervalued at present. In long term, the
phenotypic approach is more efficient in generating the first-in-class medicines and it serves as
the driving force to the drug discovery field in future244. A phenotypic screen could identify useful
compounds as tool molecules for target validation studies. It could also reveal novel molecular
mechanisms of biological systems.
Current efforts in cancer drug discovery and development are focused on target-based
screenings. One reason for favoring the target-based approach is that most molecular targets are
readily available through academic research results. Identification of a novel target without prior
knowledge could be years of work, and even once it is identified, target validation process requires
tool molecules, knockout experiments and rescue experiments. The pharmaceutical industry only
105

rewards the first one to hit the market with a drug. In this scenario, researchers are reluctant to
make the time-consuming efforts to reveal novel targets when existing targets (although they may
not be validated well yet) could yield drug candidates much faster.
Another reason for phenotypic-based screen to be less prevalent is that it may be hard to identify
the molecular targets for novel hits, if possible at all. After all, is knowing the mechanism of action
really important for disease treatment? In fact, we don’t need to know the targets of medicines as
long as they work. Lead candidates could also be approved without mechanisms being identified,
and there are drugs on the market without known mechanisms. Valproic acid and clozapine are
commonly used to treat neurological disorders, and they have been the most successful drugs
even though their targets have only been revealed recently126.
Since a phenotypic assay detects the final output of a biological system, it is not limited by
mechanism of targets or pathway-hypothesis, making it capable of identifying compounds with
polypharmacological effects. Polypharmacology has been shown to be more important than one
particular molecular target in treating complex diseases, such as cancer, cardiovascular, and
psychiatric disorders. It has been accredited for the efficacy of many drugs, and targeted
polypharmacology could help identify drugs that treat more complex, heterogeneous diseases245.
In these cases, drugs working like “magic shotguns” could be more effective than a “silver bullet”.
If phenotypic screens are useful in finding compounds with novel mechanisms, why is there not
more phenotypic-based screens? Why are we chasing after the targets that are supposed to be
involved in disease onset, rather than setting out to look for compounds that can affect the
phenotype directly? For example, within the field of cancer drug discovery, if anti-proliferation is
the desired therapeutic effect of compounds, we could simply conduct phenotypic screenings with
cell-proliferation as the readout. In fact, NCI routinely conducts anticancer screen using cell
proliferation assay123. Although their library is not featured to be drug-like or lead-like due to
chemical properties and cytotoxicity, the mechanisms of actions by which compounds work can
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yield further information about molecular targets that are important for cell proliferation. This is
also known as chemical library profiling.
Chemical library profiling can be applied to both phenotypic and target-based screening results.
We are in an era of generating data from screenings faster than the processing speed. Millions of
compounds are screened in multiple assays constantly. With the information we have already
gathered, it is possible to construct a knowledge network that can reveal important aspects of
biological systems. For example, when a common library is screened in multiple phenotypic
assays, one could gather the activity scores of compounds from different assays, and use them
to generate matrices comparing chemical structures to phenotypic activities246. One could even
multiply two matrices with different information to obtain knowledge such as predicting molecular
targets of small molecules167, generating a protein binding profile and correlate it to their cellular
function247, guiding chemical synthesis to target desired biological functions248.
One advantage of the phenotypic screen is the identification of tool compounds that can be used
for target validation. With thousands of compounds selected through different screening
campaigns as probe candidates, how to prioritize their usefulness in target validation? Recently
a research group at Novartis proposed for a tool score system249. They used machine learning to
conclude a mathematical model, combining strength and selectivity parameters for each
compound based on available information. Using the calculated tool score helps prioritize
compounds as target validation probes. More studies like this should be encouraged, so we could
also devise a similar strategy to prioritize protein targets in future drug discovery campaigns.
In the current fast pace screening, we should never stop with the results obtained from one single
screen. Instead, we should constantly seek corroboration between multiple results from
independent research groups, as this helps validate the target for a phenotype. A well curated
chemical library will facilitate the discovery of novel mechanisms of biological systems.
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5.3 Target validation
Target validation is a crucial step before any target-based HTS is conducted. The high cost seen
in pharmaceutical industry recently is driven by the high attrition rate250,251. Given that the
mainstream of drug discovery effort has been target-based approach, why do so few molecules
make it successfully to the market? One reason is that “low-hanging fruits” such as easy targets
have already been explored in such approach. Novel targets can result from phenotypic screens
that yield compounds with novel mechanisms of actions. Another reason is that targets used for
target-based approaches may not be well understood. Classical methods used in target validation
involve protein knockout or knockdown experiments, which could affect the structural functions of
the target protein other than its enzymatic activity. Small molecules that are routinely used as tool
compounds (inhibit the target protein activity without affecting its expression level) to demonstrate
proof-of-concept also have limitations, because their activities could result from their off-target
effects. This applies especially to preclinical cancer research, where tool compounds are often
not specific for just one target and down assays are used for screening.
Kaelin recently pointed out several caveats in preclinical cancer target validation252. The most
often observed mistake is to draw a causal link when simply observing a correlation between two
factors. Even in cases where a causal link does exist between a phenomenon and the proposed
underlying mechanism, it does not rule out the potential involvement of other molecular targets.
For example, many gene mutations result in tumor formation, and not one single gene mutation
is sufficient in causing the cell transformation. Therefore, they are all be necessary (blocking one
mutation product is enough to stop cell proliferation) but not sufficient. Another example is the
subcutaneous xenograft model to assess the in vivo performance of anti-tumor drug candidates,
however it can be problematic: a xenograft model requires tumor cells to have angiogenic property
which pre-select them for anti-angiogenic perturbants; immune compromised mice do not offer
normal immunity, and the tumor microenvironment is not representative of human's; the system
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focuses on tumor cell proliferation instead of host immunity or tumor metastasis. More careful
experimental designs need to be carried out for target validation.
Most preclinical cancer research are based on down assays, that is, evidence shows a loss of
cell fitness or tumor growth rate as a result of drug treatment. However, down assays are prone
to false positives, as there are more uninteresting ways to make a system work worse than ways
to make it work better. Inhibitory compounds could simple be cytotoxic or disturbing the plasma
membrane potential. To demonstrate the target as a valid one for the phenotype, rescue
experiments are often performed to assess the compounds effects. For example, cells affected
by a particular kinase inhibitor can be transfected with cDNA that codes for a mutant kinase
resistant to the inhibitor. If the mutant kinase cDNA rescued cells and restored normal phenotype,
it suggests that the target kinase is important for the phenotypic change. However, this has a
caveat that cDNA could result in constitutive kinase expression and would not apply for cell cyclerelated kinases (often presumed to be targets for tumor cell proliferation). Even when the
expression is controlled by an inducible promoter, the level of kinase expression could be much
higher than the endogenous level. Therefore, the results of rescue experiments may not be
physiologically relevant. Also, even if the rescue experiments show results as expected, it does
not eliminate the possibility that a second off-target mechanism is involved in causing the
phenotype. In other words, the sufficiency of the on-target effect by the perturbant is hard to
demonstrate. This scenario often leads to the failure of drug candidates in phase II clinical trials,
as cells in vivo could have other mechanisms to rescue the inhibited pathway.
In appendix, I will be discussing a novel approach towards target validation. Instead of relying on
a couple of tool compounds in particular to demonstrate the sufficiency of target, we could gather
an ensemble of compounds via a combined screen measuring both the phenotypic change and
the target activity.
5.4 Quality Control of HTS Assays: Univariate Z’ Factor is Not Enough
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The standard statistical tool of assessing the quality and robustness of an assay is the Z’ factor,
first introduced by Zhang et al143. The equation takes the simple mathematical ratio of the
separation band over difference of means for two groups of samples (both are presumed to have
normal distribution). Z’ factor is calculated when the equation is applied to negative and positive
control samples, and Z factor when applied to control samples and compound treated samples.
An arbitrary threshold is set for assays with excellent quality (Z’ >0.5), double assay (0~0.5) and
unacceptable assay (<0).
Since the definition of data variability band in Z’ factor is dependent on the normal distribution of
sample groups and relatively small standard deviation, Z’ factor can be affected in screens of
focused libraries where more compounds are presumed to have an effect on the assay readout.
Z' factor can also be affected by variable controls with a large standard deviation. In our assay
using anti-CD3 beads to activate TALL cells, we have seen plates with variable controls that
resulted in Z’ factor being 0~0.5. In those cases, cell activities in response to compound treatment
were compared to the average of the plate instead of the control wells, and it was assumed that
majority of compounds in the library did not have an effect. Ultra-HTS conducted in 1536-well
plates may result in lower Z’ factors than those conducted in 96- or 384-well plates, due to interwell cell number variability and extremely small volume liquid handling.
To solve the problem of low Z’ factor, it has been proposed to replace it with robust Z’ factor253. In
the robust Z’ factor calculation, standard deviation is replaced with robust standard deviation, and
mean is replaced with median, both measurements are less subject to outliers. This adjustment
in calculation eliminates the need to go through each control data point and hand-pick outliers,
which is a subjective and labor-intensive process. Robust standard deviation=median absolute
deviation*1.483 (the factor 1.483 comes from the adjustment of MAD to SD in normal distributed
data set), and MAD comes from median of absolute (data point-median of data set).
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Z’ factor or robust Z’ factor only applies to one-dimensional data where only one parameter is
collected from the screening. In cases such as high-content screening or multiplexed assay, a
more sophisticated quality control is required to assess the robustness. One way around this is
the multivariate Z’ factor proposed by Kummel254. Combining multiple parameters in high-content
screening for a multivariate Z' factor involves linear transformation of all parameters: individual
signal intensities are added up (as long as they change in the same direction, otherwise they are
subtracted), therefore reducing the multiple dimensions to one-dimensional data. In cases where
a signal is much larger than the other signals, a weighed linearization is used:
coefficient*individual signal before adding up (coefficient is different depending on signal scale,
determined by linear discriminant analysis).
However, reducing multiple dimensions of the signals into one-dimensional data will lose the
benefits and rich information of a high-content screen. As Kummel later pointed out in a review,
machine learning should be used to generate cell classifiers, and multidimensional sample
profiling should be used to record data from a high-content screen, such as matrix description of
cells255. Pattern recognition used for image-based screening and principal component analysis
could be adopted to analyze high-content data.

5.5 Bridging Academic Research & Pharmaceutical Industry
There is raising awareness that the high attrition rate in clinical trials is due to selecting poor
targets in pharmaceutical industry250. Target validation in preclinical cancer research is often
misleading when people mistake correlation for causation252. In the pharmaceutical industry
driven by profit, only the first runner gets the prize. Research and development department is
affected by the rush to move the chemicals forward into trials and registrations.
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There is a lack of funding for academic labs conducting research related to cell-based assays and
phenotypic screenings. As Eggert pointed out, traditional hypothesis-driven research has been
the focus for funding, whereas HTS, especially phenotypic screening is not hypothesis-driven, the
study outcomes from a screening project are not guaranteed; also, some early phenotypic
screens generated probes that were not useful due to low-potency or nonselectivity119. Given the
uncertain nature of a phenotypic screen, most funding agencies are reluctant to take on the risk.
Collaboration effort could offer financial support and additional resources to academic labs to
pursue more hits from their screening. Right now, all research results are protected by intellectual
property laws and they belong to the university, especially when federal funding is used to sponsor
the research labs. To further pursue any hits for chemical probe development, lead optimization
or even clinical trials, both money and multi-disciplinary team are needed, and no research lab
alone is resourceful enough see through the process. Many academic drug discovery centers
have initiated the effort to establish collaborations and seek alternative funding256. Pharmaceutical
companies also have in-house libraries that are often proprietary and used for internal screenings
exclusively. Collaborations could allow academic screening centers to use those libraries as
alternative resources.
The future of academic drug discovery still relies on the basic research and careful experiment
design. Most importantly, we shall collaborate with the pharmaceutical industry to advance our
understanding of disease onset and to improve the medicine. The future of drug discovery and
development lies beyond its boundaries today.
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Appendix: A novel FRET-based assay revealed aerobic glycolytic inhibitors and
provided support that glycolysis is a strong anticancer target in leukemic cells
6.1 Overview
The appendix describes a novel approach using an ensemble of compounds to offer unbiased
strong small molecule support for a potential anti-cancer pathway. The manuscript from this
project is in submission. Preclinical cancer drug discovery depends on small molecules as tool
compounds to validate the molecular target and to establish the target’s druggability257. However,
early tool molecules are not optimized and have multiple effects, so they provide only weak
support250. One area in which this is especially apparent is the Warburg effect, the adoption of
aerobic glycolysis by cancer cells, which is currently thought to represent an antiproliferative
target in many kinds of cancer258–260. We developed a Forster Resonance Energy Transfer
(FRET)-based assay using an ATP sensor expressed in K562 leukemic cells to look for
metabolically active compounds261. The screen of ~800 small molecules from National Cancer
Institute (NCI) mechanistic set yielded 27 inhibitors of glycolysis and oxidative phosphorylationdependent ATP production. We then mined the NCI’s data set for growth inhibitory effects of the
library compounds, and compared the effects of our ensemble of compounds to the whole library
set. Compounds selected based on glycolytic inhibition were significantly more anti-proliferative
than the overall compound collection, while inhibitors of oxidative phosphorylation-dependent
ATP production were not. We calculated the probability of obtaining compounds as
antiproliferative as the glycolysis inhibitors from the library purely by chance, and found that it was
extremely low. Based on these results, we conclude that glycolytic inhibition is likely a good
strategy for blocking leukemic cell proliferation. We propose that, rather than relying on the use
of a tool compound for target validation, a screen such as ours- a target validation screen- should
be adopted routinely as part of the drug discovery process.
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6.2 Background
6.2.1 Cancer drug discovery trend and high attrition rate
The process of biopharmaceutical research and development is time consuming and expensive.
For a new molecular entity to be approved by FDA and put on market, it usually takes 12-14 years
and almost 2 billion US dollars262. It is estimated that less than 12% of candidate medicines
entering

phase

I

clinical

trials

will

make

it

to

the

approval

stage

(http://www.phrma.org/advocacy/research-development/clinical-trials). The high attrition rate in
clinical trials is often due to lack of efficacy or safety251,263. The later into discovery and
development stage the candidate fails, the more money and resource it costs to pull it out of the
pipeline.
Cancer drug discovery in early times was conducted with phenotypic screens looking for antiproliferative compounds. Then the effort shifted to target-based screens for easier pharmaceutics
development and pharmacokinetics study. However, recent cancer drug discovery efforts fail too
often263. The current industry model puts much of the effort and resources in lead optimization
and conducting phase clinical trials, whereas the process of target selection and validation is not
emphasized enough262. The lack of a valid target often leads to failures of drug candidates in
phase clinical trials and greatly increase the cost of drug development264. Intuitively, a targetbased screen would not result in any useful drug molecules if the target is not effective in blocking
tumor cell proliferation. It has been pointed out that target selection and validation is the most
important factor in transforming pharmaceutical industry productivity250.
6.2.2 Aerobic glycolysis as a potential anticancer strategy
One area in which this is especially apparent is the study of aerobic glycolysis, also known as the
Warburg effect, a phenomenon first described by Warburg in 1926265. Often observed in tumor
cells and other proliferating cells, it refers to upregulated glucose uptake and the dependence on
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glycolysis for ATP production, even in the presence of functional mitochondria and oxygen 260,266.
The Warburg effect recently reemerged as an interesting anticancer strategy267–270. Many
enzymes involved in the Warburg effect are overexpressed in tumor cells and have been studied
extensively as anticancer targets. However, small molecules used to regulate the target protein
activity and to demonstrate the Warburg effect validity often have off-target effects and therefore
do not serve as strong support for the Warburg effect as effective anti-proliferative strategy.
There are four proposed benefits of the Warburg effect on cancer cells: in the tumor
microenvironment with limited energy source, increased level of glucose uptake by cancer cells
leaves healthy cells less glucose for energy production or immune function; the end product of
glycolysis pyruvate can be converted to lactate and secreted out of cells, which lowers tissue pH
and promotes acid-mediated tumor invasion; glycolysis supplies cancer cells with extra carbon
source for anabolic activity to produce biomass; altered oxidative phosphorylation in mitochondria
changes the reactive oxygen species (ROS) balance and signaling pathways266.

6.2.3 Three pillars for a valid target
Typically there are three approaches towards target validation in anticancer drug discovery244,257:
1) Target is overexpressed or mutated in cancer tissues. Proteomics or genomics studies of
patient samples and healthy tissues usually lead to the identification of a protein target being
overexpressed or a mutated gene that results in gain-of-function or loss-of-function for certain
kinases or channels. In aerobic glycolysis, glucose transporter 1, hexokinase 2 (HK2),
pyruvate kinase M2 are found to be upregulated and important for tumor cell growth271–274.
2) Altering target expression level reduces proliferation. Overexpressed or mutated proteins in
cancer cells can be knocked out or knocked down in cell lines or animal models with siRNA
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or genetic engineering, and researchers can use these in cellulo or in vivo models to study
the effects of target proteins on cancer cell proliferation or cancer development.
However, knocking out or knocking down a protein is not the same as regulating its activity. For
example, HK2 is the first rate-limiting enzyme involved in aerobic glycolysis, yet it is also localized
at the voltage-dependent anion channels on mitochondrial outer membrane and involved in
cytochrome c release and cell apoptosis, as well as ADP/ATP exchange activity275–277. Therefore,
knocking out HK2 will likely result in anti-proliferative effects on cells due to its multiple biological
functions.
3) A small molecule that inhibits the target blocks proliferation. Small molecules are used as tools
in preclinical studies to verify the target effectiveness without affecting target protein
expression level278. They are also important in establishing the druggability of the target.
Due to the nature of pharmaceutics discovery process, small molecules used for target validation
are not optimized for their targets and therefore often have off-target effects. For example, 3bromopyruvate (3-BrPA) and 2-deoxyglucose (2-DG) can inhibit HK2 activity and they were used
to support HK2 as an anticancer target. However, 3-BrPA is an alkylating agent that crosslinks
key thiols in the cell, generating ROS and resulting in oxidative stress279, whereas 2-DG inhibits
N-linked glycosylation process, induces ER stress and stimulates autophagy280. Their antiproliferative activities could result from their off-target effects. Even though HTS have been
conducted to look for more specific inhibitors of HK2268, researchers failed to test the inhibitors on
other potential targets such as glucose transporter in cells.
Therefore, small molecules represent the weakest support for a valid target and they fail too often
due to their non-specific nature and off-target effects. These observations led to my proposal of
conducting a target validation screen to improve small molecule support. The idea is to screen a
chemical library against a potential target and identify an ensemble of hits with similar activities:
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if a target is valid, all compounds that inhibit it will be anti-proliferative; if a target is invalid,
compounds would have the same efficacy as the library as a whole. This approach offers much
stronger support than a tool molecule for target validation.
In this project, we used K562 cells with long-term expression of a Forster Resonance Energy
Transfer (FRET)-ATP sensor in a multi-read assay to measure ATP production via glycolysis or
oxidative phosphorylation (OXPHOS)281. The assay was used to screen compounds from NCI
mechanistic set, and we identified 10 glycolytic inhibitors and 7 OXPHOS-dependent ATP
production inhibitors. After comparing their anti-proliferative activities, we found that glycolytic
inhibitors are more anti-proliferative than the library and the OXPHOS inhibitors. We concluded
that inhibiting aerobic glycolysis is a good strategy to block cell proliferation. We also propose to
replace the use of a tool compound with a target validation screen, which should be routinely
adopted in drug discovery efforts.

6.3 Methods
6.3.1 Cells, constructs, and reagents.
K562 cells were obtained from ATCC (Manassas, VA) and cultured in Iscove’s medium containing
10% newborn calf serum, 1% penicillin-streptavidin and 1% L-glutamine. Additional cell lines
tested in Figure 25 were provided by Drs. Charles Giardina and Kenneth Campellone of the
University of Connecticut. CDNAs encoding the ATeam FRET sensor281 and the FLII12pGLU600µdelta6 glucose sensor282 were obtained from Addgene (Cambridge, MA). Cells were
transfected using nucleofection and sorted based on YFP fluorescence as described
previously283. Flow cytometric measurement of FRET signals were described previously283.
Experiments with ATeam-expressing cells were conducted in Ringer’s solution with or without
added glucose as indicated. Glucose-free Ringer’s contained the same components as ES
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without glucose. Where indicated, bovine serum albumin (BSA, Sigma) was added at a final
concentration of 0.12% to simulate the protein level in cell culture medium. Sodium azide and
glucose were from Fisher (Fair Lawn, NJ). The Cell Titer-Glo 2.0 kit used for luciferase
confirmation of effects on intracellular ATP levels was purchased from Promega (Madison, WI).
The colorimetic hexokinase assay kit was purchased from BioVision (Milpitas, CA). Both kits were
used according to the manufacturer’s recommended protocols. Mechanistic Set III and powder
resupply of hit compounds was obtained from the National Cancer Institute’s Developmental
Therapeutics Program (Bethesda, MD).
6.3.2 FRET screening.
A Molecular Devices SpectraMax i3x plate reader (Sunnyvale, CA) was used to measure the
fluorescence of cells expressing ATeam and FLII12pGLU-600µ in three channels: CFP (450/9 nm
excitation, 485/15 nm emission), FRET (450/9 nm excitation, 535/15 nm emission), and YFP
(485/9 nm excitation, 535/15 nm emission). For screening with ATeam, cells were washed in
glucose-free Ringer’s and added to flat-bottomed Greiner half-area 96-well plates, with ~100,000
cells in 100 µL per well. 1 µl of DMSO or 1 µl test compounds at 1 mM were added to wells,
producing a final compound concentration of 10 µM. After addition of cells, plates were vortexed
and incubated for 30 minutes at 37 degrees in a humidified CO2 incubator.
The following equation was used to calculate FRET ratios
Equation 4 FRET ratio

𝐹𝑅𝐸𝑇 𝑟𝑎𝑡𝑖𝑜 =

𝐹𝑅𝐸𝑇𝑐 − 𝐹𝑅𝐸𝑇𝑏
𝐶𝐹𝑃𝑐 − 𝐶𝐹𝑃𝑏

where FRETc and CFPc are the fluorescence intensities of cells, while FRETb and CFPb are
background fluorescence intensities of wells containing 100 µL Ringer’s solution.
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FRET ratio was determined from cells treated with glucose but not Na azide (P), treated with
compounds (C), or treated with Na azide but not glucose (N), and percent inhibition is defined as
Equation 2 % inhibition of down assay.
6.3.3 Hit confirmation by Cell-Titer Glo.
Cells were washed in glucose-free Ringer’s and incubated with DMSO or test compounds for 30 minutes
at 37 degrees. 50 µl of Titer Glo reagent was added to 50 µl of cells (10,000 cells per well), mixed, and
incubated for 10 minutes. Luminescence was measured on the Spectramax i3x plate reader.

6.3.4 Hexokinase (HK) activity assay.
K562 cells (50,000 cells per condition) were lysed with supplied lysis buffer, and 25 µl of cell lysate
was incubated with DMSO or test compounds for 10 minutes at room temperature. 25 µl reaction
mix (freshly prepared according to manufacturer’s protocol) was added and absorbance at 450nm
was measured on the plate reader in kinetic mode. A standard curve of NADH was used to convert
deltaOD450 to HK activity.
6.3.5 Dose-response measurements.
Compounds that were confirmed active in a repeat of the primary assay were resupplied from NCI
in powder and dissolved in DMSO. Concentrations between 0.1-10 µM were tested at 2-fold
dilutions on cells. Percent inhibition data were fitted to Equation 3 Hill equation.

6.4 Results
6.4.1 Establishing a stable FRET sensor cell line to measure intracellular ATP level
K562 leukemic cells were transfected with a FRET sensor cDNA which responds to intracellular
ATP level change281. There are two reasons for choosing K562 cells: K562 cells display the
Warburg effect, as they can maintain high ATP level in the absence of OXPHOS activity but in
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the presence of glucose (confirmed by luciferase-based ATP assay on cell lysate Figure 25);
K562 belongs to the panel of 60 tumor cell lines chosen by NCI to conduct an anticancer drug
screen with their libraries123, and the anti-proliferative data of all compounds are readily accessible
for K562 cells.
K562 cells were isolated from a 53-year-old female with chronic myelogenous leukemia in
terminal blast crises and established by Lozzio. It hosts the Philadelphia chromosome and can
undergo unlimited proliferation284,285. It has routinely been used as a target for natural killer cells
due to a lack of MHC I antigens on the cell surface286,287. It is highly undifferentiated cell line of
granulocyte lineage, with the potential of becoming erythrocytic, granulocytic or monocytic cell
line288.
After two rounds of cell sorting, stable cells were obtained and named ATP cells. Majority of ATP
cells express the FRET sensor at a high level according to YFP fluorescence profile in flow
cytometry (Figure 24A), and this led us to investigate the use of plate reader to measure FRET
signals. Plate reader test was carried out with ATP cells treated with four control conditions in
repeats (Figure 24B), and ~10-fold fluorescence signal over background was observed in FRET
and CFP channels. Variations between wells could result from different cell numbers, and taking
the ratio of FRET/CFP normalized the signals and showed uniformed performance in the plate.
FRET ratio change between low and high ATP levels resulted in Z’>0.5 repeatedly, demonstrating
good assay quality to screen for inhibitors of ATP production.
To find positive and negative controls for our cell-based assay, we tested ATP cells in different
conditions and measured their fluorescence intensities (Figure 24C). When cells are in their native
solution with plenty of glucose and no inhibitor of OXPHOS-dependent ATP production, their
FRET ratio represent the high level of ATP; when cells were washed in glucose-free Ringer’s
solution, and sodium azide was added to inhibit the respiratory complex IV, there is a significant
drop in ATP level; when cells were treated with sodium azide in the presence of glucose, they can
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restore ATP to high level via aerobic glycolysis; and surprisingly, when cells were washed with
glucose-free solution, they can still maintain a high level of ATP for 3 hours, probably due to
alternative energy source such as stored amino acid and fatty acid.

Figure 24 FRET measurements using a genetically-encoded ATP sensor in K562 cells.
(A) Measuring ATeam FRET with flow cytometry. (i) Plot of forward vs. side scatter for ATeam K562 cells.
The live-cell gate is indicated. (ii) Histogram of YFP fluorescence for long-term transfectants expressing
ATeam sensor. The blue trace represents the YFP fluorescence of untransfected K562 cells. (iii and iv)
Plots of FRET ratio vs. YFP for cells washed in glucose free Ringer’s solution and treated with sodium azide
(iii) or in the presence of glucose (iv). FRET ratio was calculated as described in Materials and Methods.
(B) Measuring ATeam FRET using a plate reader. Plots of CFP fluorescence (i), FRET fluorescence (ii),
and FRET ratio (iii) for ATeam cells in a 96-well plate treated with indicated conditions. (C) K562 cells can
generate ATP in the absence of glucose or functional mitochondria but not both. (i) Average FRET ratios
for cells from (B). Data are the mean ± S.D. from 24 wells per condition. Similar results were obtained in
multiple independent experiments. (ii) Time dependence of changes in ATeam FRET ratio after cells were
washed in glucose-free Ringer’s solution (filled circles), washed in glucose-free solution and treated with
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sodium azide (open squares), treated with sodium azide and glucose (filled squares), or glucose (open
circles). Sodium azide and glucose were used at final concentrations of 5 mM and 20 mM, respectively.

The transfection of K562 with ATeam sensor did not affect their catalytic activities or ATP
production, as orthogonal assay using Cell-Titer Glo based on luciferase activity confirmed similar
ATP level changes in conditions as in Figure 24C. In addition, the Warburg effect was observed
in multiple tumor cell lines other than K562 leukemic cells, and most cell lines can maintain a high
level of ATP production even when glucose was absent (Figure 25).
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Figure 25 Using luciferase to characterize metabolism in various cell lines.
Cells were treated with indicated conditions and ATP level was measured with CellTiter-Glo 2.0 assay kit
according to manufacturer’s protocol. Sodium azide and glucose were used at final concentrations of 5 mM
and 20 mM, respectively. Data are mean ± S.D. from 3 wells per condition.
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6.4.2 Multiple-read assay design and the screen of NCI library led to the identification of
several inhibitors of ATP production
The use of plate reader led us to come up with the following assay design which involves multiple
readings with addition-only treatment of cells (Figure 26A): 1) ATP cells were first washed in
glucose free Ringer’s solution to reversibly block ATP production from glycolysis. Cells were
incubated with test compounds for 30 minutes and FRET was measured. A decrease in FRET
ratio indicates the inhibitory effects on OXPHOS-dependent, glucose-independent ATP
production; 2) sodium azide was added to all cells to block OXPHOS-dependent ATP production.
FRET was measured and a decrease in FRET ratio was observed for all conditions; 3) glucose
was added to all cells to initiate glycolysis. After 30 minutes of incubation FRET was measured,
and a decrease in FRET ratio indicates inhibitory effects on ATP production via glycolysis. The
sequential treatment of ATP cells and the addition-only steps allowed us to separate ATP
production from aerobic glycolysis from OXPHOS. We anticipated four types of effects
compounds could have on cells (Figure 26B).
We used this assay to screen ~800 small molecules from National Cancer Institute (NCI)
mechanistic set. The library was chosen because all of the compounds have been tested at
several concentrations for their effects on cell growth against the panel of NCI60 cancer cells 123.
The library also includes diverse representative compounds from each cluster of >37,000 open
compounds, so it should yield inhibitors with different mechanisms of action. From the initial
screen, we identified 50 inhibitors (6% hit rate) of glycolysis and/or OXPHOS with %
inhibition>75% at 10uM. In confirmatory assays using FRET measurement, 5 inhibitors showed
significant compound fluorescence in more than one runs and we were unable to obtain
meaningful measurement of FRET ratio. They were not included in further testing. We then used
an orthogonal assay based on luciferase activity to confirm compound activity (TiterGlo 2.0 from
Promega). 35 compounds were confirmed for their inhibitory activity (70% confirmation rate).
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We chose 30 most active inhibitors to order powder resupply from NCI for further testing, but 1
was not available in powder. Among the 29 compounds reconstituted from powder resupply, all
but two compounds were confirmed with % inhibition >75%. We categorized inhibitors into two
categories and found 14 OXPHOS inhibitors and 13 glycolysis inhibitors.
Immediate cytotoxicity was tested for all inhibitors as plate-reader based initial screen does not
offer any information on % live cell in each well. To test for cytotoxicity, cells were incubated with
compounds and regular assay flow was used to obtain confirmatory FRET measurement and
achieve the same incubation time. After the third read, PI solution was added to each well and
fluorescence 535/617 was obtained on the plate reader. Control samples were treated with DMSO
or Triton. One compound (NSC 306864) showed 67% cell killing compared to controls, and the
rest of the compounds were < 10% cytotoxic in 2 hours.
We chose 30 most active inhibitors to order powder resupply from NCI for further testing, but 1
was not available in powder. Among the 29 compounds reconstituted from powder resupply, all
but two compounds were confirmed with % inhibition >75%. We categorized inhibitors into two
categories and found 14 ox-phos inhibitors and 13 glycolysis inhibitors.
It is important to point out that, our screen of the NCI library was not to look for drug candidates
or lead molecules. Instead, it was to select a group of compounds based on their inhibitory effects
of glycolysis or OXPHOS. This is only the first step towards our target validation approach, and
next we hope to compare these two groups of inhibitors to the library set as a whole in their
effectiveness in blocking leukemic cell proliferation.
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Figure 26 A multiple-read plate reader protocol enables detection of inhibitors of both glycolysis and
OXPHOS-dependent ATP production.
(A) Design and performance of an assay with three reads. ATeam cells were washed in glucose free
solution and put into a 96-well plate. After 30 minutes of incubation, fluorescence signals were measured
and FRET ratio was calculated (1). Sodium azide was added to all but 8 control wells in column 12 and
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incubated for 30 minutes, before the second measurement was taken (2). Glucose was added to all but 8
control wells in column 1 and incubated for 30 minutes, before the third measurement was taken (3). Sodium
azide and glucose were used at final concentrations of 5 mM and 20 mM, respectively. (B) Four potential
compound effects and the ATeam response produced in the multiple read protocol. (1) No effect on ATP
production. Cells were washed with 0 glucose solution, then treated with sodium azide, then glucose; (2)
Inhibition of OXPHOS-dependent ATP production. Cells were treated with 5 mM oligomycin, then sodium
azide, then glucose; (3) Glycolysis inhibition. Cells were washed with 0 glucose solution, then treated with
sodium azide; (4) Inhibition of both glycolysis and OXPHOS-dependent ATP production. Cells were treated
with 5 mM oligomycin, then sodium azide. (C) Heat maps of FRET ratios of ATeam-expressing cells
incubated in a representative plate that contained compounds from NCI mechanistic set in columns 2-11.
Columns 1 and 12 contained control wells as described in (A). The scaling of heat maps is displayed to the
right. One well that contained a fluorescent compound is represented in white. (D) Screening 813
compounds from NCI mechanistic set. Data are presented as percent inhibition of FRET ratio compared to
control wells in each plate. Inhibition of OXPHOS-dependent ATP production and glycolysis are obtained
from readouts 1 and 3, respectively.

6.4.3 Molecular mechanism of action for glycolytic inhibitors
To gain confidence in glycolytic inhibitors activities, we wanted to assign a molecular mechanism
of action to at least some of them. Glucose uptake through glucose transporter is the first step in
glycolysis, and GLUT1 is found to be upregulated in K562 cells289. Glycolysis inhibitors were
tested on glucose uptake. To do this, we constructed another FRET-based K562 cell line using
pFLIIP glucose sensor282. Transfected cells were first washed in glucose free solution and then
treated with test compounds. Then 20 mM glucose was added and FRET fluorescence was
measured on the plate reader. As a positive control, cytochalasin B was used and showed 100%
inhibition of glucose uptake at 100 µg/ml. Only one glycolytic inhibitor (NSC 18268) blocked
glucose uptake by 100%, so it was not included in the other mechanism testing. The compound
is found to be actinomycin D, a known antitumor chemotherapeutic under the trade name
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Cosmegen. Some compounds showed increased level of intracellular glucose, likely due to the
build-up of intracellular glucose as a result of inhibited glycolysis.
With only one GLUT inhibitor identified among the mechanistically diverse library was surprising,
so the library was screened using Glucose cells and 9 inhibitors were identified to block glucose
uptake. Surprisingly, NSC 18268 was not identified in that screen. Instead, NSC 3053, an analog
of actinomycin D was identified. None of the other GLUT inhibitors overlapped with glycolytic
inhibitors identified in ATP screen. However, a closer examination of ATP cells dose-dependence
on glucose level showed that ATP level in cells is less sensitive to extracellular glucose level drop.
Combined dose responses showed that [ATP]i can be maintained at high level via glycolysis even
when [glucose]o was dropped to 1 mM. We wanted to find out whether other GLUT inhibitors
could also inhibit ATP production via glycolysis using ATP cells. In order to observe effects of
GLUT inhibitors on ATP levels in cells, we lowered the glucose used to only 0.5 mM, and found
three GLUT inhibitors that blocked ATP production by glycolysis by >75% at 10 µM (NSC 61811,
96932, 260610). None of them was identified through the ATP cell screen, likely due to the much
higher glucose concentration (20mM) used in ATP assay. Unfortunately, when powder resupplies
of GLUT inhibitors were obtained, only one was confirmed (NSC 96932).
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Figure 27 Discrepancy of GLUT inhibitors identified from ATP cells and Glc cells screens could be a result
of different dose dependence on extracellular glucose.
(A) (left) Plot of FRET ratio vs. YFP for cells washed in glucose free solution (blue) and treated with 20 mM
glucose (red). (right) Average FRET ratios obtained from cells in 96-well plate treated with indicated
conditions in repeats. Fluorescence signals were measured on the plate reader. Data are the mean ± S.D.
from 16 wells per condition. Similar results were obtained in multiple independent experiments. (B)
Structures of NSC 18268, actinomycin D (MW3808), an inhibitor identified through ATP screen; and NSC
3053, Dactinomycin (MW1255), an inhibitor identified through GLUT screen. (C) Dose-response testing
glucose and ATP levels in FRET cell lines. Cells expressing FLII12pGLU-600µdelta6 were bar coded using
0.1 uM calcein red-orange dye before being mixed with ATeam-expressing cells. The mixed cells were
washed in glucose free solution and treated with 5 mM sodium azide. Glucose was added at indicated final
concentrations and the fluorescence signal was measured on flow cytometer after 30 minutes.
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Since Dactinomycin was characterized as a GLUT inhibitor, it was not included in the powder
resupply. None of the other glycolytic inhibitors blocked glucose uptake when tested from powder
resupply. HK2 is the first enzyme in glycolytic metabolism that converts glucose to glucose-6phosphate, and it is found to be upregulated in cancer cells and associated with poor prognosis.
We tested glycolytic inhibitors on HK activity using a commercial kit that measures the production
of NADH when HK reaction was coupled with G6PDH reaction. Four inhibitors showed >75%
inhibition of HK. However, one of them was found to inhibit G6PDH from the kit. Dose responses
of the other three HK inhibitors showed µM range activities.

Figure 28 Determining molecular mechanism of action for select glycolytic inhibitors.
(A) Measuring effects of compounds on glucose influx. Long-term transfectant lines expressing a FRET
sensor for intracellular glucose were washed in glucose-free solution and incubated with indicated
glycolysis inhibitors for 30 minutes. Glucose was added at a final concentration of 20 mM and plates
incubated for an additional 30 minutes. Fluorescence signals were measured on the plate reader and FRET
ratio was calculated. Dotted lines indicate control wells and their FRET ratios. (B) Measuring effects of
compounds on hexokinase activity. Top: K562 cell lysates were incubated with indicated glycolytic inhibitors
in vitro for 10 minutes before hexokinase colorimetric assay kit was used to detect hexokinase activity. The
negative control received no lysate, and the positive control received cell lysate treated with DMSO. Bottom:
hexokinase inhibitors were tested for their effects on G6PDH. 100 µM glucose-6-phosphate was added
directly to the reaction mix. (C) Dose response curves for HK inhibitors. Filled circles, NSC 30916, open
circles NSC 400944, closed triangles NSC 68634. Data are from a single experiment, representative of two.
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6.4.4 Probability of obtaining anti-proliferative compounds based on glycolytic inhibition
We obtained the proliferation measurements of NCI compounds at 10uM (growth inhibition or
GI10), the same concentration used in ATP screen. The proliferation assay was conducted by
incubating cells with compounds for two days in culture medium, followed by the addition of a
protein binding dye123,290. Data showed the amount of total protein as a result of cell proliferation
in each compound treated well, with 100% representing normal cell growth, 0% for no cell growth,
and negative % meaning the well contained less cells than when started (Figure 29A). The
mechanistic library had a wide range of compound effects on cell proliferation, with the median
value around 49% cell growth.
To compare our metabolic inhibitors to the results from NCI proliferation test, we tested our
compounds in the presence of BSA to simulate the serum condition in culture medium, as serum
is very fluorescent and interferes with FRET measurement. 10 glycolytic inhibitors and 7
OXPHOS-dependent ATP production inhibitors were confirmed in the presence of BSA (Figure
30 and Table 4), as BSA may bind to compounds and reduce efficiencies. When comparing
confirmed inhibitors to the library as a whole for their anti-proliferative activities, OXPHOS
inhibitors (squares in Figure 29B) had a wide spread, with the mean of 40%, which is not
significantly different from the median of the library. It is as if random compounds were chosen
from the library and they all happened to be inhibitors of OXPHOS-dependent ATP production.
Screening for OXPHOS inhibition did not enrich for anti-proliferative compounds. Particularly, one
OXPHOS inhibitor did not affect cell growth at all (GI10=75.8), which eliminates inhibition of
OXPHOS-dependent ATP production as a valid strategy for blocking cell proliferation. On the
contrary, all glycolytic inhibitors (circles in Figure 29B) are effective in blocking leukemic cell
proliferation. There is a significant difference between glycolytic inhibitors as a group and the
library as a whole. Choosing compounds based on glycolytic inhibitory effects enriched for anti131

proliferative activities among the hits. Even the least effective glycolytic inhibitor had GI10 of 6%,
representing a 94% inhibition on cell proliferation. This is a very high threshold, and only 26.5%
of library compounds are as effective or more effective than this compound.
What is the chance of obtaining all glycolysis inhibitors from the top anti-proliferative compounds
among the library? The probability is given by the binomial distribution. As more hits are identified
with anti-proliferative activity, the probability for this event to happen at random decreases. For a
library with 26.5% compounds being anti-proliferative, finding 10 glycolytic inhibitors also with
anti-proliferative activity had 1.7/1000,000 chance of being a random event (Figure 29C). This
very unlikely event by chance provided unbiased strong support for inhibition of aerobic glycolysis
as an effective anti-proliferative strategy.

Figure 29 Confirming glycolysis as a valid target for tumor cell killing.
(A) Histogram of percent cell growth of NCI mechanistic set compounds tested at 10 uM (G10) in K562
cells. (B) Cumulative distribution for compounds from (A). Dotted line represents the median activity. G10
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values for inhibitors of glycolysis and OXPHOS-dependent ATP production that were active in the presence
of BSA are indicated by circles and squares, respectively. The mean and standard deviation for each group
are indicated. (C) Plot of the probability of obtaining the indicated number of hits for libraries with indicate
percentage of antiproliferative compounds. (D) Proposed scheme for conducting target validation screens.

6.5 Discussion
Based on what we observed with the ATP screen, we propose for a target validation screen to
replace the use of tool molecules (Figure 29D). Given a library collection of diverse molecules,
compounds could be tested on cell proliferation in anticancer study, then a target of interest could
be chosen to conduct the target-based assay on the library. When an inhibitor of the target is
identified, it will be determined whether it belongs to anti-proliferative group according to a
predefined threshold. Any inhibitor on the target yet without anti-proliferative activity will remove
the target from the screening effort. Otherwise the target-based screen can carry on. The number
of inhibitors required to establish high level of confidence depends on the library property. For a
library where all compounds are anti-proliferative, the chance of obtaining inhibitors of the target
with anti-proliferative activity is 100%, and vice versa, a library with no anti-proliferative
compounds would be of no use to the screen as the chance is always 0%. The more
phenotypically active compounds there are in the library, the higher the chance of obtaining
inhibitors with the desired activities, and according to binomial distribution, the more hits one
would need to identify and confirm before drawing the conclusion on target validity.
The chemical library (target validation set or TV set) does not need to contain compounds that
are lead-like or pharmaceutically desirable, because the purpose of a TV screen is not to find lead
compounds or probe molecules but rather verifying the target with an ensemble of compounds.
However, the library must be first phenotypically characterized, and the compounds in the library
need to have a wide range of activities. Compounds could be screened for anti-proliferation or
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other processes such as cell differentiation. We previously used granule exocytosis assay to
screen MLSMR, which could be used for future target-based assays as a phenotypically
characterized library for CTL function. The amount of work of screening a library against a cell
phenotype is huge investment upfront, especially when dose responses of individual compounds
are involved. However, on the long run, the effort in the beginning will be worthwhile in improving
target selection process and increasing the success rate of drug candidates.
About the confidence level: The chance of getting random event is not set to a threshold. The
model gave four scenarios of different library properties, and people could determine how many
hits they need to identify before drawing the conclusion with high level of confidence. To us,
1.7/1000,000 is a very rare event by chance, given by 10 glycolytic inhibitors as a group. If the
chance of 1/10000 is good enough, the screen can stop when 7 inhibitors were identified to be
anti-proliferative. It is true that any given compound from the inhibitor group could have off-target
effects and have anti-proliferative activity as a result of their inhibition on other cellular targets.
However, as a group, an ensemble compound approach offers unbiased support for a target.
About the hit rate: the Warburg effect covers the entire glycolytic pathway, and the hit rate (6%)
is higher than a single molecular target-based screen. Pathway-based screen is between targetbased screen and phenotypic screen. If the target validation approach were to be tested against
a glycolytic enzyme, ie HK2 (0.37% hit rate), more compounds would need to be screened in
order to obtain enough compounds to reach the desired probability.
About artificial sensor: instead of relying on what the cells offer (LAMP in CTLs), we introduced
sensors for interesting targets to relevant cell models, and therefore create targeted phenotypic
screening. This can be done with any target of choice. Other studies have used luciferase-based
gene reporter assay as a model to screen for activators of certain genes 291. Previously we used
kinase activity sensors in a multiplexed flow-based assay283. Here we introduced ATP sensor to
leukemic cell line that has the Warburg effect. Although there are commercial kits that detect ATP
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based on luciferase activity, cells would need to be lysed to release ATP, and we won’t be able
to obtain any information on the live cell functions and processes. By using FRET sensor, we can
monitor intracellular ATP level in real-time fashion and study metabolism pathways in intact cells.
Multiplexed assay vs. multiread assay: both approaches can yield multiple cell measurements in
one screening, so they are both high-content assays. Multiplexed assay employs cell barcoding
technique and reads the mixture of cell samples at one-time point, and different barcodes
represent different subsets of cells, so multiple protein targets can be interrogated at the same
time. Information about how compounds work in cells could be gathered as the initial screening
is being completed. Multiread assay uses sequential treatment of cells to achieve the
measurement of different cell activities, and they yield hits that target different cell processes. To
identify the molecular targets of hits, follow-up assays must be conducted following the initial
screen. However, a plate-reader based multiread assay can be combined with long-term cell
viability/proliferation test, and this can generate the library phenotypic profile at the same time of
target validation screening.
6.5.1 Future Direction: Target validation approach applied to an alternative target
In this appendix, we proposed for a target validation approach to offer strong support for a
molecular target. Instead of depending on the traditional RNAi knockout or knockdown and a
handful of tool compounds that could all have multiple targets, we sought to combine our targetbased screening results with the phenotypic information of a characterized library. However, this
validation screen theory is not tested. One of the future direction that we can take to verify the
theory is by library profiling and data mining. There have already been efforts by NCI to predict
potential targets for library compounds123,167,292. If we could categorize those targets as either
causing or not causing tumor cell proliferation based on published literature, we would hope to
find that all compounds presumed to share the same valid target would have anti-proliferative
effects on cells as well. For an invalid target, the group of compounds would have both anti135

proliferative and no effects. One caveat is that all potential mechanisms and targets are predicted
but not tested. If experiments were to be carried out to determine the effects of library compounds
on individual molecular target, less targets can be examined due to expense and time of screening
efforts.
Within the scope of this study, how to further verify that aerobic glycolysis is a good target for
blocking tumor proliferation? Theoretically, if we could generate cell lines that are resistant to
Warburg effect, we can treat them with glycolytic inhibitors and expect to see no ATP change and
no effect on cell proliferation rate. Replacing glucose with glutamate in culture medium could
enable the cells to grown independent of glucose. It is unclear how glycolytic inhibition could result
in anti-proliferation effect. Build-up of intermediate metabolites could initiate transcription factors
to activate genes related to cell apoptosis. From the standpoint of tumor microenvironment, this
could be a strategy of the tumor cell colony to preserve energy resource.
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Figure 30 Structures of glycolytic inhibitors (1-13) and oxidative phosphorylation-dependent ATP production
inhibitors (14-27).
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For more information see Table 4. Compounds are displayed in the same order.
Table 4 Metabolically-Active compounds in NCI Mechanistic Set III

1
2
3
4
5
6
7
8
9
10
11
12
13

NSC
Number
136037
105808
111041
697923
328587
400944*
686349*
30916*
635448
659997
631529
168597
164914

Inhibiton of
glycolytic ATP
production a
111 ± 3; 113 ± 6
107 ± 3; 110 ± 5
110 ± 3; 97 ± 14
99 ± 13; 86 ±2 2
108 ± 3; 101 ± 7
89 ± 11; -10 ± 2
90 ± 9; 90 ± 6
106 ± 6; 73 ± 13
98 ± 9; 43 ± 12
118 ± 4; 107 ± 6
102 ± 4; 70 ± 13
113 ± 3; 86 ± 11
85 ± 8; 45 ± 8

Inhibition of nonglycolytic ATP
productionb
3 ± 2; 4 ± 5
8 ± 5; 2 ± 3
8 ± 3; 28 ± 6
9 ± 9; 2 ± 2
13 ± 8; 3 ± 3
20 ± 7; 3 ± 3
36 ± 24; 7 ± 5
51 ± 20; 43 ± 11
71 ± 16; 59 ± 10
87 ± 6; 45 ± 10
99 ± 8; 25 ± 19
120 ± 11; 112 ± 3
124 ± 11; 113 ± 7

IC50 (uM)c
1.5 ± 0.3
3.3 ± 0.2
4.4 ± 0.4
>10uM
2 ± 0.4
1.7 ± 0.3
4.2 ± 0.5
4 ± 0.4
5.6 ± 1
1.1 ± 0.2
>5uM
2.2 ± 0.4
2.8 ± 0.4

Hill slopec
2.1 ± 0.8
4.8 ± 1
5.2 ± 2.8

14
15
16
17
18
19
20
21
22
23
24
25
26
27

377
52141
126771
658285
379531
79451
667467
5890
328477
79456
76455
664329
104129
82025

-3 ± 4; -28 ± 4
-1 ± 6; -4 ± 3
-15 ± 5; -40 ± 8
-20 ± 8; -13 ± 19
3 ± 3; -6 ± 5
-5 ± 7; -23 ± 3
-14 ± 8; -10 ± 4
-6 ± 4; -11 ± 2
-9 ± 3; -24 ±1 0
-6 ± 8; -27 ± 7
-9 ± 7; -7 ± 3
-13 ± 7; -8 ± 4
-2 ± 7; -12 ± 4
-9 ± 5; -27 ± 5

110 ± 2; 100 ± 6
109 ± 2; 93 ± 3
109 ± 7; -14 ± 27
106 ± 8; -14 ± 10
102 ± 2; 93 ± 3
101 ± 2; 76 ± 3
98 ± 7; 52 ± 6
97 ± 3; 80 ± 13
94 ± 5; 70 ± 5
90 ± 5; 65 ± 7
81 ± 9; 83 ± 5
80 ± 12; 18 ± 4
79 ± 10; 34 ± 9
79 ± 9; -31 ± 10

0.04 ± 0.02
2.9 ± 2
4.3 ± 0.2
3.8 ± 0.7
0.2 ± 0
1 ± 0.1
6 ± 0.6
1.4 ± 0.2
0.4 ± 0
0.7 ± 0.1
<0.1uM
6.9 ± 0.5
5 ± 1.1
>10uM

1.98 ± 0.84
1.6 ± 1.4
5.6 ± 1.2
3 ± 1.2
2.7 ± 1.2
2.9 ± 0.6
5.3 ± 2.1
2.4 ± 0.8
4.6 ± 1.5
10.4 ± 11.4

1.9 ± 0.5
5.4 ± 2.9
2.8 ± 0.8
3.6 ± 1
4.2 ± 3.1
2.2 ± 1
1.4 ± 0.3
1.5 ± 0.3

5.5 ± 1
1.8 ± 0.5

G10d
-4.9
-34.6
-49.4
-24.2
6.3
47.4
-36.6
-35.7
-41.3
-19
-38
-2.2
-54.3
35.8
4.5
15.6
90.7
56.3
55
72.2
75.8
46.7
69.9
8.5
96
60.2
67.9

Compounds are numbered in the same order as their structures are displayed in Figure 30.*indicates
hexokinase inhibitors.
aMeasured

from read 3, expressed as percent control. Data are mean + S.E.M. from 4 measurements from

powder resupply. The first value was obtained in the absence of BSA, the second in its presence.
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bMeasured

from read 1, expressed as percent control. Data are mean + S.E.M. from 4 measurements from

powder resupply. The first value was obtained in the absence of BSA, the second in its presence.
cFrom

fits to the Hill equation for data from 3 separate experiments including doses ranging from 0.1-10uM.

When dose-response curves can not be fit, range of inhibitory concentrations is indicated. Performed with
resupplied compounds.
dCompiled

from NCI data. In some cases, multiple reported values were averaged.
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